Amedeo Smart

Free Medical Literature Service

 

Amedeo

Vaccines
  Free Subscription

Articles published in
Vaccine
    August 2022
  1. DE MUNTER AC, Hautvast JLA, Ruijs WLM, Henri Spaan D, et al
    Deciding about maternal pertussis vaccination: associations between intention, and needs and values in a vaccine-hesitant religious group.
    Vaccine. 2022 Aug 1. pii: S0264-410X(22)00924.
    >> Share

  2. NARSINGAM S, Munson J, Drescher F
    Comparative effectiveness of individual pneumococcal vaccines with dual pneumococcal vaccination in older United States Veterans.
    Vaccine. 2022 Aug 1. pii: S0264-410X(22)00922.
    >> Share

    July 2022
  3. SHINKAI M, Sonoyama T, Kamitani A, Shibata RY, et al
    Immunogenicity and safety of booster dose of S-268019-b or BNT162b2 in Japanese participants: An interim report of phase 2/3, randomized, observer-blinded, noninferiority study.
    Vaccine. 2022;40:4328-4333.
    >> Share

  4. DE BROUWER L, David D, Espitia Ballestas M, Sloots A, et al
    Prevalidation of the cAMP-PTx reporter assay for quantitative assessment of pertussis toxin activity.
    Vaccine. 2022;40:4513-4521.
    >> Share

  5. COWLING BJ, Wong IOL, Shiu EYC, Lai AYT, et al
    Strength and durability of antibody responses to BNT162b2 and CoronaVac.
    Vaccine. 2022;40:4312-4317.
    >> Share

  6. SADOFF J, Le Gars M, Brandenburg B, Cardenas V, et al
    Durable antibody responses elicited by 1 dose of Ad26.COV2.S and substantial increase after boosting: 2 randomized clinical trials.
    Vaccine. 2022;40:4403-4411.
    >> Share

  7. LIU Z, Hosomi K, Kunisawa J
    Utilization of gut environment-mediated control system of host immunity in the development of vaccine adjuvants.
    Vaccine. 2022 Jul 30. pii: S0264-410X(22)00918.
    >> Share

  8. NOWALK MP, D'Agostino H, Dauer K, Stiegler M, et al
    Estimating the burden of adult hospitalized RSV infection including special populations.
    Vaccine. 2022;40:4121-4127.
    >> Share

  9. BOTTCHER J, Bauer BU, Ambros C, Alex M, et al
    Long-term control of Coxiellosis in sheep by annual primary vaccination of gimmers.
    Vaccine. 2022 Jul 29. pii: S0264-410X(22)00917.
    >> Share

  10. ROSE O, Erzkamp S, Schobel W, Grajeda M, et al
    COVID-19 vaccinations in German pharmacies: A survey on patient and provider satisfaction.
    Vaccine. 2022 Jul 28. pii: S0264-410X(22)00925.
    >> Share

  11. MARIN-LOPEZ A, Wang Y, Jiang J, Ledizet M, et al
    Erratum to "AgBR1 and NeSt1 antisera protect mice from Aedes aegypti-borne Zika infection" [Vaccine 39(12) (2021) 1675-1679].
    Vaccine. 2022 Jul 27. pii: S0264-410X(22)00608.
    >> Share

  12. BYRNE C, Coombs D, Gantt S
    Modestly protective cytomegalovirus vaccination of young children effectively prevents congenital infection at the population level.
    Vaccine. 2022 Jul 27. pii: S0264-410X(22)00913.
    >> Share

  13. RAMMAURO F, Carrion F, Olivero-Deibe N, Flo M, et al
    Humoral immune response characterization of heterologous prime-boost vaccination with CoronaVac and BNT162b2.
    Vaccine. 2022 Jul 27. pii: S0264-410X(22)00911.
    >> Share

  14. QUIAMBAO B, Montalban C, Minutello AM, Guinet-Morlot F, et al
    Serum-free purified Vero rabies vaccine is safe and immunogenic in children: Results of a randomized phaseII pre-exposure prophylaxis regimen study.
    Vaccine. 2022 Jul 26. pii: S0264-410X(22)00830.
    >> Share

  15. O'KENNEDY MM, Coetzee P, Koekemoer O, du Plessis L, et al
    Protective immunity of plant-produced African horse sickness virus serotype 5 chimaeric virus-like particles (VLPs) and viral protein 2 (VP2) vaccines in IFNAR(-/-) mice.
    Vaccine. 2022 Jul 25. pii: S0264-410X(22)00848.
    >> Share

  16. SPENCER CLINTON JL, Hoornweg TE, Tan J, Peng R, et al
    EEHV1A glycoprotein B subunit vaccine elicits humoral and cell-mediated immune responses in mice.
    Vaccine. 2022 Jul 22. pii: S0264-410X(22)00891.
    >> Share

  17. CHANG MJ, Ollivault-Shiflett M, Schuman R, Ngoc Nguyen S, et al
    Genetically detoxified tetanus toxin as a vaccine and conjugate carrier protein.
    Vaccine. 2022 Jul 21. pii: S0264-410X(22)00886.
    >> Share

  18. SIMSEK C, Bloemen M, Jansen D, Descheemaeker P, et al
    Rotavirus vaccine-derived cases in Belgium: Evidence for reversion of attenuating mutations and alternative causes of gastroenteritis.
    Vaccine. 2022 Jul 21. pii: S0264-410X(22)00853.
    >> Share

  19. PAWASKAR M, Gil-Rojas Y, Irene Parellada C, Rey-Velasco A, et al
    The impact of universal varicella vaccination on the clinical burden of varicella in Colombia: A National database Analysis, 2008-2019.
    Vaccine. 2022 Jul 21. pii: S0264-410X(22)00889.
    >> Share

  20. MCADAMS D, Estrada M, Holland D, Singh J, et al
    Concordance of in vitro and in vivo measures of non-replicating rotavirus vaccine potency.
    Vaccine. 2022 Jul 21. pii: S0264-410X(22)00892.
    >> Share

  21. LORENZETTI L, Haydarov R, Namey E, Lawton A, et al
    Exploring public perceptions of vaccine-derived poliovirus and a novel oral polio vaccine in the Democratic Republic of the Congo, Kenya, and Nigeria.
    Vaccine. 2022 Jul 20. pii: S0264-410X(22)00591.
    >> Share

  22. DUGORD C, Franc C
    Trajectories and individual determinants of repeated seasonal flu vaccination use over the long term using data from the French E3N cohort.
    Vaccine. 2022 Jul 18. pii: S0264-410X(22)00855.
    >> Share

  23. MCMILLAN CLD, Amarilla AA, Modhiran N, Choo JJY, et al
    Skin-patch delivered subunit vaccine induces broadly neutralising antibodies against SARS-CoV-2 variants of concern.
    Vaccine. 2022 Jul 18. pii: S0264-410X(22)00888.
    >> Share

  24. SETHY G, Chisema M, Sharma L, Joshi K, et al
    COVID-19 vaccine express strategy in Malawi: An effort to reach the un-reach.
    Vaccine. 2022 Jul 18. pii: S0264-410X(22)00887.
    >> Share

  25. MIMURA W, Ishiguro C, Fukuda H
    Influenza vaccine effectiveness against hospitalization during the 2018/2019 season among older persons aged>/=75years in Japan: The LIFE-VENUS Study.
    Vaccine. 2022 Jul 15. pii: S0264-410X(22)00852.
    >> Share

  26. WALTON S, Cortina-Borja M, Dezateux C, Griffiths LJ, et al
    Linking cohort data and Welsh routine health records to investigate children at risk of delayed primary vaccination.
    Vaccine. 2022 Jul 13. pii: S0264-410X(22)00849.
    >> Share

  27. IMANISHI Y, Kinoshita T, Sakamoto M, Ichimiya M, et al
    Importance of human papillomavirus vaccination leaflets focusing on the safety profile targeted pediatricians in Japan.
    Vaccine. 2022 Jul 13. pii: S0264-410X(22)00861.
    >> Share

  28. VASUDEVAN L, Bruening R, Hung A, Woolson S, et al
    COVID-19 vaccination intention and activation among health care system employees: A mixed methods study.
    Vaccine. 2022 Jul 13. pii: S0264-410X(22)00884.
    >> Share

  29. ORTQVIST AK, Dahlqwist E, Magnus MC, Ljung R, et al
    COVID-19 vaccination in pregnant women in Sweden and Norway.
    Vaccine. 2022 Jul 12. pii: S0264-410X(22)00859.
    >> Share

  30. PRIDDY FH, Williams M, Carson S, Lavender B, et al
    Immunogenicity of BNT162b2 COVID-19 vaccine in New Zealand adults.
    Vaccine. 2022 Jul 12. pii: S0264-410X(22)00885.
    >> Share

  31. GODDARD K, Lewis N, Fireman B, Weintraub E, et al
    Risk of myocarditis and pericarditis following BNT162b2 and mRNA-1273 COVID-19 vaccination.
    Vaccine. 2022 Jul 12. pii: S0264-410X(22)00860.
    >> Share

  32. CUFFEL A, Maylin S, Le Buanec H, Delaugerre C, et al
    Humoral and cellular responses to SARS-CoV-2 BNT162b2 vaccination in allogeneic hematopoietic stem cell transplantation recipients.
    Vaccine. 2022 Jul 11. pii: S0264-410X(22)00857.
    >> Share

  33. PADRON-REGALADO E, Medina-Rivero E
    Perspectives for licensing vaccines in Mexico.
    Vaccine. 2022 Jul 11. pii: S0264-410X(22)00854.
    >> Share

  34. HATFALUDI T, Rezaee MS, Liebhart D, Bilic I, et al
    Experimental reproduction of histomonosis caused by Histomonas meleagridis genotype 2 in turkeys can be prevented by oral vaccination of day-old birds with a monoxenic genotype 1 vaccine candidate.
    Vaccine. 2022 Jul 11. pii: S0264-410X(22)00851.
    >> Share

  35. COURCIER EA, Collins SF, McCormick CM, Arnold ME, et al
    The impact of BCG strains and repeat vaccinations on immunodiagnostic tests in Eurasian badgers (Meles meles).
    Vaccine. 2022 Jul 9. pii: S0264-410X(22)00850.
    >> Share

  36. WYPLOSZ B, Fernandes J, Sultan A, Roche N, et al
    Pneumococcal and influenza vaccination coverage among at-risk adults: A 5-year French national observational study.
    Vaccine. 2022 Jul 7. pii: S0264-410X(22)00841.
    >> Share

  37. MISCHLINGER J, Jaeger VK, Ciurea A, Gabay C, et al
    Long-term persistence of antibodies after diphtheria/tetanus vaccination in immunosuppressed patients with inflammatory rheumatic diseases and healthy controls.
    Vaccine. 2022 Jul 7. pii: S0264-410X(22)00760.
    >> Share

  38. ZHANG Y, Wang Y, Jia C, Li G, et al
    Immunogenicity and safety of an egg culture-based quadrivalent inactivated non-adjuvanted subunit influenza vaccine in subjects >/=3 years: A randomized, multicenter, double-blind, active-controlled phase III, non-inferiority trial.
    Vaccine. 2022 Jul 7. pii: S0264-410X(22)00846.
    >> Share

  39. BADRAN G, Angrand L, Masson JD, Crepeaux G, et al
    Physico-chemical properties of aluminum adjuvants in vaccines: Implications for toxicological evaluation.
    Vaccine. 2022 Jul 6. pii: S0264-410X(22)00833.
    >> Share

  40. REINHARDT A, Rossmann C, Engel E
    Radio public service announcements to promote vaccinations for older adults: Effects of framing and distraction.
    Vaccine. 2022 Jul 6. pii: S0264-410X(22)00805.
    >> Share

  41. CHADWICK C, Friede M, Moen A, Nannei C, et al
    Technology transfer programme for influenza vaccines - Lessons from the past to inform the future.
    Vaccine. 2022 Jul 6. pii: S0264-410X(22)00826.
    >> Share

  42. OSTROPOLETS A, Shoener Dunham L, Johnson KD, Liu J, et al
    Pneumococcal vaccination coverage among adults newly diagnosed with underlying medical conditions and regional variation in the U.S.
    Vaccine. 2022 Jul 5. pii: S0264-410X(22)00837.
    >> Share

  43. XIRIDOU M, Adam P, Meiberg A, Visser M, et al
    The impact of the COVID-19 pandemic on hepatitis B virus vaccination and transmission among men who have sex with men: A mathematical modelling study.
    Vaccine. 2022 Jul 4. pii: S0264-410X(22)00847.
    >> Share

  44. MCCORMICK DW, Konkle SL, Magleby R, Chakrabarti AK, et al
    SARS-CoV-2 infection risk among vaccinated and unvaccinated household members during the Alpha variant surge - Denver, Colorado, and San Diego, California, January-April 2021.
    Vaccine. 2022 Jul 4. pii: S0264-410X(22)00835.
    >> Share

  45. CASTILLO-CANO B, Martin-Perez M, Llorente-Garcia A, Montero-Corominas D, et al
    Assessment of thyroiditis risk associated with HPV vaccination among girls aged 9-18 years: A time-varying cohort study.
    Vaccine. 2022 Jul 2. pii: S0264-410X(22)00829.
    >> Share

  46. BARNARD JG, Marsh R, Anderson-Mellies A, Williams JL, et al
    Pre-implementation evaluation for an HPV vaccine provider communication intervention among primary care clinics.
    Vaccine. 2022 Jul 2. pii: S0264-410X(22)00844.
    >> Share

  47. HOU Z, Guo J, Lai X, Zhang H, et al
    Influenza vaccination hesitancy and its determinants among elderly in China: A national cross-sectional study.
    Vaccine. 2022 Jul 1. pii: S0264-410X(22)00832.
    >> Share

  48. SKIRROW H, Barnett S, Bell S, Mounier-Jack S, et al
    Women's views and experiences of accessing pertussis vaccination in pregnancy and infant vaccinations during the COVID-19 pandemic: A multi-methods study in the UK.
    Vaccine. 2022 Jul 1. pii: S0264-410X(22)00845.
    >> Share

  49. BARRALL AL, Hoff NA, Nkamba DM, Musene K, et al
    Hesitancy to receive the novel coronavirus vaccine and potential influences on vaccination among a cohort of healthcare workers in the Democratic Republic of the Congo.
    Vaccine. 2022 Jul 1. pii: S0264-410X(22)00842.
    >> Share

    June 2022
  50. NASREEN S, Gebretekle GB, Lynch M, Kurdina A, et al
    Understanding predictors of pneumococcal vaccine uptake in older adults aged 65 years and older in high-income countries across the globe: A scoping review.
    Vaccine. 2022 Jun 30. pii: S0264-410X(22)00825.
    >> Share

  51. HILLS T, Paterson A, Woodward R, Middleton F, et al
    The effect of needle length and skin to deltoid muscle distance in adults receiving an mRNA COVID-19 vaccine.
    Vaccine. 2022 Jun 29. pii: S0264-410X(22)00839.
    >> Share

  52. PICHON S, Moureau A, Petit C, Chu L, et al
    Safety and immunogenicity of a serum-free purified Vero rabies vaccine in healthy adults: A randomised phase II pre-exposure prophylaxis study.
    Vaccine. 2022 Jun 28. pii: S0264-410X(22)00806.
    >> Share

  53. BETTENCOURT C, Nogueira P, Paulo Gomes J, Joao Simoes M, et al
    Vaccines against Neisseria meningitidis serogroup B strains - What does genomics reveal on the Portuguese strain's coverage.
    Vaccine. 2022 Jun 28. pii: S0264-410X(22)00807.
    >> Share

  54. MEDEIROS MZ, Soares PF, Fialho BC, Gauss L, et al
    Vaccine innovation model: A technology transfer perspective in pandemic contexts.
    Vaccine. 2022 Jun 27. pii: S0264-410X(22)00823.
    >> Share

  55. WONG SC, Chan VW, Lam GKM, Yuen LL, et al
    The impact of personal coaching on influenza vaccination among healthcare workers before and during COVID-19 pandemic.
    Vaccine. 2022 Jun 27. pii: S0264-410X(22)00836.
    >> Share

  56. MOGHNIEH R, Abdallah D, Sayegh MH, Rahman Bizri A, et al
    Response to letter to the editor: Immunophenotyping of SARS-CoV-2 and vaccine design.
    Vaccine. 2022;40:3987-3988.
    >> Share

  57. CIMOLAI N
    Immunophenotyping of SARS-CoV-2 and vaccine design.
    Vaccine. 2022;40:3985-3986.
    >> Share

  58. HU G, Jin WP, Yang ZH, Lv SY, et al
    Efficacy of Coxsackievirus A2 vaccine candidates correlating to humoral immunity in mice challenged with a mouse-adapted strain.
    Vaccine. 2022 Jun 24. pii: S0264-410X(22)00768.
    >> Share

  59. STRAUS W, Rubin H
    COVID-19 vaccine safety monitoring in low and middle income countries - Time for a bold new approach.
    Vaccine. 2022 Jun 24. pii: S0264-410X(22)00822.
    >> Share

  60. SHIVJI R, Conocchia R, Korakianiti E, Jekerle V, et al
    Considerations for the chemistry, manufacturing and Controls (CMC) - quality package for COVID-19 vaccines- interim lessons learnt by the European medicines Agency (EMA).
    Vaccine. 2022 Jun 24. pii: S0264-410X(22)00827.
    >> Share

  61. SEYRAN M
    Artificial intelligence and clinical data suggest the T cell-mediated SARS-CoV-2 nonstructural protein intranasal vaccines for global COVID-19 immunity.
    Vaccine. 2022 Jun 24. pii: S0264-410X(22)00821.
    >> Share

  62. AL-MUSTAPHA AI, Okechukwu O, Olayinka A, Muhammed OR, et al
    A national survey of COVID-19 vaccine acceptance in Nigeria.
    Vaccine. 2022 Jun 23. pii: S0264-410X(22)00818.
    >> Share

  63. LOHMANN S, Albarracin D
    Trust in the public health system as a source of information on vaccination matters most when environments are supportive.
    Vaccine. 2022 Jun 23. pii: S0264-410X(22)00759.
    >> Share

  64. HUANG L, Wasserman M, Grant L, Farkouh R, et al
    Burden of pneumococcal disease due to serotypes covered by the 13-valent and new higher-valent pneumococcal conjugate vaccines in the United States.
    Vaccine. 2022 Jun 23. pii: S0264-410X(22)00773.
    >> Share

  65. ZHAO Z, Liao Y, Li Y, Jiang G, et al
    Immunogenicity and safety of the inactivated enterovirus 71 vaccine administered concomitantly with the measles-rubella vaccine in infants aged 8 months in China: A noninferiority randomized controlled trial.
    Vaccine. 2022 Jun 23. pii: S0264-410X(22)00776.
    >> Share

  66. CARTANYA-HUESO A, Martinez-Sanchez JM, Carlos Martin-Sanchez J, Lidon-Moyano C, et al
    Relationship between double COVID-19 vaccine uptake and trust in effectiveness and safety of vaccination in general in 23 Member states of the European Union: an ecological study.
    Vaccine. 2022 Jun 23. pii: S0264-410X(22)00820.
    >> Share

  67. MAERTENS K, Leuridan E, Munoz FM, Zimmermann P, et al
    Impact of vaccination during pregnancy on infants' immune responses to vaccinations- definitions and statistical approaches.
    Vaccine. 2022 Jun 21. pii: S0264-410X(22)00811.
    >> Share

  68. BRAZ HMB, Silva MF, Carvalho TP, Silva LAD, et al
    Pathogenesis of Brucella ovis in pregnant mice and protection induced by the candidate vaccine strain B. Ovis DeltaabcBA.
    Vaccine. 2022 Jun 21. pii: S0264-410X(22)00812.
    >> Share

  69. RONZANI P, Panizza F, Martini C, Savadori L, et al
    Countering vaccine hesitancy through medical expert endorsement.
    Vaccine. 2022 Jun 21. pii: S0264-410X(22)00780.
    >> Share

  70. SOARES GH, Sethi S, Hedges J, Jamieson L, et al
    Disparities in Human Papillomavirus vaccination coverage among adolescents in Australia: A geospatial analysis.
    Vaccine. 2022 Jun 21. pii: S0264-410X(22)00777.
    >> Share

  71. WANG L, Zhang J, Meng S, Ge L, et al
    Safety and immunogenicity of human rabies vaccine for the Chinese population after PEP: A systematic review and meta-analysis.
    Vaccine. 2022 Jun 21. pii: S0264-410X(22)00784.
    >> Share

  72. HONDA-OKUBO Y, Cartee RT, Thanawastien A, Seung Yang J, et al
    A typhoid fever protein capsular matrix vaccine candidate formulated with Advax-CpG adjuvant induces a robust and durable anti-typhoid Vi polysaccharide antibody response in mice, rabbits and nonhuman primates.
    Vaccine. 2022 Jun 21. pii: S0264-410X(22)00809.
    >> Share

  73. KORVES C, Izurieta HS, Smith J, Zwain GM, et al
    Relative effectiveness of booster vs. 2-dose mRNA Covid-19 vaccination in the Veterans Health Administration: Self-controlled risk interval analysis.
    Vaccine. 2022 Jun 21. pii: S0264-410X(22)00816.
    >> Share

  74. ULANOVA M, Huska B, Dubois S, McCready W, et al
    Opsonophagocytic activity against Streptococcus pneumoniae in Indigenous and non-Indigenous patients with severe chronic kidney disease immunized with 13-valent pneumococcal conjugate vaccine.
    Vaccine. 2022 Jun 20. pii: S0264-410X(22)00810.
    >> Share

  75. DIONATO FAV, Jalalizadeh M, Buosi K, Visacri MB, et al
    BCG vaccine safety in COVID-19 convalescent adults: BATTLE a randomized controlled trial.
    Vaccine. 2022 Jun 20. pii: S0264-410X(22)00803.
    >> Share

  76. KASAIJA PD, Contreras M, Kabi F, Mugerwa S, et al
    Oral vaccine formulation combining tick Subolesin with heat inactivated mycobacteria provides control of cross-species cattle tick infestations.
    Vaccine. 2022 Jun 18. pii: S0264-410X(22)00804.
    >> Share

  77. CASAGRANDE TZ, Costa-Rocha IAD, Gavi MBRO, Miyamoto ST, et al
    Previous biological therapy and impairment of the IFN-gamma/IL-10 axis are associated with low immune response to 17DD-YF vaccination in patients with spondyloarthritis.
    Vaccine. 2022 Jun 18. pii: S0264-410X(22)00703.
    >> Share

  78. ATWELL JE, Lutz CS, Sparrow EG, Feikin DR, et al
    Biological factors that may impair transplacental transfer of RSV antibodies: Implications for maternal immunization policy and research priorities for low- and middle-income countries.
    Vaccine. 2022 Jun 17. pii: S0264-410X(22)00783.
    >> Share

  79. UWAMINO Y, Kurafuji T, Takato K, Sakai A, et al
    Dynamics of antibody titers and cellular immunity among Japanese healthcare workers during the 6 months after receiving two doses of BNT162b2 mRNA vaccine.
    Vaccine. 2022 Jun 16. pii: S0264-410X(22)00763.
    >> Share

  80. CANADAY LM, Resnick JD, Liu H, Powell H, et al
    HA and M2 sequences alter the replication of 2013-16 H1 live attenuated influenza vaccine infection in human nasal epithelial cell cultures.
    Vaccine. 2022 Jun 16. pii: S0264-410X(22)00733.
    >> Share

  81. TAY S, Bowen AC, Blyth CC, Clifford P, et al
    A quality improvement study: Optimizing pneumococcal vaccination rates in children with cochlear implants.
    Vaccine. 2022 Jun 16. pii: S0264-410X(22)00769.
    >> Share

  82. MOUTA NUNES DE OLIVEIRA P, Mendes-de-Almeida DP, Bertollo Gomes Porto V, Crespo Cordeiro C, et al
    Vaccine-induced immune thrombotic thrombocytopenia after COVID-19 vaccination: Description of a series of 39 cases in Brazil.
    Vaccine. 2022 Jun 16. pii: S0264-410X(22)00761.
    >> Share

  83. GAMBRELL A, Sundaram M, Bednarczyk RA
    Estimating the number of US children susceptible to measles resulting from COVID-19-related vaccination coverage declines.
    Vaccine. 2022 Jun 15. pii: S0264-410X(22)00782.
    >> Share

  84. TSENG HF, Sy LS, Ackerson BK, Lee GS, et al
    Safety of tetanus, diphtheria, acellular pertussis (Tdap) vaccination during pregnancy.
    Vaccine. 2022 Jun 15. pii: S0264-410X(22)00756.
    >> Share

  85. BRAUNFELD JB, Carson HN, Williams SR, Schwartz LM, et al
    Clinical endpoints to inform vaccine policy: A systematic review of outcome measures from pediatric influenza vaccine efficacy trials.
    Vaccine. 2022 Jun 15. pii: S0264-410X(22)00778.
    >> Share

  86. ARAUJO BC, Simakawa R, Munhoz LG, Carmo FB, et al
    Rubella antibodies in vertically and horizontally HIV-infected young adults vaccinated early in life and response to a booster dose in those with seronegative results.
    Vaccine. 2022 Jun 15. pii: S0264-410X(22)00774.
    >> Share

  87. FOLEGATTI PM, Jenkin D, Morris S, Gilbert S, et al
    Vaccines based on the replication-deficient simian adenoviral vector ChAdOx1: Standardized template with key considerations for a risk/benefit assessment.
    Vaccine. 2022 Jun 14. pii: S0264-410X(22)00755.
    >> Share

  88. HERNANDEZ LM, Sumathy K, Sahastrabuddhe S, Excler JL, et al
    A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for an inactivated viral vaccine against Chikungunya virus.
    Vaccine. 2022 Jun 14. pii: S0264-410X(22)00753.
    >> Share

  89. CHUNG JR, Kim SS, Flannery B, Smith ME, et al
    Vaccine-associated attenuation of subjective severity among outpatients with influenza.
    Vaccine. 2022 Jun 14. pii: S0264-410X(22)00767.
    >> Share

  90. RAZZAGHI H, Yankey D, Vashist K, Lu PJ, et al
    COVID-19 vaccination coverage and intent among women aged 18-49 years by pregnancy status, United States, April-November 2021.
    Vaccine. 2022 Jun 13. pii: S0264-410X(22)00779.
    >> Share

  91. PHATARPHEKAR A, Vidyadhar Reddy GEC, Gokhale A, Karanam G, et al
    RelCoVax(R), a two antigen subunit protein vaccine candidate against SARS-CoV-2 induces strong immune responses in mice.
    Vaccine. 2022 Jun 13. pii: S0264-410X(22)00775.
    >> Share

  92. SHOOTS-REINHARD B, Lawrence ER, Schulkin J, Peters E, et al
    Excluding numeric side-effect information produces lower vaccine intentions.
    Vaccine. 2022 Jun 10. pii: S0264-410X(22)00747.
    >> Share

  93. ROLLIER CS, Dold C, Blackwell L, Linder A, et al
    Immunogenicity of a single 4CMenB vaccine booster in adolescents 11 years after childhood immunisation.
    Vaccine. 2022 Jun 10. pii: S0264-410X(22)00539.
    >> Share

  94. HEININGER U
    Referring to: Wilkinson K, Righolt CH, Elliott LJ, Fanella S, Mahmud SM. Pertussis vaccine effectiveness and duration of protection - a systematic review and meta-analysis. Vaccine. 2021 May 27;39(23):3120-3130.
    Vaccine. 2022;40:3530.
    >> Share

  95. WIEMKEN TL, Salas J, Hoft DF, Jacobs C, et al
    In response to: JVAC-D-21-02863, detection of a potential error in the results of the manuscript, dementia risk following influenza vaccination in a large veteran cohort, that could call into question the main conclusion.
    Vaccine. 2022;40:3529.
    >> Share

  96. VUICHARD-GYSIN D, Schoenenberger A
    Detection of a potential error in the results of the manuscript "Dementia risk following influenza vaccination in a large veteran cohort" that could eventually call into question the main conclusion.
    Vaccine. 2022;40:3528.
    >> Share

  97. SCHENK J, Abrams S, Litzroth A, Cornelissen L, et al
    Identifying immunity gaps for measles using Belgian serial serology data.
    Vaccine. 2022;40:3676-3683.
    >> Share

  98. POLLET J, Strych U, Chen WH, Versteeg L, et al
    Receptor-binding domain recombinant protein on alum-CpG induces broad protection against SARS-CoV-2 variants of concern.
    Vaccine. 2022;40:3655-3663.
    >> Share

  99. SPARROW E, Adetifa I, Chaiyakunapruk N, Cherian T, et al
    WHO preferred product characteristics for monoclonal antibodies for passive immunization against respiratory syncytial virus (RSV) disease in infants - Key considerations for global use.
    Vaccine. 2022;40:3506-3510.
    >> Share

  100. EVANS B, Jombart T
    Worldwide routine immunisation coverage regressed during the first year of the COVID-19 pandemic.
    Vaccine. 2022;40:3531-3535.
    >> Share

  101. ZHAO FJ, Liu LT, Wang Z, Wang NX, et al
    Development and immunogenicity evaluation of porcine deltacoronavirus inactivated vaccine with different adjuvants in mice.
    Vaccine. 2022 Jun 9. pii: S0264-410X(22)00721.
    >> Share

  102. HALME J, Syrjanen RK, Baum U, Palmu AA, et al
    Effectiveness of trivalent influenza vaccines against hospitalizations due to laboratory-confirmed influenza a in the elderly: Comparison of test-negative design with register-based designs.
    Vaccine. 2022 Jun 9. pii: S0264-410X(22)00716.
    >> Share

  103. KUNASEKARAN MP, Chughtai AA, Heslop DJ, Poulos CJ, et al
    Influenza cases in nine aged care facilities in Sydney, Australia over a three-year surveillance period, 2018-2020.
    Vaccine. 2022 Jun 9. pii: S0264-410X(22)00476.
    >> Share

  104. LEAV B, Straus W, White P, Leav A, et al
    A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for the Moderna COVID-19 Vaccine (mRNA-1273).
    Vaccine. 2022 Jun 9. pii: S0264-410X(22)00752.
    >> Share

  105. DIAZ-MENENDEZ M, de la Calle-Prieto F, Montejano R, Arsuaga M, et al
    Clinical characteristics and outcome of hospitalized elderly patients with COVID- 19 after vaccine failure.
    Vaccine. 2022 Jun 8. pii: S0264-410X(22)00751.
    >> Share

  106. LIGHTOWLER MS, Manangazira P, Nackers F, Van Herp M, et al
    Effectiveness of typhoid conjugate vaccine in Zimbabwe used in response to an outbreak among children and young adults: A matched case control study.
    Vaccine. 2022 Jun 8. pii: S0264-410X(22)00552.
    >> Share

  107. CHICHILI GR, Smulders R, Santos V, Cywin B, et al
    Phase 1/2 study of a novel 24-valent pneumococcal vaccine in healthy adults aged 18 to 64 years and in older adults aged 65 to 85 years.
    Vaccine. 2022 Jun 8. pii: S0264-410X(22)00715.
    >> Share

  108. OKUNO H, Satoh H, Morino S, Arai S, et al
    Characteristics and incidence of vaccine adverse events after Bacille Calmette-Guerin vaccination: A national surveillance study in Japan from 2013 to 2017.
    Vaccine. 2022 Jun 8. pii: S0264-410X(22)00672.
    >> Share

  109. LIN K, Liu M, Bao L, Lv Q, et al
    Safety and protective capability of an inactivated SARS-CoV-2 vaccine on pregnancy, lactation and the growth of offspring in hACE2 mice.
    Vaccine. 2022 Jun 8. pii: S0264-410X(22)00765.
    >> Share

  110. ZHANG H, Li Y, Peng S, Jiang Y, et al
    The effect of health literacy on COVID-19 vaccine hesitancy among community population in China: The moderating role of stress.
    Vaccine. 2022 Jun 8. pii: S0264-410X(22)00762.
    >> Share

  111. KOBAYASHI T, Nishina Y, Tomoi H, Harada K, et al
    Corowa-kun: A messenger app chatbot delivers COVID-19 vaccine information, Japan 2021.
    Vaccine. 2022 Jun 8. pii: S0264-410X(22)00754.
    >> Share

  112. BASS JR, Poland GA
    Shoulder injury related to vaccine administration (SIRVA) after COVID-19 vaccination.
    Vaccine. 2022 Jun 8. pii: S0264-410X(22)00750.
    >> Share

  113. NIESSEN FA, Knol MJ, Hahne SJM, Bonten MJM, et al
    Vaccine effectiveness against COVID-19 related hospital admission in the Netherlands: A test-negative case-control study.
    Vaccine. 2022 Jun 8. pii: S0264-410X(22)00758.
    >> Share

  114. SMITH WJ, Ahl PL, Wang B, Hamm M, et al
    Analytical technology development to monitor the stability of Polysaccharide-Protein conjugate vaccines.
    Vaccine. 2022 Jun 7. pii: S0264-410X(22)00673.
    >> Share

  115. SLOTTE P, Karlsson LC, Soveri A
    Attitudes towards mandatory vaccination and sanctions for vaccination refusal.
    Vaccine. 2022 Jun 7. pii: S0264-410X(22)00697.
    >> Share

  116. WALKER JL, Schultze A, Tazare J, Tamborska A, et al
    Safety of COVID-19 vaccination and acute neurological events: A self-controlled case series in England using the OpenSAFELY platform.
    Vaccine. 2022 Jun 7. pii: S0264-410X(22)00757.
    >> Share

  117. WYNBERG E, Han AX, Boyd A, van Willigen HDG, et al
    The effect of SARS-CoV-2 vaccination on post-acute sequelae of COVID-19 (PASC): A prospective cohort study.
    Vaccine. 2022 Jun 7. pii: S0264-410X(22)00748.
    >> Share

  118. DAYTON L, Miller J, Strickland J, Davey-Rothwell M, et al
    A socio-ecological perspective on parents' intentions to vaccinate their children against COVID-19.
    Vaccine. 2022 Jun 6. pii: S0264-410X(22)00736.
    >> Share

  119. EL-SHESHENY R, El Taweel A, Gomaa MR, Roshdy WH, et al
    Induced humoral immunity of different types of vaccines against most common variants of SARS-CoV-2 in Egypt prior to Omicron outbreak.
    Vaccine. 2022 Jun 6. pii: S0264-410X(22)00734.
    >> Share

  120. SHANMUGARAJ B, Khorattanakulchai N, Panapitakkul C, Malla A, et al
    Preclinical evaluation of a plant-derived SARS-CoV-2 subunit vaccine: Protective efficacy, immunogenicity, safety, and toxicity.
    Vaccine. 2022 Jun 6. pii: S0264-410X(22)00735.
    >> Share

  121. HASHIMOTO M, Nagata N, Homma T, Maeda H, et al
    Immunogenicity and protective efficacy of SARS-CoV-2 recombinant S-protein vaccine S-268019-b in cynomolgus monkeys.
    Vaccine. 2022 Jun 6. pii: S0264-410X(22)00718.
    >> Share

  122. EUGENIA-TOLEDO-ROMANI M, Verdecia-Sanchez L, Rodriguez-Gonzalez M, Rodriguez-Noda L, et al
    Safety and immunogenicity of anti-SARS CoV-2 vaccine SOBERANA 02 in homologous or heterologous scheme: Open label phase I and phase IIa clinical trials.
    Vaccine. 2022 Jun 6. pii: S0264-410X(22)00717.
    >> Share

  123. FLYNN JA, Weber T, Cejas PJ, Cox KS, et al
    Characterization of humoral and cell-mediated immunity induced by mRNA vaccines expressing influenza hemagglutinin stem and nucleoprotein in mice and nonhuman primates.
    Vaccine. 2022 Jun 6. pii: S0264-410X(22)00382.
    >> Share

  124. SLARVE M, Holznecht N, Reza H, Gilkes A, et al
    Recombinant Aspergillus fumigatus antigens Asp f 3 and Asp f 9 in liposomal vaccine protect mice against invasive pulmonary aspergillosis.
    Vaccine. 2022 Jun 6. pii: S0264-410X(22)00674.
    >> Share

  125. WATANABE A, Nishida S, Burcu T, Shibahara T, et al
    Safety and immunogenicity of a quadrivalent seasonal influenza vaccine adjuvanted with hydroxypropyl-beta-cyclodextrin: A phase 1 clinical trial.
    Vaccine. 2022 Jun 4. pii: S0264-410X(22)00677.
    >> Share

  126. AB RAHMAN N, Lim MT, Lee FY, Lee SC, et al
    Risk of serious adverse events after the BNT162b2, CoronaVac, and ChAdOx1 vaccines in Malaysia: A self-controlled case series study.
    Vaccine. 2022 Jun 3. pii: S0264-410X(22)00700.
    >> Share

  127. JANSSEN DF
    A familiar species of Crank: Anti-Vaccinationists in medical history.
    Vaccine. 2022 Jun 3. pii: S0264-410X(22)00665.
    >> Share

  128. BILGIN GM, Lokuge K, Glass K
    Modelling the impact of maternal pneumococcal vaccination on infant pneumococcal disease in low-income settings.
    Vaccine. 2022 Jun 3. pii: S0264-410X(22)00684.
    >> Share

  129. STEAD M, Ford A, Eadie D, Biggs H, et al
    A "step too far" or "perfect sense"? A qualitative study of British adults' views on mandating COVID-19 vaccination and vaccine passports.
    Vaccine. 2022 Jun 3. pii: S0264-410X(22)00696.
    >> Share

    May 2022
  130. AHMED S, Iqbal J, Sadiq K, Umrani F, et al
    Association of Anti-Rotavirus IgA Seroconversion with Growth, Environmental Enteric Dysfunction and Enteropathogens in Rural Pakistani Infants.
    Vaccine. 2022;40:3444-3451.
    >> Share

  131. PILLSBURY M, Carias C, Samant S, Greenberg D, et al
    Comparison of performance of varicella vaccines via infectious disease modeling.
    Vaccine. 2022 May 31. pii: S0264-410X(22)00574.
    >> Share

  132. HISYAM BIN ISMAIL CMK, Raihan Mohammad Shabani N, Chuah C, Hassan Z, et al
    Shigella iron-binding proteins: An insight into molecular physiology, pathogenesis, and potential target vaccine development.
    Vaccine. 2022 May 31. pii: S0264-410X(22)00679.
    >> Share

  133. TOOR J, Li X, Jit M, Trotter CL, et al
    COVID-19 impact on routine immunisations for vaccine-preventable diseases: Projecting the effect of different routes to recovery.
    Vaccine. 2022 May 30. pii: S0264-410X(22)00698.
    >> Share

  134. WOO EJ, Dimova RB
    Thrombocytopenia after Ad.26.COV2.S COVID-19 vaccine: Reports to the vaccine adverse event reporting system.
    Vaccine. 2022 May 30. pii: S0264-410X(22)00704.
    >> Share

  135. MERRICK E, Weissman JP, Patel SJ
    Utilizing Google trends to monitor coronavirus vaccine interest and hesitancies.
    Vaccine. 2022 May 30. pii: S0264-410X(22)00699.
    >> Share

  136. FISHMAN J, Salmon MK, Scheitrum D, Aleks Schaefer K, et al
    Comparative effectiveness of mandates and financial policies targeting COVID-19 vaccine hesitancy: A randomized, controlled survey experiment.
    Vaccine. 2022 May 30. pii: S0264-410X(22)00702.
    >> Share

  137. HEMMING-HARLO M, Gylling A, Herse F, Haavisto I, et al
    Long-term surveillance of rotavirus vaccination after implementation of a national immunization program in Finland (2008-2018).
    Vaccine. 2022 May 28. pii: S0264-410X(22)00584.
    >> Share

  138. KLEINWAKS G, Schmit V, Morrison J
    Corrigendum to "Considering human challenge trials for tuberculosis vaccine development" [Vaccine 40(2) (2022) 173-174].
    Vaccine. 2022 May 28. pii: S0264-410X(22)00675.
    >> Share

  139. SHAPIRO BEN DAVID S, Mizrahi B, Rahamim-Cohen D, Supino-Rosin L, et al
    Robust antibody response after a third BNT162b2 vaccine compared to the second among immunocompromised and healthy individuals, a prospective longitudinal cohort study.
    Vaccine. 2022 May 28. pii: S0264-410X(22)00668.
    >> Share

  140. SHIOHARA M, Suzuki S, Shichinohe S, Ishigaki H, et al
    Inactivated whole influenza virus particle vaccines induce neutralizing antibodies with an increase in immunoglobulin gene subclones of B-lymphocytes in cynomolgus macaques.
    Vaccine. 2022 May 28. pii: S0264-410X(22)00640.
    >> Share

  141. RODES-SANCHEZ M, Spencer J, Tantri A, Mitrovich R, et al
    Working towards a sustainable, healthy market for vaccines: A framework to support evidence-based policymaking.
    Vaccine. 2022 May 27. pii: S0264-410X(22)00671.
    >> Share

  142. MACDONALD NE, Dube E, Comeau JL
    Have vaccine hesitancy models oversimplified a complex problem to our detriment? The Adapted Royal Society of Canada vaccine uptake framework.
    Vaccine. 2022 May 27. pii: S0264-410X(22)00669.
    >> Share

  143. SAVULESCU C, Krizova P, Valentiner-Branth P, Ladhani S, et al
    Effectiveness of 10 and 13-valent pneumococcal conjugate vaccines against invasive pneumococcal disease in European children: SpIDnet observational multicentre study.
    Vaccine. 2022 May 27. pii: S0264-410X(22)00581.
    >> Share

  144. LAI X, Li M, Hou Z, Guo J, et al
    Factors associated with caregivers' hesitancy to vaccinate children against influenza: A cross-sectional survey in China.
    Vaccine. 2022 May 27. pii: S0264-410X(22)00606.
    >> Share

  145. PATEL KM, Shafiq M, Malik AA, Cobanoglu A, et al
    Relationship between the use of nonpharmaceutical interventions and COVID-19 vaccination among U.S. child care providers: A prospective cohort study.
    Vaccine. 2022 May 27. pii: S0264-410X(22)00680.
    >> Share

  146. SOEGIARTO G, Wulandari L, Purnomosari D, Dhia Fahmita K, et al
    Hypertension is associated with antibody response and breakthrough infection in health care workers following vaccination with inactivated SARS-CoV-2.
    Vaccine. 2022 May 27. pii: S0264-410X(22)00676.
    >> Share

  147. DUBE C, Paris-Robidas S, Andreani G, Gutzeit C, et al
    Broad neutralization against SARS-CoV-2 variants induced by ancestral and B.1.351 AS03-Adjuvanted recombinant Plant-Derived Virus-Like particle vaccines.
    Vaccine. 2022 May 27. pii: S0264-410X(22)00641.
    >> Share

  148. MOSS P, Berenbaum F, Curigliano G, Grupper A, et al
    Benefit-risk evaluation of COVID-19 vaccination in special population groups of interest.
    Vaccine. 2022 May 27. pii: S0264-410X(22)00682.
    >> Share

  149. HALSTEAD IN, McKay RT, Lewis GJ
    COVID-19 and seasonal flu vaccination hesitancy: Links to personality and general intelligence in a large, UK cohort.
    Vaccine. 2022 May 27. pii: S0264-410X(22)00678.
    >> Share

  150. MOUSSAOUI S, Combes S, Ibanez G, Gautier A, et al
    Are immigrants living in France more reluctant to receive vaccines than native-born French citizens? findings from the national health Barometer study.
    Vaccine. 2022 May 26. pii: S0264-410X(22)00636.
    >> Share

  151. ILESANMI MM, Adeyinka DA, Olakunde BO
    Sustainable Development Goals and childhood measles vaccination in Ekiti State, Nigeria: Results from spatial and interrupted time series analyses.
    Vaccine. 2022 May 26. pii: S0264-410X(22)00632.
    >> Share

  152. LARSEN L, Bistrup C, Sorensen SS, Boesby L, et al
    Immunogenicity and safety of double dosage of pneumococcal vaccines in adult kidney transplant recipients and waiting list patients: A non-blinded, randomized clinical trial.
    Vaccine. 2022 May 26. pii: S0264-410X(22)00635.
    >> Share

  153. TAFURI S, Bianchi FP, Stefanizzi P
    The public health and the question of the "best vaccine".
    Vaccine. 2022 May 26. pii: S0264-410X(22)00639.
    >> Share

  154. HOFFMAN BL, Batra Hershey T, Chu KH, Sidani JE, et al
    Moving vaccination beyond partisan politics.
    Vaccine. 2022 May 26. pii: S0264-410X(22)00664.
    >> Share

  155. ZHOU Y, Hu X, Chen R, Wu J, et al
    Impact of maternal and pre-existing antibodies on immunogenicity of inactivated rotavirus vaccines.
    Vaccine. 2022 May 26. pii: S0264-410X(22)00620.
    >> Share

  156. JANKO MM, Joffe J, Michael D, Earl L, et al
    Cost-effectiveness of rotavirus vaccination in children under five years of age in 195 countries: A meta-regression analysis.
    Vaccine. 2022 May 25. pii: S0264-410X(22)00637.
    >> Share

  157. DUBE E, Gagnon D, MacDonald N
    Between persuasion and compulsion: The case of COVID-19 vaccination in Canada.
    Vaccine. 2022 May 25. pii: S0264-410X(22)00670.
    >> Share

  158. GAGHAN C, Adams D, Mohammed J, Crespo R, et al
    Characterization of vaccine-induced immune responses against coccidiosis in broiler chickens.
    Vaccine. 2022 May 25. pii: S0264-410X(22)00638.
    >> Share

  159. ABRAHAM N, Spruin S, Rossi T, Fireman B, et al
    Myocarditis and/or pericarditis risk after mRNA COVID-19 vaccination: A Canadian head to head comparison of BNT162b2 and mRNA-1273 vaccines.
    Vaccine. 2022 May 25. pii: S0264-410X(22)00667.
    >> Share

  160. BECK E, Biundo E, Devlin N, Doherty TM, et al
    Capturing the value of vaccination within health technology assessment and health economics: Literature review and novel conceptual framework.
    Vaccine. 2022 May 23. pii: S0264-410X(22)00490.
    >> Share

  161. MALTER KB, Tugel ME, Gil-Rodriguez M, de la Guardia G, et al
    Corrigendum to "Variability in non-core vaccination rates of dogs and cats in veterinary clinics across the United States" [Vaccine 40(7) (2022) 1001-1009].
    Vaccine. 2022 May 23. pii: S0264-410X(22)00619.
    >> Share

  162. QUINN MK, Edmond KM, Fawzi WW, Hurt L, et al
    Non-specific effects of BCG and DTP vaccination on infant mortality: An analysis of birth cohorts in Ghana and Tanzania.
    Vaccine. 2022 May 23. pii: S0264-410X(22)00536.
    >> Share

  163. CHANG CM, Awanye AM, Marsay L, Dold C, et al
    Application of a Neisseria meningitidis antigen microarray to identify candidate vaccine proteins from a human Phase I clinical trial.
    Vaccine. 2022 May 21. pii: S0264-410X(22)00616.
    >> Share

  164. MOLLER A, Schwamborn K, Spillmann A, Hoogstraate J, et al
    Travel vaccines are strongly associated to reduced mortality in prostate cancer patients - a real effect or residual confounding?
    Vaccine. 2022 May 21. pii: S0264-410X(22)00611.
    >> Share

  165. OSMAN S, Crowcroft N, McLachlan E, Hatchette T, et al
    Population immunity to measles in Canada using Canadian Health Measures survey data - A Canadian Immunization Research Network (CIRN) study.
    Vaccine. 2022;40:3228-3235.
    >> Share

  166. LLAVE CL, Uy MEV, Lam HY, Aldaba JG, et al
    The cost-effectiveness of human papillomavirus vaccination in the Philippines.
    Vaccine. 2022 May 20. pii: S0264-410X(22)00609.
    >> Share

  167. FOO D, Sarna M, Pereira G, Moore HC, et al
    Maternal influenza vaccination and child mortality: Longitudinal, population-based linked cohort study.
    Vaccine. 2022 May 20. pii: S0264-410X(22)00614.
    >> Share

  168. KITCHEN M, Leierer G, Kistner O, Wodal W, et al
    High seroprotection rates and geometric mean titre increases after repeated annual influenza vaccinations in a cohort of HIV-infected adults in Austria.
    Vaccine. 2022 May 20. pii: S0264-410X(22)00575.
    >> Share

  169. MCELFISH PA, Selig JP, Scott AJ, Rowland B, et al
    Associations between 5-year influenza vaccination and sociodemographic factors and healthcare access among Arkansans.
    Vaccine. 2022 May 20. pii: S0264-410X(22)00615.
    >> Share

  170. SZANYI J, Wilson T, Scott N, Blakely T, et al
    A log-odds system for waning and boosting of COVID-19 vaccine effectiveness.
    Vaccine. 2022 May 20. pii: S0264-410X(22)00634.
    >> Share

  171. SIQUEIRA PG, Duarte HO, Moura MDC
    Risk-based cost-benefit analysis of alternative vaccines against COVID-19 in Brazil: Coronavac vs. Astrazeneca vs. Pfizer.
    Vaccine. 2022 May 19. pii: S0264-410X(22)00633.
    >> Share

  172. CARSON B, Isaacs J, Carilli T
    Jabbing together? The complementarity between social capital, formal public health rules, and COVID-19 vaccine rates in the United States.
    Vaccine. 2022 May 19. pii: S0264-410X(22)00612.
    >> Share

  173. STEELFISHER GK, Caporello H, McIntosh R, Muhammad Safdar R, et al
    Preventing erosion of oral polio vaccine acceptance: A role for vaccinator visits and social norms.
    Vaccine. 2022 May 19. pii: S0264-410X(22)00567.
    >> Share

  174. ZHANG Y, Lin L, Yang J, Lv Q, et al
    Two Bordetella bronchiseptica attenuated vaccine candidates confer protection against lethal challenge with B. Bronchiseptica and Pasteurella multocida toxin in mouse models.
    Vaccine. 2022 May 19. pii: S0264-410X(22)00604.
    >> Share

  175. POSTMA M, Biundo E, Chicoye A, Devlin N, et al
    Capturing the value of vaccination within health technology assessment and health economics: Country analysis and priority value concepts.
    Vaccine. 2022 May 18. pii: S0264-410X(22)00442.
    >> Share

  176. VESIKARI T, Saez-Llorens X, Blazevic V, Lopez P, et al
    Immunogenicity of a bivalent virus-like particle norovirus vaccine in children from 1 to 8 years of age: A phase 2 randomized, double-blind study.
    Vaccine. 2022 May 17. pii: S0264-410X(22)00550.
    >> Share

  177. SALO-TUOMINEN K, Teros-Jaakkola T, Toivonen L, Ollila H, et al
    Parental socioeconomic and psychological determinants of the 2009 pandemic influenza A(H1N1) vaccine uptake in children.
    Vaccine. 2022 May 17. pii: S0264-410X(22)00582.
    >> Share

  178. ROBERTSON DA, Mohr KS, Barjakova M, Lunn PD, et al
    Experimental pre-tests of public health communications on the COVID-19 vaccine: A null finding for medical endorsement, risk and altruism.
    Vaccine. 2022 May 16. pii: S0264-410X(22)00613.
    >> Share

  179. NAZURDINOV A, Azizov Z, Mullojonova M, Sadykova U, et al
    Impact and effectiveness of monovalent rotavirus vaccine in Tajik children.
    Vaccine. 2022 May 14. pii: S0264-410X(22)00589.
    >> Share

  180. SULIS G, Horn M, Borrow R, Basta NE, et al
    A comparison of national vaccination policies to prevent serogroup B meningococcal disease.
    Vaccine. 2022 May 14. pii: S0264-410X(22)00568.
    >> Share

  181. POLAND GA, van Dijk N
    John D. Bailey retiring after more than 20years of service to Vaccine.
    Vaccine. 2022 May 13. pii: S0264-410X(22)00618.
    >> Share

  182. CHAMBERS C, Deeks SL, Sutradhar R, Cox J, et al
    Increases in human papillomavirus vaccine coverage over 12 months among a community-recruited cohort of gay, bisexual, and other men who have sex with men in Canada.
    Vaccine. 2022 May 13. pii: S0264-410X(22)00590.
    >> Share

  183. KUMAR SURI R, Hayman B, Prasad SD, Makhoana M, et al
    Vaccines: New challenges, new paradigms, new opportunities: Report of the 22nd DCVMN Annual General Meeting.
    Vaccine. 2022 May 13. pii: S0264-410X(22)00576.
    >> Share

  184. DUC DANG A, Dinh Vu T, Hai Vu H, Thanh Ta V, et al
    Safety and immunogenicity of an egg-based inactivated Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomized, placebo-controlled, phase 1/2 trial in Vietnam.
    Vaccine. 2022 May 13. pii: S0264-410X(22)00526.
    >> Share

  185. TSAI SY, Yeh TY, Chiu NC, Huang CT, et al
    National safety surveillance of quadrivalent recombinant influenza vaccine in Taiwan during NH 20/21.
    Vaccine. 2022 May 13. pii: S0264-410X(22)00588.
    >> Share

  186. RUSKIN AC, Rice S, O'Connor M, Ruskin KJ, et al
    Effects of vaccination status in the United States on willingness to undergo surgery during a pandemic: A prospective survey study.
    Vaccine. 2022 May 13. pii: S0264-410X(22)00583.
    >> Share

  187. LI F, Freed D, Heidecker G, Galli J, et al
    A novel high throughput assay to quantify Epstein-Barr virus neutralizing antibody activity against B-cell and epithelial cell infections for vaccine and therapeutic developments.
    Vaccine. 2022 May 13. pii: S0264-410X(22)00569.
    >> Share

  188. IWATA S, Sonoyama T, Kamitani A, Shibata R, et al
    Phase 1/2 clinical trial of COVID-19 vaccine in Japanese participants: A report of interim findings.
    Vaccine. 2022 May 13. pii: S0264-410X(22)00494.
    >> Share

  189. ALYA WA, Maraqa B, Nazzal Z, Odeh M, et al
    COVID-19 vaccine uptake and its associated factors among Palestinian healthcare workers: Expectations beaten by reality.
    Vaccine. 2022 May 13. pii: S0264-410X(22)00610.
    >> Share

  190. MANCARELLA M, Natarelli F, Bertolini C, Zagari A, et al
    Catch-up vaccination campaign in children between 6 and 8 years old during COVID-19 pandemic: The experience in a COVID hub in Milan, Italy.
    Vaccine. 2022 May 12. pii: S0264-410X(22)00573.
    >> Share

  191. CUMMINS NW, Badley AD
    Could proteasome inhibition improve therapeutic vaccine response in HIV?
    Vaccine. 2022 May 12. pii: S0264-410X(22)00578.
    >> Share

  192. CHONG-VALBUENA A, De-Jesus-Maria I, Agurto-Ramirez A, Puchades-Gimeno F, et al
    Safety of Pfizer-BioNTech vaccine in a cohort of healthcare providers: Differences between naive and previously infected by SARS-CoV-2.
    Vaccine. 2022 May 12. pii: S0264-410X(22)00586.
    >> Share

  193. OSTER G, Bornheimer R, Ottino K, Stevenson C, et al
    Adult immunization against hepatitis B: Does the number of jabs matter?
    Vaccine. 2022 May 12. pii: S0264-410X(22)00534.
    >> Share

  194. TEASDALE CA, Ratzan S, Stuart Lathan H, Rauh L, et al
    Acceptability of COVID-19 vaccine mandates among New York City parents, November 2021.
    Vaccine. 2022 May 11. pii: S0264-410X(22)00580.
    >> Share

  195. SHAUM A, Mujuru HA, Takamiya M, Ticklay I, et al
    Enhanced surveillance for adverse events following immunization during the 2019 typhoid conjugate vaccine campaign in Harare, Zimbabwe.
    Vaccine. 2022 May 11. pii: S0264-410X(22)00551.
    >> Share

  196. FERNANDES C, Alves J, Rodrigues A, Azevedo J, et al
    Corrigendum to "Epidemiological impact of the human papillomavirus vaccination program on genital warts in Portugal: A retrospective, chart review study" [Vaccine 40(2) (2022) 275-281].
    Vaccine. 2022 May 11. pii: S0264-410X(22)00537.
    >> Share

  197. ISLAM N, Xu C, Lau CL, Mills DJ, et al
    Persistence of antibodies, boostability, and interchangeability of Japanese encephalitis vaccines: A systematic review and dose-response meta-analysis.
    Vaccine. 2022 May 11. pii: S0264-410X(22)00535.
    >> Share

  198. GUPTA C, Sachdeva A, Khamar J, Bu C, et al
    Effectiveness of the influenza vaccine at reducing adverse events in patients with heart failure: A systematic review and meta-analysis.
    Vaccine. 2022 May 10. pii: S0264-410X(22)00468.
    >> Share

  199. KITRO A, Sirikul W, Thongkum W, Soponpong S, et al
    Dynamic of anti-spike receptor binding domain (RBD) levels and short-term adverse events following a heterologous booster dose of BNT162b2 after two doses of CoronaVac in Thai health care workers.
    Vaccine. 2022;40:2915-2924.
    >> Share

  200. MARTIN J, Barrett ADT, Lei D, Minor P, et al
    WHO working group meeting to amend WHO Recommendations to assure the quality, safety and efficacy of live attenuated yellow fever vaccines.
    Vaccine. 2022 May 9. pii: S0264-410X(22)00548.
    >> Share

  201. ZOLA MATUVANGA T, Lariviere Y, Lemey G, De Bie J, et al
    Setting-up an Ebola vaccine trial in a remote area of the Democratic Republic of the Congo: Challenges, mitigations, and lessons learned.
    Vaccine. 2022 May 9. pii: S0264-410X(22)00544.
    >> Share

  202. YI S, Choe YJ, Lim DS, Lee HR, et al
    Impact of national Covid-19 vaccination Campaign, South Korea.
    Vaccine. 2022 May 8. pii: S0264-410X(22)00572.
    >> Share

  203. BIFULCO M, Di Zazzo E, Pisanti S, Martini M, et al
    The nineteenth-century experience of the kingdom of the two Sicilies on mandatory vaccination: An Italian phenomenon?
    Vaccine. 2022 May 6. pii: S0264-410X(22)00492.
    >> Share

  204. CROTHERS JW, Ross Colgate E, Cowan KJ, Dickson DM, et al
    Corrigendum to "Intradermal fractional-dose inactivated polio vaccine (fIPV) adjuvanted with double mutant Enterotoxigenic Escherichia coli heat labile toxin (dmLT) is well-tolerated and augments a systemic immune response to all three poliovirus sero
    Vaccine. 2022 May 6. pii: S0264-410X(22)00571.
    >> Share

  205. LUMBRERAS ARETA M, Valiton A, Diana A, Morales M, et al
    Flu and pertussis vaccination during pregnancy in Geneva during the COVID-19 pandemic: A multicentric, prospective, survey-based study.
    Vaccine. 2022 May 6. pii: S0264-410X(22)00533.
    >> Share

  206. YU Y, Ma YL, Luo S, Wang S, et al
    Prevalence and factors of influenza vaccination during the COVID-19 pandemic among university students in China.
    Vaccine. 2022 May 5. pii: S0264-410X(22)00532.
    >> Share

  207. COLE JW, Chen AMH, McGuire K, Berman S, et al
    Erratum to "Motivational interviewing and vaccine acceptance in children: The MOTIVE study" [Vaccine 40(12) (2022) 1846-1854].
    Vaccine. 2022 May 5. pii: S0264-410X(22)00538.
    >> Share

  208. VELICER C, Luxembourg A, Chen YT, Kohn M, et al
    Using observational data to explore the hypothesis that a single dose of current HPV vaccines can provide durable protection.
    Vaccine. 2022 May 5. pii: S0264-410X(22)00542.
    >> Share

  209. NAULT L, Marchitto L, Goyette G, Tremblay-Sher D, et al
    Covid-19 vaccine immunogenicity in people living with HIV-1.
    Vaccine. 2022 May 5. pii: S0264-410X(22)00543.
    >> Share

  210. GASTEIGER N, Gasteiger C, Vedhara K, Broadbent E, et al
    Characteristics associated with the willingness to receive a COVID-19 vaccine and an exploration of the general public's perceptions: A mixed-methods approach.
    Vaccine. 2022 May 5. pii: S0264-410X(22)00547.
    >> Share

  211. REES F, Geiger M, Lilleholt L, Zettler I, et al
    Measuring parents' readiness to vaccinate themselves and their children against COVID-19.
    Vaccine. 2022 May 5. pii: S0264-410X(22)00549.
    >> Share

  212. LEIGH JP, Moss SJ, White TM, Picchio CA, et al
    Factors affecting COVID-19 vaccine hesitancy among healthcare providers in 23 countries.
    Vaccine. 2022 May 5. pii: S0264-410X(22)00545.
    >> Share

  213. PERSSON U, Olofsson S, Althin R, Palmborg A, et al
    Acceptance and application of a broad population health perspective when evaluating vaccine.
    Vaccine. 2022 May 4. pii: S0264-410X(22)00425.
    >> Share

  214. LIU W, Lien YH, Lee PI, Chan TC, et al
    Impact of prior infection and repeated vaccination on post-vaccination antibody titers of the influenza A(H1N1)pdm09 strain in Taiwan schoolchildren: Implications for public health.
    Vaccine. 2022 May 4. pii: S0264-410X(22)00358.
    >> Share

  215. GUTIERREZ-TOBAR IF, Londono-Ruiz JP, Marino-Drews C, Beltran-Higuera S, et al
    Epidemiological characteristics and serotype distribution of culture-confirmed pediatric pneumococcal pneumonia before and after PCV 10 introduction, a multicenter study in Bogota, Colombia, 2008-2019.
    Vaccine. 2022;40:2875-2883.
    >> Share

  216. BOTHUN LS, Feeder SE, Poland GA
    Readability of COVID-19 vaccine information for the general public.
    Vaccine. 2022 May 3. pii: S0264-410X(22)00546.
    >> Share

  217. NANTANEE R, Aikphaibul P, Jaru-Ampornpan P, Sodsai P, et al
    Immunogenicity and reactogenicity after booster dose with AZD1222 via intradermal route among adult who had received CoronaVac.
    Vaccine. 2022 May 2. pii: S0264-410X(22)00521.
    >> Share

  218. FEIKIN DR, Abu-Raddad LJ, Andrews N, Davies MA, et al
    Assessing vaccine effectiveness against severe COVID-19 disease caused by omicron variant. Report from a meeting of the World Health Organization.
    Vaccine. 2022 May 2. pii: S0264-410X(22)00523.
    >> Share

    April 2022
  219. TOLL M, Li A
    Vaccine mandates on childcare entry without conscientious objection exemptions: A quasi-experimental panel study.
    Vaccine. 2022 Apr 29. pii: S0264-410X(22)00461.
    >> Share

  220. GREYSON D, Carpiano RM, Bettinger JA
    Support for a vaccination documentation mandate in British Columbia, Canada.
    Vaccine. 2022 Apr 29. pii: S0264-410X(22)00247.
    >> Share

  221. TAMURA K, Kohnoe M, Takashino A, Kobayashi K, et al
    TAK - 021, an inactivated Enterovirus 71 vaccine candidate, provides cross-protection against heterologous sub-genogroups in human scavenger receptor B2 transgenic mice.
    Vaccine. 2022 Apr 29. pii: S0264-410X(22)00518.
    >> Share

  222. MASUDA T, Murakami K, Sugiura K, Sakui S, et al
    Safety and immunogenicity of NVX-CoV2373 (TAK-019) vaccine in healthy Japanese adults: Interim report of a phase I/II randomized controlled trial.
    Vaccine. 2022 Apr 29. pii: S0264-410X(22)00463.
    >> Share

  223. HUSSAIN B, Latif A, Timmons S, Nkhoma K, et al
    Overcoming COVID-19 vaccine hesitancy among ethnic minorities: A systematic review of UK studies.
    Vaccine. 2022 Apr 28. pii: S0264-410X(22)00446.
    >> Share

  224. DEMIR E, Dheir H, Safak S, Serra Artan A, et al
    Differences in clinical outcomes of COVID-19 among vaccinated and unvaccinated kidney transplant recipients.
    Vaccine. 2022 Apr 27. pii: S0264-410X(22)00519.
    >> Share

  225. TAMURA K, Chang B, Shimbashi R, Watanabe H, et al
    Dynamic changes in clinical characteristics and serotype distribution of invasive pneumococcal disease among adults in Japan after introduction of the pediatric 13-valent pneumococcal conjugate vaccine in 2013-2019.
    Vaccine. 2022 Apr 27. pii: S0264-410X(22)00502.
    >> Share

  226. NASREEN S, Calzavara A, Buchan SA, Thampi N, et al
    Background incidence rates of adverse events of special interest related to COVID-19 vaccines in Ontario, Canada, 2015 to 2020, to inform COVID-19 vaccine safety surveillance.
    Vaccine. 2022 Apr 27. pii: S0264-410X(22)00520.
    >> Share

  227. LV H, Wang S, Liang Z, Yu W, et al
    Immunogenicity and safety of the 9-valent human papillomavirus vaccine in Chinese females 9-45 years of age: A phase 3 open-label study.
    Vaccine. 2022 Apr 26. pii: S0264-410X(22)00205.
    >> Share

  228. MARKOVITZ NH, Strome AL, Patel PK
    Commentary: "The vaccine Selfie" and its influence on COVID-19 vaccine acceptance.
    Vaccine. 2022 Apr 26. pii: S0264-410X(22)00503.
    >> Share

  229. JAFFLIN K, Deml MJ, Schwendener CL, Kiener L, et al
    Parental and provider vaccine hesitancy and non-timely childhood vaccination in Switzerland.
    Vaccine. 2022 Apr 26. pii: S0264-410X(22)00472.
    >> Share

  230. KOULIDIATI JL, Kabore R, I Nebie E, Sidibe A, et al
    Timely completion of childhood vaccination and its predictors in Burkina Faso.
    Vaccine. 2022 Apr 26. pii: S0264-410X(22)00497.
    >> Share

  231. MCCOSKER LK, El-Heneidy A, Seale H, Ware RS, et al
    Strategies to improve vaccination rates in people who are homeless: A systematic review.
    Vaccine. 2022 Apr 25. pii: S0264-410X(22)00436.
    >> Share

  232. KRUPP K, Galea J, Madhivanan P, Gerald L, et al
    Conversational artificial intelligence: A new approach for increasing influenza vaccination rates in children with asthma?
    Vaccine. 2022 Apr 25. pii: S0264-410X(22)00496.
    >> Share

  233. YUKI Y, Nojima M, Kashima K, Sugiura K, et al
    Oral MucoRice-CTB vaccine is safe and immunogenic in healthy US adults.
    Vaccine. 2022 Apr 25. pii: S0264-410X(22)00491.
    >> Share

  234. ZHU FC, Zeng H, Li JX, Wang B, et al
    Evaluation of a recombinant five-antigen Staphylococcus aureus vaccine: The randomized, single-centre phase 1a/1b clinical trials.
    Vaccine. 2022 Apr 23. pii: S0264-410X(22)00462.
    >> Share

  235. PERCIACCANTE A, Asensi V, Cucu AI, Charlier P, et al
    War, pandemic and vaccination - Upcoming health problems by the refugee wave in Europe?
    Vaccine. 2022 Apr 23. pii: S0264-410X(22)00465.
    >> Share

  236. BEYER WEP, Palache AM, Boulfich M, Osterhaus ADME, et al
    Clinical relevance of increased antibody titres in older adults upon vaccination with squalene-adjuvanted versus non-adjuvanted influenza vaccines.
    Vaccine. 2022 Apr 23. pii: S0264-410X(22)00489.
    >> Share

  237. STRECKENBACH B, Baldt J, Heidler F, Frahm N, et al
    General vaccination willingness and current vaccination status in relation to clinical and psychological variables in patients with multiple sclerosis.
    Vaccine. 2022 Apr 23. pii: S0264-410X(22)00428.
    >> Share

  238. ONNIS V, Moriconi A, Paludi M, Giannini S, et al
    Clinically proven specification setting for a meningococcal serogroup a conjugate vaccine.
    Vaccine. 2022 Apr 23. pii: S0264-410X(22)00493.
    >> Share

  239. ANTONOPOULOU T, Athanassakis I
    SARS-CoV-2 immunogenicity: Is S protein the best target for vaccination?
    Vaccine. 2022 Apr 22. pii: S0264-410X(22)00501.
    >> Share

  240. SHEA LL, Becker A, Lee BK, Miller KK, et al
    Self-reported COVID-19 vaccination acceptance and hesitancy among autistic adults.
    Vaccine. 2022 Apr 22. pii: S0264-410X(22)00500.
    >> Share

  241. HAMID FA, Marker CL, Raleigh MD, Khaimraj A, et al
    Pre-clinical safety and toxicology profile of a candidate vaccine to treat oxycodone use disorder.
    Vaccine. 2022 Apr 22. pii: S0264-410X(22)00364.
    >> Share

  242. SEPPALA E, Brathen Kristoffersen A, Boas H, Frimann Vestrheim D, et al
    Pertussis epidemiology including direct and indirect effects of the childhood pertussis booster vaccinations, Norway, 1998-2019.
    Vaccine. 2022 Apr 22. pii: S0264-410X(22)00466.
    >> Share

  243. BEULENS C, Raven SFH, van Jaarsveld CHM, van Loo I, et al
    Evaluation of a personalized, dose-sparing revaccination strategy in hepatitis B vaccine non-responders.
    Vaccine. 2022 Apr 22. pii: S0264-410X(22)00470.
    >> Share

  244. STALPERS CAL, Retmana IA, Pennings JLA, Vandebriel RJ, et al
    Corrigendum to "Variability of in vivo potency tests of Diphtheria, Tetanus and acellular Pertussis (DTaP) vaccines" [Vaccine 39(18) (2021) 2506-2516].
    Vaccine. 2022 Apr 22. pii: S0264-410X(22)00475.
    >> Share

  245. SALO H, Lehtonen T, Auranen K, Baum U, et al
    Predictors of hospitalisation and death due to SARS-CoV-2 infection in Finland: A population-based register study with implications to vaccinations.
    Vaccine. 2022 Apr 22. pii: S0264-410X(22)00495.
    >> Share

  246. TAMANG ST, Dorji T
    COVID-19 vaccinations in Bhutan - Mix-and-Match to Boosters: An experience.
    Vaccine. 2022 Apr 22. pii: S0264-410X(22)00499.
    >> Share

  247. ORTIZ JR, Spearman PW, Goepfert PA, Cross K, et al
    Safety and immunogenicity of monovalent H7N9 influenza vaccine with AS03 adjuvant given sequentially or simultaneously with a seasonal influenza vaccine: A randomized clinical trial.
    Vaccine. 2022 Apr 21. pii: S0264-410X(22)00366.
    >> Share

  248. CAN G, Acar HC, Aydin SN, Balkan II, et al
    Waning effectiveness of CoronaVac in real life: A retrospective cohort study in health care workers.
    Vaccine. 2022;40:2574-2579.
    >> Share

  249. LEBLANC JJ, ElSherif M, Ye L, MacKinnon-Cameron D, et al
    Recalibrated estimates of non-bacteremic and bacteremic pneumococcal community acquired pneumonia in hospitalized Canadian adults from 2010 to 2017 with addition of an extended spectrum serotype-specific urine antigen detection assay.
    Vaccine. 2022;40:2635-2646.
    >> Share

  250. THOMPSON D, Metz SW, Abad C, Beaty S, et al
    Immunological implications of diverse production approaches for Chikungunya virus-like particle vaccines.
    Vaccine. 2022 Apr 19. pii: S0264-410X(22)00435.
    >> Share

  251. GARTNER BC, Weinke T, Wahle K, Kwetkat A, et al
    Importance and value of adjuvanted influenza vaccine in the care of older adults from a European perspective - A systematic review of recently published literature on real-world data.
    Vaccine. 2022 Apr 19. pii: S0264-410X(22)00440.
    >> Share

  252. LI L, Honda-Okubo Y, Baldwin J, Bowen R, et al
    Covax-19/Spikogen(R) vaccine based on recombinant spike protein extracellular domain with Advax-CpG55.2 adjuvant provides single dose protection against SARS-CoV-2 infection in hamsters.
    Vaccine. 2022 Apr 18. pii: S0264-410X(22)00469.
    >> Share

  253. WANLAPAKORN N, Suntronwong N, Phowatthanasathian H, Yorsaeng R, et al
    Immunogenicity of heterologous inactivated and adenoviral-vectored COVID-19 vaccine: Real-world data.
    Vaccine. 2022 Apr 18. pii: S0264-410X(22)00471.
    >> Share

  254. SAADE A, Cha L, Tadie E, Jurado B, et al
    Delay between COVID-19 complete vaccination and SARS-CoV-2 infection among healthcare workers.
    Vaccine. 2022 Apr 18. pii: S0264-410X(22)00473.
    >> Share

  255. CHRISSIAN AA, Oyoyo UE, Patel P, Lawrence Beeson W, et al
    Impact of COVID-19 vaccine-associated side effects on health care worker absenteeism and future booster vaccination.
    Vaccine. 2022 Apr 18. pii: S0264-410X(22)00474.
    >> Share

  256. XU S, Hong V, Sy LS, Glenn SC, et al
    Changes in incidence rates of outcomes of interest in vaccine safety studies during the COVID-19 pandemic.
    Vaccine. 2022 Apr 18. pii: S0264-410X(22)00464.
    >> Share

  257. SINGH BK, Walker J, Paul P, Reddy S, et al
    De-escalation of asymptomatic testing and potential of future COVID-19 outbreaks in US nursing homes amidst rising community vaccination coverage: A modeling study.
    Vaccine. 2022 Apr 18. pii: S0264-410X(22)00467.
    >> Share

  258. ANDERSON A
    Attitudes towards vaccination and knowledge about antibiotics: Analysis of Wellcome Monitor survey data.
    Vaccine. 2022 Apr 15. pii: S0264-410X(22)00429.
    >> Share

  259. BAROUTSOU V, Wymann M, Zens K, Sinniger P, et al
    National and regional variations in timely adherence to recommended measles vaccination scheme in 2-years old in Switzerland, 2005-2019.
    Vaccine. 2022 Apr 15. pii: S0264-410X(22)00424.
    >> Share

  260. KUSHNER T, Huang V, Janssen R
    Safety and immunogenicity of HepB-CpG in women with documented pregnancies post-vaccination: A retrospective chart review.
    Vaccine. 2022 Apr 13. pii: S0264-410X(22)00443.
    >> Share

  261. FENOLLAR F, Thomas L, Raoult D, Gautret P, et al
    Screening for SARS-CoV-2 antibodies to save vaccine doses.
    Vaccine. 2022 Apr 12. pii: S0264-410X(22)00444.
    >> Share

  262. YAN Y, Naito T, Tabe Y, Ito K, et al
    Increased delta variant SARS-CoV-2 infections in a highly vaccinated medical center in Japan.
    Vaccine. 2022 Apr 12. pii: S0264-410X(22)00445.
    >> Share

  263. BRAEYE T, Catteau L, Brondeel R, van Loenhout JAF, et al
    Vaccine effectiveness against onward transmission of SARS-CoV2-infection by variant of concern and time since vaccination, Belgian contact tracing, 2021.
    Vaccine. 2022 Apr 12. pii: S0264-410X(22)00441.
    >> Share

  264. MORO PL, Olson CK, Clark E, Marquez P, et al
    Post-authorization surveillance of adverse events following COVID-19 vaccines in pregnant persons in the vaccine adverse event reporting system (VAERS), December 2020 - October 2021.
    Vaccine. 2022 Apr 12. pii: S0264-410X(22)00447.
    >> Share

  265. ZHU XM, Yan W, Sun J, Liu L, et al
    Patterns and influencing factors of COVID-19 vaccination willingness among college students in China.
    Vaccine. 2022 Apr 11. pii: S0264-410X(22)00433.
    >> Share

  266. SHINJOH M, Furuichi M, Kobayashi H, Yamaguchi Y, et al
    Trends in effectiveness of inactivated influenza vaccine in children by age groups in seven seasons immediately before the COVID-19 era.
    Vaccine. 2022 Apr 11. pii: S0264-410X(22)00449.
    >> Share

  267. SPRINGER S, Kaatz M, Zieger M
    Evaluation of weekly COVID-19 vaccination and case data supports negative correlation between incidence and vaccination in German federal states and cities during 4th wave.
    Vaccine. 2022 Apr 11. pii: S0264-410X(22)00430.
    >> Share

  268. CEYLAN ME, Onen Unsalver B, Donmez A, Kaya Yertutanol FD, et al
    A case of myocarditis and isolated hypopotassemia after Biontech-Pfizer vaccine for Covid-19.
    Vaccine. 2022 Apr 11. pii: S0264-410X(22)00432.
    >> Share

  269. LJUNG R, Feychting M, Burstrom B, Moller J, et al
    Differences by region of birth in SARS-CoV-2 vaccine coverage and positive SARS-CoV-2 test among 400 000 healthcare workers and the general population in Sweden.
    Vaccine. 2022 Apr 11. pii: S0264-410X(22)00431.
    >> Share

  270. OKTARIA V, Bines JE, Murni IK, Dinari R, et al
    Timeliness of routine childhood vaccinations in Indonesian infants in the first year of life.
    Vaccine. 2022 Apr 11. pii: S0264-410X(22)00420.
    >> Share

  271. BENINGER P
    Need for a contingency dimension when planning vaccine development in a pandemic environment.
    Vaccine. 2022 Apr 11. pii: S0264-410X(22)00401.
    >> Share

  272. PARK SJ, Kang YM, Cho HK, Kim DY, et al
    Corrigendum to 'Cross-protective efficacy of inactivated whole influenza vaccines against Korean Y280 and Y439 lineage H9N2 viruses in mice' [Vaccine 39 (2021) 6213-6220].
    Vaccine. 2022 Apr 9. pii: S0264-410X(22)00221.
    >> Share

  273. AINSLIE KEC, Riley S
    Is annual vaccination best? A modelling study of influenza vaccination strategies in children.
    Vaccine. 2022 Apr 8. pii: S0264-410X(22)00384.
    >> Share

  274. TIANSHUO Z, Hanyu L, Bingfeng H, Bei L, et al
    Evaluation of the reliability and validity of a vaccine hesitancy scale on knowledge, attitude, trust and vaccination environment (KATE-S) in Chinese parents.
    Vaccine. 2022 Apr 8. pii: S0264-410X(22)00388.
    >> Share

  275. MAYFIELD HJ, Lau CL, Sinclair JE, Brown SJ, et al
    Designing an evidence-based Bayesian network for estimating the risk versus benefits of AstraZeneca COVID-19 vaccine.
    Vaccine. 2022 Apr 8. pii: S0264-410X(22)00418.
    >> Share

  276. BELDA F, Mora O, Lopez Martinez M, Torres N, et al
    Seroconversion panels demonstrate anti-SARS-CoV-2 antibody development after administration of the mRNA-1273 vaccine.
    Vaccine. 2022 Apr 8. pii: S0264-410X(22)00419.
    >> Share

  277. ERFANI P, Sandoval RS, Rich KM, Ojo A, et al
    Ask Me Anything": Lessons learned in implementing a COVID-19 vaccine information initiative in Massachusetts jails.
    Vaccine. 2022 Apr 8. pii: S0264-410X(22)00439.
    >> Share

  278. KENIGSBERG TA, Hause AM, McNeil MM, Nelson JC, et al
    Dashboard development for near real-time visualization of COVID-19 vaccine safety surveillance data in the vaccine safety datalink.
    Vaccine. 2022 Apr 8. pii: S0264-410X(22)00426.
    >> Share

  279. LINKINS LA, Iorio A, Little J, Lavis J, et al
    Extended reporting guidance for vaccine effectiveness studies for variants of concern for COVID-19.
    Vaccine. 2022 Apr 7. pii: S0264-410X(22)00422.
    >> Share

  280. DE-LOS-RIOS-PINTO A, Fernandez-Guzman D, Soriano-Moreno DR, Sangster-Carrasco L, et al
    Factors associated with the intention to participate in COVID-19 vaccine clinical trials: A cross-sectional study in Peru.
    Vaccine. 2022 Apr 7. pii: S0264-410X(22)00421.
    >> Share

  281. SHAH S, Gui H, Chua PEY, Tan JB, et al
    Factors associated with COVID-19 vaccination intent in Singapore, Australia and Hong Kong.
    Vaccine. 2022 Apr 5. pii: S0264-410X(22)00381.
    >> Share

  282. HASSAN PM, Ali T, Saber E, Asghar A, et al
    Potency, toxicity and protection evaluation of PastoCoAd candidate vaccines: Novel preclinical mix and match rAd5 S, rAd5 RBD-N and SOBERANA dimeric-RBD protein.
    Vaccine. 2022 Apr 4. pii: S0264-410X(22)00385.
    >> Share

  283. LEWIS RM, Markowitz LE
    Disparities in human papillomavirus vaccination coverage in the United States, National Health and Nutrition Examination Survey, January 2017-March 2020.
    Vaccine. 2022 Apr 4. pii: S0264-410X(22)00317.
    >> Share

  284. WALTERS JN, Schouest B, Patel A, Reuschel EL, et al
    Prime-boost vaccination regimens with INO-4800 and INO-4802 augment and broaden immune responses against SARS-CoV-2 in nonhuman primates.
    Vaccine. 2022 Apr 4. pii: S0264-410X(22)00368.
    >> Share

  285. ENTRICAN G, Francis MJ
    Applications of platform technologies in veterinary vaccinology and the benefits for one health.
    Vaccine. 2022 Apr 2. pii: S0264-410X(22)00371.
    >> Share

  286. FRISE R, Baillon L, Zhou J, Kugathasan R, et al
    A self-amplifying RNA vaccine protects against SARS-CoV-2 (D614G) and Alpha variant of concern (B.1.1.7) in a transmission-challenge hamster model.
    Vaccine. 2022 Apr 1. pii: S0264-410X(22)00383.
    >> Share

  287. MA C, Sun W, Tang T, Jia M, et al
    Effectiveness of adenovirus type 5 vectored and inactivated COVID-19 vaccines against symptomatic COVID-19, COVID-19 pneumonia, and severe COVID-19 caused by the B.1.617.2 (Delta) variant: Evidence from an outbreak in Yunnan, China, 2021.
    Vaccine. 2022 Apr 1. pii: S0264-410X(22)00386.
    >> Share

  288. SUGHAYER MA, Souan L, Abu Alhowr MM, Al Rimawi D, et al
    Comparison of the effectiveness and duration of anti-RBD SARS-CoV-2 IgG antibody response between different types of vaccines: Implications for vaccine strategies.
    Vaccine. 2022 Apr 1. pii: S0264-410X(22)00387.
    >> Share

    March 2022
  289. GERTOSIO C, Licari A, De Silvestri A, Rebuffi C, et al
    Efficacy, immunogenicity, and safety of available vaccines in children on biologics: A systematic review and meta-analysis.
    Vaccine. 2022 Mar 31. pii: S0264-410X(22)00341.
    >> Share

  290. TEJADA RA, Malagon T, Franco EL
    Cost-effectiveness of human papillomavirus vaccination in girls living in Latin American countries: A systematic review and meta-analysis.
    Vaccine. 2022 Mar 31. pii: S0264-410X(22)00357.
    >> Share

  291. VANDOORN E, Parys A, Chepkwony S, Chiers K, et al
    Efficacy of the NS1-truncated live attenuated influenza virus vaccine for swine against infection with viruses of major North American and European H3N2 lineages.
    Vaccine. 2022 Mar 30. pii: S0264-410X(22)00362.
    >> Share

  292. BURNY W, Herve C, Caubet M, Yarzabal JP, et al
    Utility of urinary cytokine levels as predictors of the immunogenicity and reactogenicity of AS01-adjuvanted hepatitis B vaccine in healthy adults.
    Vaccine. 2022 Mar 30. pii: S0264-410X(22)00361.
    >> Share

  293. CROTHERS JW, Ross Colgate E, Cowan KJ, Dickson DM, et al
    Intradermal fractional-dose inactivated polio vaccine (fIPV) adjuvanted with double mutant Enterotoxigenic Escherichia coli heat labile toxin (dmLT) is well-tolerated and augments a systemic immune response to all three poliovirus serotypes in a rando
    Vaccine. 2022 Mar 30. pii: S0264-410X(22)00367.
    >> Share

  294. EFUA SACKEY M, Markey K, Grealish A
    Healthcare professional's promotional strategies in improving Human papillomavirus (HPV) vaccination uptake in adolescents: A systematic review.
    Vaccine. 2022 Mar 30. pii: S0264-410X(22)00365.
    >> Share

  295. TADDIO A, Gudzak V, Jantzi M, Logeman C, et al
    Impact of the CARD (Comfort Ask Relax Distract) system on school-based vaccinations: A cluster randomized trial.
    Vaccine. 2022 Mar 29. pii: S0264-410X(22)00224.
    >> Share

  296. MCRAE J, Blyth CC, Cheng AC, Quinn HE, et al
    Preventing severe influenza in Australian infants: Maternal influenza vaccine effectiveness in the PAEDS-FluCAN networks using the test-negative design.
    Vaccine. 2022 Mar 29. pii: S0264-410X(22)00353.
    >> Share

  297. ESTIVARIZ CF, Kovacs SD, Mach O
    Review of use of inactivated poliovirus vaccine in campaigns to control type 2 circulating vaccine derived poliovirus (cVDPV) outbreaks.
    Vaccine. 2022 Mar 29. pii: S0264-410X(22)00304.
    >> Share

  298. ISITT C, Sjoholm D, Hergens MP, Granath F, et al
    The early impact of vaccination against SARS-CoV-2 in Region Stockholm, Sweden.
    Vaccine. 2022 Mar 29. pii: S0264-410X(22)00372.
    >> Share

  299. KATO H, Miyakawa K, Ohtake N, Yamaoka Y, et al
    Vaccine-induced humoral response against SARS-CoV-2 dramatically declined but cellular immunity possibly remained at 6 months post BNT162b2 vaccination.
    Vaccine. 2022 Mar 29. pii: S0264-410X(22)00369.
    >> Share

  300. LI K, Yu T, Seabury SA, Dor A, et al
    Trends and disparities in the utilization of influenza vaccines among commercially insured US adults during the COVID-19 pandemic.
    Vaccine. 2022 Mar 29. pii: S0264-410X(22)00370.
    >> Share

  301. JUDDOO V, Juddoo S, Megarbane B
    Erythema nodosum triggered by BNT162b2 mRNA COVID-19 vaccine.
    Vaccine. 2022 Mar 28. pii: S0264-410X(22)00363.
    >> Share

  302. BREAKWELL L, Marke D, Kaiser R, Tejada-Strop A, et al
    Assessing the impact of the routine childhood hepatitis B immunization program and the need for hepatitis B vaccine birth dose in Sierra Leone, 2018.
    Vaccine. 2022 Mar 28. pii: S0264-410X(22)00360.
    >> Share

  303. FUNK PR, Yogurtcu ON, Forshee RA, Anderson SA, et al
    Benefit-risk assessment of COVID-19 vaccine, mRNA (Comirnaty) for age 16-29 years.
    Vaccine. 2022 Mar 28. pii: S0264-410X(22)00329.
    >> Share

  304. WELLS K, Moore KL, Bednarczyk R
    Supporting immunization programs to address COVID-19 vaccine hesitancy: Recommendations for national and community-based stakeholders.
    Vaccine. 2022 Mar 28. pii: S0264-410X(22)00339.
    >> Share

  305. RICKETSON LJ, Bettinger JA, Sadarangani M, Halperin SA, et al
    Vaccine effectiveness of the 7-valent and 13-valent pneumococcal conjugate vaccines in Canada: An IMPACT study.
    Vaccine. 2022 Mar 26. pii: S0264-410X(22)00359.
    >> Share

  306. SIMMONS LA, Whipps MDM, Phipps JE, Satish NS, et al
    Understanding COVID-19 vaccine uptake during pregnancy: 'Hesitance', knowledge, and evidence-based decision-making.
    Vaccine. 2022 Mar 25. pii: S0264-410X(22)00355.
    >> Share

  307. FARAH W, Breeher L, Shah V, Hainy C, et al
    Disparities in COVID-19 vaccine uptake among health care workers.
    Vaccine. 2022 Mar 25. pii: S0264-410X(22)00356.
    >> Share

  308. NOMURA Y, Noda K, Oohashi Y, Okuda S, et al
    Proposal for the revision of the guidelines for Non-clinical studies of vaccines for the prevention of infectious diseases in Japan.
    Vaccine. 2022 Mar 24. pii: S0264-410X(22)00354.
    >> Share

  309. NANTHAPISAL S, Puthanakit T, Jaru-Ampornpan P, Nantanee R, et al
    A randomized clinical trial of a booster dose with low versus standard dose of AZD1222 in adult after 2 doses of inactivated vaccines.
    Vaccine. 2022 Mar 24. pii: S0264-410X(22)00336.
    >> Share

  310. ST JEAN DT, Rogawski McQuade ET, Edwards JK, Thompson P, et al
    Effect of early life antibiotic use on serologic responses to oral rotavirus vaccine in the MAL-ED birth cohort study.
    Vaccine. 2022 Mar 24. pii: S0264-410X(22)00300.
    >> Share

  311. LEACH K, Checchi F
    The utilisation of vaccines in humanitarian crises, 2015-2019: A review of practice.
    Vaccine. 2022 Mar 24. pii: S0264-410X(22)00335.
    >> Share

  312. VOORMAN A, Lyons H, Bennette C, Kovacs S, et al
    Analysis of population immunity to poliovirus following cessation of trivalent oral polio vaccine.
    Vaccine. 2022 Mar 23. pii: S0264-410X(22)00277.
    >> Share

  313. LIU X, Yu W, Yin Z, Rodewald L, et al
    Vaccine events raising public concern and associated immunization program policy and practice changes, China, 2005-2021.
    Vaccine. 2022 Mar 23. pii: S0264-410X(22)00334.
    >> Share

  314. ABDEL-QADER DH, Hazza Alkhatatbeh I, Hayajneh W, Annab H, et al
    IgA nephropathy in a pediatric patient after receiving the first dose of Pfizer-BioNTech COVID-19 vaccine.
    Vaccine. 2022 Mar 23. pii: S0264-410X(22)00265.
    >> Share

  315. SNIDER CJ, Boualam L, Tallis G, Takashima Y, et al
    Concurrent outbreaks of circulating vaccine-derived poliovirus types 1 and 2 affecting the Republic of the Philippines and Malaysia, 2019-2021.
    Vaccine. 2022 Mar 22. pii: S0264-410X(22)00145.
    >> Share

  316. MALTEZOU HC, Medic S, Cassimos DC, Effraimidou E, et al
    Decreasing routine vaccination rates in children in the COVID-19 era.
    Vaccine. 2022 Mar 22. pii: S0264-410X(22)00333.
    >> Share

  317. FANO V, Crielesi A, Coviello E, Fabiani M, et al
    Effectiveness of the Comirnaty and the Vaxzevria vaccines in preventing SARS-CoV-2 infection among residents in Lazio region (Italy).
    Vaccine. 2022 Mar 22. pii: S0264-410X(22)00208.
    >> Share

  318. FERDINANDS JM, Patel M
    Influence of disease attenuation on relative influenza vaccine effectiveness by vaccine type.
    Vaccine. 2022 Mar 21. pii: S0264-410X(22)00274.
    >> Share

  319. JIAN-BIN L, Lau EYH, Chan DKC
    Why do Hong Kong parents have low intention to vaccinate their children against COVID-19? testing health belief model and theory of planned behavior in a large-scale survey.
    Vaccine. 2022 Mar 21. pii: S0264-410X(22)00340.
    >> Share

  320. YUEN WLP, Loh SYJ, Wang DB
    SIRVA (Shoulder Injury Related to Vaccine Administration) following mRNA COVID-19 Vaccination: Case discussion and literature review.
    Vaccine. 2022 Mar 21. pii: S0264-410X(22)00337.
    >> Share

  321. ZERBO O, Modaressi S, Goddard K, Lewis E, et al
    Safety of measles and pertussis-containing vaccines in children with autism spectrum disorders.
    Vaccine. 2022 Mar 18. pii: S0264-410X(22)00331.
    >> Share

  322. CALLAGHAN T, Washburn D, Goidel K, Nuzhath T, et al
    Imperfect messengers? An analysis of vaccine confidence among primary care physicians.
    Vaccine. 2022 Mar 18. pii: S0264-410X(22)00302.
    >> Share

  323. ESPOSITO S, Nauta J, Lapini G, Montomoli E, et al
    Efficacy and safety of a quadrivalent influenza vaccine in children aged 6-35 months: A global, multiseasonal, controlled, randomized Phase III study.
    Vaccine. 2022 Mar 18. pii: S0264-410X(22)00263.
    >> Share

  324. BILGIN H, Marku M, Yilmaz SS, Karahasan Yagci A, et al
    The effect of immunization with inactivated SARS-CoV-2 vaccine (CoronaVac) and/or SARS-CoV-2 infection on antibody levels, plasmablasts, long-lived-plasma-cells, and IFN-gamma release by natural killer cells.
    Vaccine. 2022 Mar 18. pii: S0264-410X(22)00264.
    >> Share

  325. GRUHN S, Witte J, Greiner W, Damm O, et al
    Epidemiology and economic burden of meningococcal disease in Germany: A systematic review.
    Vaccine. 2022;40:1932-1947.
    >> Share

  326. WANG H, Ypma E, Nicolay U
    Managing multiplicity in clinical vaccine studies - A case study using a gatekeeping testing strategy.
    Vaccine. 2022 Mar 17. pii: S0264-410X(22)00244.
    >> Share

  327. GRAFFIGNA G, Palamenghi L, Barello S, Boccia S, et al
    Erratum to ""Cultivating" acceptance of a COVID-19 vaccination program: Lessons from Italy" [Vaccine 38(48) (2020) 7585-7586].
    Vaccine. 2022 Mar 17. pii: S0264-410X(22)00295.
    >> Share

  328. BATOOL R, Yousafzai MT, Qureshi S, Ali M, et al
    Corrigendum to "Effectiveness of typhoid conjugate vaccine against culture-confirmed typhoid in a peri-urban setting in Karachi: A case-control study". [Vaccine 39 (2021) 5858-5865].
    Vaccine. 2022 Mar 17. pii: S0264-410X(22)00294.
    >> Share

  329. MACKLIN G, Peak C, Eisenhawer M, Kurji F, et al
    Enabling accelerated vaccine roll-out for Public Health Emergencies of International Concern (PHEICs): Novel Oral Polio Vaccine type 2 (nOPV2) experience.
    Vaccine. 2022 Mar 17. pii: S0264-410X(22)00195.
    >> Share

  330. SADIGH K, Fox G, Khetsuriani N, Gao H, et al
    Policy and practice of checking vaccination status at school in 2018, a global overview.
    Vaccine. 2022 Mar 17. pii: S0264-410X(22)00266.
    >> Share

  331. GAO Z, Chen L, Song T, Pan X, et al
    A candidate multi-epitope vaccine against porcine reproductive and respiratory syndrome virus and Mycoplasma hyopneumoniae induces robust humoral and cellular response in mice.
    Vaccine. 2022 Mar 17. pii: S0264-410X(22)00296.
    >> Share

  332. GUL A, Doskaya M, Can H, Karakavuk M, et al
    Immunogenicity of a xenogeneic multi-epitope HER2(+) breast cancer DNA vaccine targeting the dendritic cell restricted antigen-uptake receptor DEC205.
    Vaccine. 2022 Mar 16. pii: S0264-410X(22)00279.
    >> Share

  333. BEESLAAR J, Mather S, Absalon J, Eiden JJ, et al
    Safety data from the MenB-FHbp clinical development program in healthy individuals aged 10 years and older.
    Vaccine. 2022;40:1872-1878.
    >> Share

  334. KHETSURIANI N, Zaika O, Slobodianyk L, Scobie HM, et al
    Diphtheria and tetanus seroepidemiology among children in Ukraine, 2017.
    Vaccine. 2022;40:1810-1820.
    >> Share

  335. CAMARA J, Gonzalez-Diaz A, Barrabeig I, Fernandez-Huerta M, et al
    SARS-CoV-2 outbreak in a nursing home after vaccination with BNT162b2: A role for the quantification of circulating antibodies.
    Vaccine. 2022 Mar 15. pii: S0264-410X(22)00303.
    >> Share

  336. ROTOLO B, Dube E, Vivion M, MacDonald SE, et al
    Hesitancy towards COVID-19 vaccines on social media in Canada.
    Vaccine. 2022 Mar 15. pii: S0264-410X(22)00301.
    >> Share

  337. MOSCARDINO U, Musso P, Inguglia C, Ceccon C, et al
    Sociodemographic and psychological correlates of COVID-19 vaccine hesitancy and resistance in the young adult population in Italy.
    Vaccine. 2022 Mar 14. pii: S0264-410X(22)00293.
    >> Share

  338. MORGA A, Kimura T, Feng Q, Rozario N, et al
    Compliance to Advisory Committee on Immunization Practices recommendations for pneumococcal vaccination.
    Vaccine. 2022 Mar 12. pii: S0264-410X(22)00269.
    >> Share

  339. LAMORI J, Feng X, Pericone CD, Mesa-Frias M, et al
    Real-world evidence on adherence and completion of the two-dose recombinant zoster vaccine and associated factors in U.S. adults, 2017-2021.
    Vaccine. 2022 Mar 12. pii: S0264-410X(22)00268.
    >> Share

  340. HUANG HJ, Yang M, Chen HW, Wang S, et al
    A novel chimeric dengue vaccine candidate composed of consensus envelope protein domain III fused to C-terminal-modified NS1 protein.
    Vaccine. 2022 Mar 11. pii: S0264-410X(22)00225.
    >> Share

  341. GU YOON J, Jang AY, Ja Kim M, Bin Seo Y, et al
    Persistent serotype 3 and 19A invasive pneumococcal diseases in adults in vaccine era: Serotype-dependent difference in ceftriaxone susceptibility.
    Vaccine. 2022 Mar 10. pii: S0264-410X(22)00267.
    >> Share

  342. KAKATSAKI I, Vergadi E, Paraskakis E, Galanakis E, et al
    Attitudes of junior healthcare professionals towards mandatory vaccination.
    Vaccine. 2022 Mar 10. pii: S0264-410X(22)00275.
    >> Share

  343. HARUTYUNYAN V, Quddus A, Pallansch M, Zipursky S, et al
    Global oral poliovirus vaccine stockpile management as an essential preparedness and response mechanism for type 2 poliovirus outbreaks following global oral poliovirus vaccine type 2 withdrawal.
    Vaccine. 2022 Mar 10. pii: S0264-410X(22)00204.
    >> Share

  344. VAN DEN HOOGEN LL, Smits G, van Hagen CCE, Wong D, et al
    Seropositivity to Nucleoprotein to detect mild and asymptomatic SARS-CoV-2 infections: A complementary tool to detect breakthrough infections after COVID-19 vaccination?
    Vaccine. 2022 Mar 9. pii: S0264-410X(22)00272.
    >> Share

  345. THOMAS CM, Searle K, Galvan A, Liebman AK, et al
    Healthcare worker perspectives on COVID-19 vaccines: Implications for increasing vaccine acceptance among healthcare workers and patients.
    Vaccine. 2022 Mar 9. pii: S0264-410X(22)00276.
    >> Share

  346. WILKINSON K, Righolt CH, Kwong JC, Schwartz KL, et al
    Corrigendum to "A nested case-control study measuring pertussis vaccine effectiveness and duration of protection in Manitoba, Canada, 1992-2015: A Canadian Immunization Research Network Study" [Vaccine 37(48) (2019) 7132-7137].
    Vaccine. 2022 Mar 7. pii: S0264-410X(22)00240.
    >> Share

  347. YUEN VWH
    Political attitudes and efficacy of health expert communication on the support for COVID-19 vaccination program: Findings from a survey in Hong Kong.
    Vaccine. 2022 Mar 7. pii: S0264-410X(22)00261.
    >> Share

  348. BANSAL P, Raj A, Mani Shukla D, Sunder N, et al
    COVID-19 vaccine preferences in India.
    Vaccine. 2022 Mar 7. pii: S0264-410X(22)00241.
    >> Share

  349. ULRICH AK, Sundaram ME, Basta NE
    Supporting individual vaccine decision-making: A role for vaccination counselors.
    Vaccine. 2022 Mar 4. pii: S0264-410X(22)00135.
    >> Share

  350. MASCHERINI M, Nivakoski S
    Social media use and vaccine hesitancy in the European Union.
    Vaccine. 2022 Mar 3. pii: S0264-410X(22)00206.
    >> Share

  351. KLUMPP M, Monfared IG, Vollmer S
    Public opinion on global distribution of COVID-19 vaccines: Evidence from two nationally representative surveys in Germany and the United States.
    Vaccine. 2022 Mar 3. pii: S0264-410X(22)00259.
    >> Share

  352. COULAUD PJ, Ablona A, Bolduc N, Fast D, et al
    COVID-19 vaccine intention among young adults: Comparative results from a cross-sectional study in Canada and France.
    Vaccine. 2022 Mar 3. pii: S0264-410X(22)00260.
    >> Share

  353. ROBERTSON LJ, Price R, Moore JS, Curry G, et al
    IgG antibody production and persistence to 6 months following SARS-CoV-2 vaccination: A Northern Ireland observational study.
    Vaccine. 2022 Mar 3. pii: S0264-410X(22)00262.
    >> Share

  354. KREPS SE, Kriner DL
    How do COVID-19 vaccine mandates affect attitudes toward the vaccine and participation in mandate-affected activities? Evidence from the United States.
    Vaccine. 2022 Mar 2. pii: S0264-410X(22)00258.
    >> Share

  355. WONDIMU A, Postma MJ, van Hulst M
    Cost-effectiveness analysis of quadrivalent and nonavalent human papillomavirus vaccines in Ethiopia.
    Vaccine. 2022 Mar 2. pii: S0264-410X(22)00245.
    >> Share

  356. YU M, Yao X, Liu G, Wu J, et al
    Barriers and facilitators to uptake and promotion of influenza vaccination among health care workers in the community in Beijing, China: A qualitative study.
    Vaccine. 2022 Mar 2. pii: S0264-410X(22)00207.
    >> Share

  357. POINTON L, Howe AS, Hobbs M, Paynter J, et al
    Evidence of suboptimal maternal vaccination coverage in pregnant New Zealand women and increasing inequity over time: A nationwide retrospective cohort study.
    Vaccine. 2022 Mar 2. pii: S0264-410X(22)00243.
    >> Share

  358. LAI FTT, Leung MTY, Chan EWW, Huang L, et al
    Self-reported reactogenicity of CoronaVac (Sinovac) compared with Comirnaty (Pfizer-BioNTech): A prospective cohort study with intensive monitoring.
    Vaccine. 2022;40:1390-1396.
    >> Share

  359. DENNY L
    HPV vaccine introduction and implementation in LMICs.
    Vaccine. 2022 Mar 1. pii: S0264-410X(22)00227.
    >> Share

  360. GU J, Dor A, Li K, Broniatowski DA, et al
    The impact of Facebook's vaccine misinformation policy on user endorsements of vaccine content: An interrupted time series analysis.
    Vaccine. 2022 Mar 1. pii: S0264-410X(22)00209.
    >> Share

  361. SEXSON TEJTEL SK, Munoz FM, Al-Ammouri I, Savorgnan F, et al
    Myocarditis and pericarditis: Case definition and guidelines for data collection, analysis, and presentation of immunization safety data.
    Vaccine. 2022;40:1499-1511.
    >> Share

  362. MOURA C, Truche P, Sousa Salgado L, Meireles T, et al
    The impact of COVID-19 on routine pediatric vaccination delivery in Brazil.
    Vaccine. 2022 Mar 1. pii: S0264-410X(22)00242.
    >> Share

    February 2022
  363. SINGH JA, Kochhar S, Wolff J, Atuire C, et al
    WHO guidance on COVID-19 vaccine trial designs in the context of authorized COVID-19 vaccines and expanding global access: Ethical considerations.
    Vaccine. 2022 Feb 28. pii: S0264-410X(22)00175.
    >> Share

  364. MCANDREW T, Cambeiro J, Besiroglu T
    Aggregating human judgment probabilistic predictions of the safety, efficacy, and timing of a COVID-19 vaccine.
    Vaccine. 2022 Feb 28. pii: S0264-410X(22)00200.
    >> Share

  365. LAU YL, Fan Leung T, Sirvan Cetin B, Cagri Dinleyici E, et al
    Safety and reactogenicity of a liquid formulation of human rotavirus vaccine (porcine circovirus-free): A phase III, observer-blind, randomized, multi-country study.
    Vaccine. 2022 Feb 26. pii: S0264-410X(22)00218.
    >> Share

  366. SALIOU P, Duteil Q, Plotkin SA, Gentilini M, et al
    The scourge of vaccine falsification.
    Vaccine. 2022 Feb 26. pii: S0264-410X(22)00119.
    >> Share

  367. SCHAFER W, Reinders T, Schink T
    Second dose of measles-mumps-rubella-varicella vaccine (MMRV) and the risk of febrile convulsions.
    Vaccine. 2022 Feb 26. pii: S0264-410X(22)00222.
    >> Share

  368. DANIELS V, Saxena K, Patterson-Lomba O, Gomez-Lievano A, et al
    Modeling the health and economic implications of adopting a 1-dose 9-valent human papillomavirus vaccination regimen in a high-income country setting: An analysis in the United Kingdom.
    Vaccine. 2022 Feb 26. pii: S0264-410X(22)00220.
    >> Share

  369. KAGEYAMA T, Tanaka S, Etori K, Hattori K, et al
    Immunological features that associate with the strength of antibody responses to BNT162b2 mRNA vaccine against SARS-CoV-2.
    Vaccine. 2022 Feb 25. pii: S0264-410X(22)00192.
    >> Share

  370. MULLER KE, Dohos D, Sipos Z, Kiss S, et al
    Immune response to influenza and pneumococcal vaccines in adults with inflammatory bowel disease: A systematic review and meta-analysis of 1429 patients.
    Vaccine. 2022 Feb 25. pii: S0264-410X(22)00163.
    >> Share

  371. MCGOLDRICK M, Gastineau T, Wilkinson D, Campa C, et al
    How to accelerate the supply of vaccines to all populations worldwide? Part II: Initial industry lessons learned and detailed technical reflections leveraging the COVID-19 situation.
    Vaccine. 2022;40:1223-1230.
    >> Share

  372. MCGOLDRICK M, Gastineau T, Wilkinson D, Campa C, et al
    How to accelerate the supply of vaccines to all populations worldwide? Part I: Initial industry lessons learned and practical overarching proposals leveraging the COVID-19 situation.
    Vaccine. 2022;40:1215-1222.
    >> Share

  373. DIXON MG, Tapia MD, Wannemuehler K, Luce R, et al
    Measles susceptibility in maternal-infant dyads-Bamako, Mali.
    Vaccine. 2022;40:1316-1322.
    >> Share

  374. HAO F, Shao W
    Understanding the influence of political orientation, social network, and economic recovery on COVID-19 vaccine uptake among Americans.
    Vaccine. 2022 Feb 22. pii: S0264-410X(22)00219.
    >> Share

  375. NIE J, Sun Y, Feng K, Huang L, et al
    The efficient development of a novel recombinant adenovirus zoster vaccine perfusion production process.
    Vaccine. 2022 Feb 22. pii: S0264-410X(22)00159.
    >> Share

  376. EL-HENEIDY A, Grimwood K, Lambert SB, Sarna M, et al
    Association between vaccination status, symptom identification and healthcare use: Implications for test negative design observational studies.
    Vaccine. 2022 Feb 22. pii: S0264-410X(22)00198.
    >> Share

  377. ABBATECOLA AM, Incalzi RA, Malara A, Palmieri A, et al
    Monitoring COVID-19 vaccine use in Italian long term care centers: The GeroCovid VAX study.
    Vaccine. 2022 Feb 22. pii: S0264-410X(22)00217.
    >> Share

  378. CHOOI WH, Ng PW, Hussain Z, Ming LC, et al
    Vaccine contamination: Causes and control.
    Vaccine. 2022 Feb 21. pii: S0264-410X(22)00169.
    >> Share

  379. TAWINPRAI K, Siripongboonsitti T, Porntharukchareon T, Wittayasak K, et al
    Immunogenicity and safety of an intradermal fractional third dose of ChAdOx1 nCoV-19/AZD1222 vaccine compared with those of a standard intramuscular third dose in volunteers who previously received two doses of CoronaVac: A randomized controlled trial
    Vaccine. 2022 Feb 21. pii: S0264-410X(22)00143.
    >> Share

  380. ISMAIL ALHOSANI F, Eduardo Stanciole A, Aden B, Timoshkin A, et al
    Impact of the Sinopharm's BBIBP-CorV vaccine in preventing hospital admissions and death in infected vaccinees: Results from a retrospective study in the emirate of Abu Dhabi, United Arab Emirates (UAE).
    Vaccine. 2022 Feb 19. pii: S0264-410X(22)00174.
    >> Share

  381. FILIA A, Rota MC, Grossi A, Martinelli D, et al
    Are vaccine shortages a relevant public health issue in Europe? Results from a survey conducted in the framework of the EU Joint Action on Vaccination.
    Vaccine. 2022 Feb 19. pii: S0264-410X(22)00187.
    >> Share

  382. WINTER T, Riordan BC, Scarf D, Jose PE, et al
    Conspiracy beliefs and distrust of science predicts reluctance of vaccine uptake of politically right-wing citizens.
    Vaccine. 2022 Feb 18. pii: S0264-410X(22)00074.
    >> Share

  383. STANDAERT B, Strens D, Raes M, Benninghoff B, et al
    Explaining the formation of a plateau in rotavirus vaccine impact on rotavirus hospitalisations in Belgium.
    Vaccine. 2022 Feb 18. pii: S0264-410X(22)00199.
    >> Share

  384. LEE GY, Inthasorn P, Laowahutanont P, Lawpoolsri S, et al
    Long-term effectiveness of human papillomavirus vaccines among adult women: A real-world scenario.
    Vaccine. 2022 Feb 18. pii: S0264-410X(22)00188.
    >> Share

  385. SCHMALING KB
    Couples and COVID-19 vaccination: Frequency and reasons for discordance.
    Vaccine. 2022 Feb 18. pii: S0264-410X(22)00202.
    >> Share

  386. TRUMP BD, Golan MS, Keisler JM, Cegan JC, et al
    Vaccine supply chain: Resilience-by-design and resilience-by-intervention.
    Vaccine. 2022 Feb 17. pii: S0264-410X(22)00172.
    >> Share

  387. HENSCHKE N, Bergman H, Hungerford D, Cunliffe NA, et al
    The efficacy and safety of rotavirus vaccines in countries in Africa and Asia with high child mortality.
    Vaccine. 2022 Feb 17. pii: S0264-410X(22)00125.
    >> Share

  388. KASSTAN B, Mounier-Jack S, Letley L, Gaskell KM, et al
    Localising vaccination services: Qualitative insights on public health and minority group collaborations to co-deliver coronavirus vaccines.
    Vaccine. 2022 Feb 17. pii: S0264-410X(22)00201.
    >> Share

  389. MERKLEY E, Loewen PJ
    The correlates and dynamics of COVID-19 vaccine-specific hesitancy.
    Vaccine. 2022 Feb 17. pii: S0264-410X(22)00168.
    >> Share

  390. LAZO L, Bequet-Romero M, Lemos G, Musacchio A, et al
    A recombinant SARS-CoV-2 receptor-binding domain expressed in an engineered fungal strain of Thermothelomyces heterothallica induces a functional immune response in mice.
    Vaccine. 2022;40:1162-1169.
    >> Share

  391. JOG P, Memon IA, Thisyakorn U, Hozbor D, et al
    Pertussis in Asia: Recent country-specific data and recommendations.
    Vaccine. 2022;40:1170-1179.
    >> Share

  392. STEFANIZZI P, Larocca AMV, Martinelli A, Soldano S, et al
    Immune response to one dose of BNT162b2 mRNA Covid-19 vaccine followed by SARS-CoV-2 infection: An Italian prospective observational study.
    Vaccine. 2022 Feb 16. pii: S0264-410X(22)00124.
    >> Share

  393. KALASKA B, Miklosz J, Swieton J, Jakimczuk A, et al
    The effect of ChAdOx1 nCov-19 vaccine on arterial thrombosis development and platelet aggregation in female rats.
    Vaccine. 2022 Feb 16. pii: S0264-410X(22)00173.
    >> Share

  394. BUCKLEY A, Lager K
    Efficacy of an inactivated Senecavirus A vaccine in weaned pigs and mature sows.
    Vaccine. 2022 Feb 16. pii: S0264-410X(22)00142.
    >> Share

  395. ANUGULRUENGKITT S, Angsuwatcharakon P, Puthanakit T, Bunjoungmanee P, et al
    Seroprevalence of mumps among children and adolescents in Thailand, 2020.
    Vaccine. 2022;40:1061-1064.
    >> Share

  396. HUSKA B, Kubinec C, Sadarangani M, Ulanova M, et al
    Seroprevalence of IgG and IgM antibodies to Haemophilus influenzae type a in Canadian children.
    Vaccine. 2022;40:1128-1134.
    >> Share

  397. ARAKELIAN T, Oosterhuis K, Tondini E, Los M, et al
    Pyroptosis-inducing active caspase-1 as a genetic adjuvant in anti-cancer DNA vaccination.
    Vaccine. 2022 Feb 15. pii: S0264-410X(22)00162.
    >> Share

  398. SALEH OA, Halperin O
    Influenza virus vaccine compliance among pregnant women during the COVID-19 pandemic (pre-vaccine era) in Israel and future intention to uptake BNT162b2 mRNA COVID-19 vaccine.
    Vaccine. 2022 Feb 15. pii: S0264-410X(22)00160.
    >> Share

  399. HIDLE A, Brennan T, Garon J, An Q, et al
    Cost of human papillomavirus vaccine delivery at district and health facility levels in Zimbabwe: A school-based vaccination program targeting multiple cohorts.
    Vaccine. 2022 Feb 15. pii: S0264-410X(22)00047.
    >> Share

  400. QUITIAN LM, Rodriguez-Martinez CE, Sossa-Briceno MP, Cortes JA, et al
    Disease burden and vaccination priorities in Colombia.
    Vaccine. 2022 Feb 15. pii: S0264-410X(22)00029.
    >> Share

  401. TANI N, Chong Y, Kurata Y, Gondo K, et al
    Relation of fever intensity and antipyretic use with specific antibody response after two doses of the BNT162b2 mRNA vaccine.
    Vaccine. 2022 Feb 14. pii: S0264-410X(22)00158.
    >> Share

  402. AMMETER T, Lang P, Czock A
    Overview of the influenza vaccination activities and legal frameworks in 26 Swiss cantons during the influenza season 2019/20.
    Vaccine. 2022 Feb 14. pii: S0264-410X(22)00132.
    >> Share

  403. MUCHIRI SK, Muthee R, Kiarie H, Sitienei J, et al
    Unmet need for COVID-19 vaccination coverage in Kenya.
    Vaccine. 2022 Feb 14. pii: S0264-410X(22)00167.
    >> Share

  404. GAFFNEY KK, Jana Broadhurst M, Brett-Major DM
    Mumps to COVID-19: Vaccinated persons remain vulnerable when community uptake is low.
    Vaccine. 2022 Feb 14. pii: S0264-410X(22)00193.
    >> Share

  405. YAMAMOTO S, Fukunaga A, Tanaka A, Takeuchi JS, et al
    Association between reactogenicity and SARS-CoV-2 antibodies after the second dose of the BNT162b2 COVID-19 vaccine.
    Vaccine. 2022 Feb 14. pii: S0264-410X(22)00196.
    >> Share

  406. UWAMINO Y, Yokoyama T, Shimura T, Nishimura T, et al
    The effect of the E484K mutation of SARS-CoV-2 on the neutralizing activity of antibodies from BNT162b2 vaccinated individuals.
    Vaccine. 2022 Feb 14. pii: S0264-410X(22)00191.
    >> Share

  407. GAO F, An C, Bian L, Wang Y, et al
    Establishment of the first Chinese national standard for protein subunit SARS-CoV-2 vaccine.
    Vaccine. 2022 Feb 14. pii: S0264-410X(22)00194.
    >> Share

  408. CHAN IL, Mowson R, Alonso JP, Roberti J, et al
    Promoting immunization equity in Latin America and the Caribbean: Case studies, lessons learned, and their implication for COVID-19 vaccine equity.
    Vaccine. 2022 Feb 14. pii: S0264-410X(22)00197.
    >> Share

  409. CHRYSI P, Stella M, Marios K, Despo C, et al
    Exploring vaccination coverage and attitudes of health care workers towards influenza vaccine in Cyprus.
    Vaccine. 2022 Feb 12. pii: S0264-410X(22)00141.
    >> Share

  410. HELLER O, Chun Y, Shlomo Y, Gewirtz-Meydan A, et al
    Public perceptions and the willingness to get vaccinated against COVID-19: Lessons from Israel.
    Vaccine. 2022 Feb 11. pii: S0264-410X(22)00165.
    >> Share

  411. KOCHHAR S, Barreira D, Beattie P, Cavaleri M, et al
    Building the concept for WHO Evidence Considerations for Vaccine Policy (ECVP): Tuberculosis vaccines intended for adults and adolescents as a test case.
    Vaccine. 2022 Feb 11. pii: S0264-410X(21)01395.
    >> Share

  412. DIETRICH LG, Luthy A, Lucas Ramanathan P, Baldesberger N, et al
    Healthcare professional and professional stakeholders' perspectives on vaccine mandates in Switzerland: A mixed-methods study.
    Vaccine. 2022 Feb 11. pii: S0264-410X(22)00007.
    >> Share

  413. TIBBELS NJ, Dosso A, Fordham C, Benie W, et al
    "On the last day of the last month, I will go": A qualitative exploration of COVID-19 vaccine confidence among Ivoirian adults.
    Vaccine. 2022 Feb 11. pii: S0264-410X(22)00166.
    >> Share

  414. KAPLONEK P, Yao L, Reppe K, Voss F, et al
    A semisynthetic glycoconjugate provides expanded cross-serotype protection against Streptococcus pneumoniae.
    Vaccine. 2022;40:1038-1046.
    >> Share

  415. ABHILASH KPP, Mathiyalagan P, Krishnaraj VRK, Selvan S, et al
    Impact of prior vaccination with Covishield(TM) and Covaxin(R) on mortality among symptomatic COVID-19 patients during the second wave of the pandemic in South India during April and May 2021: a cohort study.
    Vaccine. 2022 Feb 10. pii: S0264-410X(22)00157.
    >> Share

  416. DEBELLUT F, Mkisi R, Masoo V, Chisema M, et al
    Projecting the cost of introducing typhoid conjugate vaccine (TCV) in the national immunization program in Malawi using a standardized costing framework.
    Vaccine. 2022 Feb 10. pii: S0264-410X(22)00139.
    >> Share

  417. COLE JW, M H Chen A, McGuire K, Berman S, et al
    Motivational interviewing and vaccine acceptance in children: The MOTIVE study.
    Vaccine. 2022 Feb 10. pii: S0264-410X(22)00114.
    >> Share

  418. PAOLINO KM, Regules JA, Moon JE, Ruck RC, et al
    Safety and immunogenicity of a plant-derived recombinant protective antigen (rPA)-based vaccine against Bacillus anthracis: A Phase 1 dose-escalation study in healthy adults.
    Vaccine. 2022 Feb 10. pii: S0264-410X(22)00093.
    >> Share

  419. BERGMANN ESTEVES S, Moreira Santos C, Ferreira Salgado F, Paldes Goncales A, et al
    Efficacy of commercially available vaccines against canine leptospirosis: A systematic review and meta-analysis.
    Vaccine. 2022 Feb 10. pii: S0264-410X(22)00144.
    >> Share

  420. DREYER N, Reynolds MW, Albert L, Brinkley E, et al
    How frequent are acute reactions to COVID-19 vaccination and who is at risk?
    Vaccine. 2022 Feb 9. pii: S0264-410X(22)00103.
    >> Share

  421. PRAMOD S, Govindan D, Ramasubramani P, Kar SS, et al
    Effectiveness of Covishield vaccine in preventing Covid-19 - A test-negative case-control study.
    Vaccine. 2022 Feb 9. pii: S0264-410X(22)00138.
    >> Share

  422. DE LUCA C, Schachner A, Heidl S, Hess M, et al
    Vaccination with a fowl adenovirus chimeric fiber protein (crecFib-4/11) simultaneously protects chickens against hepatitis-hydropericardium syndrome (HHS) and inclusion body hepatitis (IBH).
    Vaccine. 2022 Feb 9. pii: S0264-410X(22)00116.
    >> Share

  423. SCHALTZ-BUCHHOLZER F, Toldi G
    The association between parental and neonatal BCG vaccination and neonatal T helper 17 cell expansion.
    Vaccine. 2022 Feb 9. pii: S0264-410X(22)00128.
    >> Share

  424. CARLOW DA, Lai JCY, Kollmann TR, Sadarangani M, et al
    Cutaneous CpG adjuvant conditioning to enhance vaccine responses.
    Vaccine. 2022 Feb 8. pii: S0264-410X(21)01668.
    >> Share

  425. MASUDA T, Murakami K, Sugiura K, Sakui S, et al
    A phase 1/2 randomised placebo-controlled study of the COVID-19 vaccine mRNA-1273 in healthy Japanese adults: An interim report.
    Vaccine. 2022 Feb 8. pii: S0264-410X(22)00164.
    >> Share

  426. PEREZ-RODRIGUEZ S, de la Caridad Rodriguez-Gonzalez M, Ochoa-Azze R, Climent-Ruiz Y, et al
    A randomized, double-blind phase I clinical trial of two recombinant dimeric RBD COVID-19 vaccine candidates: Safety, reactogenicity and immunogenicity.
    Vaccine. 2022 Feb 8. pii: S0264-410X(22)00161.
    >> Share

  427. LADHANI SN, Campbell H, Amin-Chowdhury Z, Lucidarme J, et al
    Timing of meningococcal vaccination with 4CMenB (Bexsero(R)) in children with invasive meningococcal group B (MenB) disease in England.
    Vaccine. 2022 Feb 8. pii: S0264-410X(21)01618.
    >> Share

  428. CORNISH MJ, Hedrick JA, Gabrielsen AA, Johnson AD, et al
    Safety and immunogenicity of an investigational quadrivalent meningococcal tetanus toxoid conjugate vaccine (MenACYW-TT) co-administered with routine pediatric vaccines in infants and toddlers: A Phase II study.
    Vaccine. 2022 Feb 7. pii: S0264-410X(22)00096.
    >> Share

  429. DENG JZ, Lancaster C, Winters MA, Phillips KM, et al
    Multi-attribute characterization of pneumococcal conjugate vaccine by Size-exclusion chromatography coupled with UV-MALS-RI detections.
    Vaccine. 2022 Feb 7. pii: S0264-410X(22)00076.
    >> Share

  430. WALKER B, Anderson A, Stoecker C, Shao Y, et al
    COVID-19 and Routine Childhood and Adolescent Immunizations: Evidence from Louisiana Medicaid.
    Vaccine. 2022;40:837-840.
    >> Share

  431. CRUVINEL E, P Richter K, S Scheuermann T, M Machado N, et al
    The impact of COVID-19 on income and employment and willingness to become vaccinated among African Americans enrolled in a smoking cessation randomized trial.
    Vaccine. 2022 Feb 7. pii: S0264-410X(22)00120.
    >> Share

  432. MEWHIRTER J, Sagir M, Sanders R
    Towards a predictive model of COVID-19 vaccine hesitancy among American adults.
    Vaccine. 2022 Feb 7. pii: S0264-410X(22)00134.
    >> Share

  433. DOMNICH A, Orsi A, Sticchi L, Panatto D, et al
    Effect of the 2020/21 season influenza vaccine on SARS-CoV-2 infection in a cohort of Italian healthcare workers.
    Vaccine. 2022 Feb 7. pii: S0264-410X(22)00137.
    >> Share

  434. BELLOS I, Karageorgiou V, Viskin D
    Myocarditis following mRNA Covid-19 vaccination: A pooled analysis.
    Vaccine. 2022 Feb 7. pii: S0264-410X(22)00140.
    >> Share

  435. SPRENGHOLZ P, Korn L, Eitze S, Felgendreff L, et al
    Attitude toward a mandatory COVID-19 vaccination policy and its determinants: Evidence from serial cross-sectional surveys conducted throughout the pandemic in Germany.
    Vaccine. 2022 Feb 7. pii: S0264-410X(22)00130.
    >> Share

  436. WONODI C, Obi-Jeff C, Adewumi F, Keluo-Udeke SC, et al
    Conspiracy theories and misinformation about COVID-19 in Nigeria: Implications for vaccine demand generation communications.
    Vaccine. 2022 Feb 7. pii: S0264-410X(22)00126.
    >> Share

  437. WALKER J, Paul P, Dooling K, Oliver S, et al
    Modeling strategies for the allocation of SARS-CoV-2 vaccines in the United States.
    Vaccine. 2022 Feb 7. pii: S0264-410X(22)00136.
    >> Share

  438. HU S, Logan N, Puenpa J, Wanlapakorn N, et al
    Evaluation of the effect of maternally derived antibody on response to MMR vaccine in Thai infants.
    Vaccine. 2022 Feb 5. pii: S0264-410X(22)00095.
    >> Share

  439. AKGUN O, Kayaalp GK, Demirkan FG, Cakmak F, et al
    Exploring the attitudes, concerns, and knowledge regarding COVID-19 vaccine by the parents of children with rheumatic disease: Cross-sectional online survey.
    Vaccine. 2022 Feb 4. pii: S0264-410X(22)00117.
    >> Share

  440. NONVIGNON J, Owusu R, Asare B, Adjagba A, et al
    Estimating the cost of COVID-19 vaccine deployment and introduction in Ghana using the CVIC tool.
    Vaccine. 2022 Feb 4. pii: S0264-410X(22)00070.
    >> Share

  441. OLIANI F, Savoia A, Gallo G, Tiwana N, et al
    Italy's rollout of COVID-19 vaccinations: The crucial contribution of the first experimental mass vaccination site in Lombardy.
    Vaccine. 2022 Feb 3. pii: S0264-410X(22)00115.
    >> Share

  442. GORSE GJ, Grimes S, Buck H, Mulla H, et al
    MAS-1, a novel water-in-oil adjuvant/delivery system, with reduced seasonal influenza vaccine hemagglutinin dose may enhance potency, durability and cross-reactivity of antibody responses in the elderly.
    Vaccine. 2022 Feb 3. pii: S0264-410X(22)00059.
    >> Share

  443. IRVING SA, Groom HC, Dandamudi P, Daley MF, et al
    A decade of data: Adolescent vaccination in the vaccine safety datalink, 2007 through 2016.
    Vaccine. 2022 Feb 3. pii: S0264-410X(22)00091.
    >> Share

  444. TAKESHITA K, Ishiwada N, Takeuchi N, Ohkusu M, et al
    Immunogenicity and safety of routine 13-valent pneumococcal conjugate vaccination outside recommended age range in patients with hematological malignancies and solid tumors.
    Vaccine. 2022 Feb 3. pii: S0264-410X(22)00102.
    >> Share

  445. GORSE GJ, Grimes S, Buck H, Mulla H, et al
    A phase 1 dose-sparing, randomized clinical trial of seasonal trivalent inactivated influenza vaccine combined with MAS-1, a novel water-in-oil adjuvant/delivery system.
    Vaccine. 2022 Feb 3. pii: S0264-410X(22)00058.
    >> Share

  446. ELLITHORPE ME, Alade F, Adams RB, Nowak GJ, et al
    Looking ahead: Caregivers' COVID-19 vaccination intention for children 5 years old and younger using the health belief model.
    Vaccine. 2022 Feb 1. pii: S0264-410X(22)00097.
    >> Share

  447. HEYERDAHL LW, Vray M, Lana B, Tvardik N, et al
    Conditionality of COVID-19 vaccine acceptance in European countries.
    Vaccine. 2022 Feb 1. pii: S0264-410X(22)00099.
    >> Share

  448. SHAW J, Anderson KB, Fabi RE, Thompson CA, et al
    COVID-19 vaccination intention and behavior in a large, diverse, U.S. refugee population.
    Vaccine. 2022 Feb 1. pii: S0264-410X(22)00100.
    >> Share

  449. YOUSAF M, Hassan Raza S, Mahmood N, Core R, et al
    Immunity debt or vaccination crisis? A multi-method evidence on vaccine acceptance and media framing for emerging COVID-19 variants.
    Vaccine. 2022 Feb 1. pii: S0264-410X(22)00101.
    >> Share

    January 2022
  450. YANG YL, Kim J, Jeong Y, Jang YS, et al
    Intranasal immunization with a Middle East respiratory syndrome-coronavirus antigen conjugated to the M-cell targeting ligand Co4B enhances antigen-specific mucosal and systemic immunity and protects against infection.
    Vaccine. 2022;40:714-725.
    >> Share

  451. JANSSEN YF, Feitsma EA, Boersma HH, Alleva DG, et al
    Phase I interim results of a phase I/II study of the IgG-Fc fusion COVID-19 subunit vaccine, AKS-452.
    Vaccine. 2022 Jan 31. pii: S0264-410X(22)00077.
    >> Share

  452. PANWAR K, Godi A, Cocuzza CE, Andrews N, et al
    Binding antibody levels to vaccine (HPV6/11/16/18) and non-vaccine (HPV31/33/45/52/58) HPV antigens up to 7 years following immunization with either Cervarix(R) or Gardasil(R) vaccine.
    Vaccine. 2022 Jan 31. pii: S0264-410X(22)00075.
    >> Share

  453. SANDMANN FG, van Leeuwen E, Bernard-Stoecklin S, Casado I, et al
    Health and economic impact of seasonal influenza mass vaccination strategies in European settings: A mathematical modelling and cost-effectiveness analysis.
    Vaccine. 2022 Jan 31. pii: S0264-410X(22)00039.
    >> Share

  454. PITTET LF, Cox L, Freyne B, Germano S, et al
    Hepatitis B vaccine co-administration influences the heterologous effects of neonatal BCG vaccination in a sex-differential manner.
    Vaccine. 2022 Jan 29. pii: S0264-410X(22)00020.
    >> Share

  455. MORGAN C, Giattas MR, Holroyd T, Pfitzer A, et al
    Integration of other services with human papillomavirus vaccination; lessons from earlier in the life course highlight the need for new policy and implementation evidence.
    Vaccine. 2022 Jan 29. pii: S0264-410X(21)01674.
    >> Share

  456. SHERIDAN S, McIntyre P, Liu B, Fathima P, et al
    Pertussis burden and acellular pertussis vaccine effectiveness in high risk children.
    Vaccine. 2022 Jan 28. pii: S0264-410X(21)01322.
    >> Share

  457. MSUSA KP, Rogalski-Salter T, Mandi H, Clemens R, et al
    Critical success factors for conducting human challenge trials for vaccine development in low- and middle-income countries.
    Vaccine. 2022 Jan 28. pii: S0264-410X(22)00072.
    >> Share

  458. KANTELE A, Rombo L, Vene S, Kundi M, et al
    Three-dose versus four-dose primary schedules for tick-borne encephalitis (TBE) vaccine FSME-immun for those aged 50 years or older: A single-centre, open-label, randomized controlled trial.
    Vaccine. 2022 Jan 28. pii: S0264-410X(22)00048.
    >> Share

  459. KALNIN KV, Plitnik T, Kishko M, Huang D, et al
    Pan-SARS neutralizing responses after third boost vaccination in non-human primate immunogenicity model.
    Vaccine. 2022 Jan 28. pii: S0264-410X(22)00045.
    >> Share

  460. WHITE AA, Neelon B, Martin RH, Cartmell KB, et al
    Spatial patterns of HPV and Tdap vaccine dose administration and the association of health department clinic access in Georgia counties.
    Vaccine. 2022 Jan 28. pii: S0264-410X(21)01647.
    >> Share

  461. DING H, Huang J, Ngai CH, Sun Q, et al
    The cost-effectiveness of starting 23-valent pneumococcal polysaccharide vaccine and influenza vaccination at 50 vs. 65 years: A comparative modelling study.
    Vaccine. 2022 Jan 28. pii: S0264-410X(22)00057.
    >> Share

  462. STEPPERT P, Mosor M, Stanek L, Burgstaller D, et al
    A scalable, integrated downstream process for production of a recombinant measles virus-vectored vaccine.
    Vaccine. 2022 Jan 27. pii: S0264-410X(22)00019.
    >> Share

  463. HE Q, Xiao J, Liu M, Li Z, et al
    Immunogenicity of meningococcal polysaccharide conjugate vaccine as a replacement for meningococcal polysaccharide vaccine in children in Guangzhou, China.
    Vaccine. 2022 Jan 27. pii: S0264-410X(21)01200.
    >> Share

  464. JAFFE AE, Graupensperger S, Blayney JA, Duckworth JC, et al
    The role of perceived social norms in college student vaccine hesitancy: Implications for COVID-19 prevention strategies.
    Vaccine. 2022 Jan 26. pii: S0264-410X(22)00073.
    >> Share

  465. KARAFILLAKIS E, Peretti-Watel P, Verger P, Chantler T, et al
    'I trust them because my mum trusts them': Exploring the role of trust in HPV vaccination decision-making among adolescent girls and their mothers in France.
    Vaccine. 2022 Jan 25. pii: S0264-410X(22)00046.
    >> Share

  466. IANNINO F, Uriza PJ, Duarte CM, Pepe MV, et al
    Development of a Salmonella-based oral vaccine to control intestinal colonization of Shiga-toxin-producing Escherichia coli (STEC) in animals.
    Vaccine. 2022 Jan 24. pii: S0264-410X(22)00056.
    >> Share

  467. OGUTI B, Ali A, Andrews N, Barug D, et al
    The half-life of maternal transplacental antibodies against diphtheria, tetanus, and pertussis in infants: an individual participant data meta-analysis.
    Vaccine. 2022;40:450-458.
    >> Share

  468. ZINTGRAFF J, Gagetti P, Napoli D, Sanchez Eluchans N, et al
    Invasive Streptococcus pneumoniae isolates from pediatric population in Argentina for the period 2006-2019. Temporal progression of serotypes distribution and antibiotic resistance.
    Vaccine. 2022;40:459-470.
    >> Share

  469. BLUNCK BN, Aideyan L, Ye X, Avadhanula V, et al
    Antibody responses of healthy adults to the p27 peptide of respiratory syncytial virus fusion protein.
    Vaccine. 2022;40:536-543.
    >> Share

  470. KIMOTO T
    Development of a safe and effective novel synthetic mucosal adjuvant SF-10 derived from physiological metabolic pathways and function of human pulmonary surfactant.
    Vaccine. 2022;40:544-553.
    >> Share

  471. TANGUAY M, Boutin M, Laumaea A, Salaciak M, et al
    B-cell cytopenia and time to last B-cell-depleting therapy predict response to SARS-COV-2 vaccines in patients with lymphoproliferative disorders.
    Vaccine. 2022 Jan 24. pii: S0264-410X(22)00071.
    >> Share

  472. TRICOU V, Gottardo R, Egan MA, Clement F, et al
    Characterization of the cell-mediated immune response to Takeda's live-attenuated tetravalent dengue vaccine in adolescents participating in a phase 2 randomized controlled trial conducted in a dengue-endemic setting.
    Vaccine. 2022 Jan 22. pii: S0264-410X(22)00040.
    >> Share

  473. HIDALGO-RUIZ M, Mejia-Lopez S, Perez-Serrano RM, Zaldivar-Lelo de Larrea G, et al
    Babesia bovis AMA-1, MSA-2c and RAP-1 contain conserved B and T-cell epitopes, which generate neutralizing antibodies and a long-lasting Th1 immune response in vaccinated cattle.
    Vaccine. 2022 Jan 22. pii: S0264-410X(22)00049.
    >> Share

  474. GHASWALLA PK, Bengtson LGS, Marshall GS, Buikema AR, et al
    Corrigendum to 'Meningococcal vaccination in patients with newly diagnosed asplenia in the United States' [Vaccine 39 (2021) 272-281].
    Vaccine. 2022 Jan 22. pii: S0264-410X(21)00994.
    >> Share

  475. TRENT MJ, Salmon DA, MacIntyre CR
    Predictors of pneumococcal vaccination among Australian adults at high risk of pneumococcal disease.
    Vaccine. 2022 Jan 22. pii: S0264-410X(22)00026.
    >> Share

  476. STEBBINGS R, Armour G, Pettis V, Goodman J, et al
    AZD1222 (ChAdOx1 nCov-19): A Single-Dose biodistribution study in mice.
    Vaccine. 2022;40:192-195.
    >> Share

  477. DRAZAN D, Czajka H, Maguire JD, Pregaldien JL, et al
    A phase 3 study to assess the immunogenicity, safety, and tolerability of MenB-FHbp administered as a 2-dose schedule in adolescents and young adults.
    Vaccine. 2022;40:351-358.
    >> Share

  478. RUSTANDI RR, Xu Q
    Reactivity characterization of bromoacetyl derivatized polyribosylribitol polysaccharide in Haemophilus influenzae type b for PedvaxHIB(R) by NMR spectroscopy.
    Vaccine. 2022;40:187-191.
    >> Share

  479. TUN ZM, Ring Z, Tam CC
    Factors associated with maternal tetanus vaccination in Myanmar: An analysis of demographic and health survey data.
    Vaccine. 2022 Jan 20. pii: S0264-410X(22)00042.
    >> Share

  480. LIU F, Feng C, Xu S, Wu Q, et al
    An AAV vaccine targeting the RBD of the SARS-CoV-2 S protein induces effective neutralizing antibody titers in mice and canines.
    Vaccine. 2022 Jan 20. pii: S0264-410X(22)00054.
    >> Share

  481. LIAO Q, Cowling BJ, Xiao J, Yuan J, et al
    Priming with social benefit information of vaccination to increase acceptance of COVID-19 vaccines.
    Vaccine. 2022 Jan 20. pii: S0264-410X(22)00055.
    >> Share

  482. LI LL, Zheng C, La J, Do NV, et al
    Impact of prior SARS-CoV-2 infection on incidence of hospitalization and adverse events following mRNA SARS-CoV-2 vaccination: A nationwide, retrospective cohort study.
    Vaccine. 2022 Jan 19. pii: S0264-410X(22)00051.
    >> Share

  483. PITCOVSKI J, Gruzdev N, Abzach A, Katz C, et al
    Oral subunit SARS-CoV-2 vaccine induces systemic neutralizing IgG, IgA and cellular immune responses and can boost neutralizing antibody responses primed by an injected vaccine.
    Vaccine. 2022 Jan 19. pii: S0264-410X(22)00050.
    >> Share

  484. ZHU D, Lv M, Bai Y, Wu J, et al
    Cost-effectiveness analysis of quadrivalent seasonal influenza vaccines in Beijing: A modeling analysis.
    Vaccine. 2022 Jan 19. pii: S0264-410X(22)00024.
    >> Share

  485. PASSARETTI CL, Priem JS, Agner TG, McCurdy L, et al
    Reducing the rates of household transmission: The impact of COVID-19 vaccination in healthcare workers with a known household exposure.
    Vaccine. 2022 Jan 19. pii: S0264-410X(22)00044.
    >> Share

  486. TUSE D, Malm M, Tamminen K, Diessner A, et al
    Safety and immunogenicity studies in animal models support clinical development of a bivalent norovirus-like particle vaccine produced in plants.
    Vaccine. 2022 Jan 18. pii: S0264-410X(22)00022.
    >> Share

  487. ROLFES L, Harmark L, Kant A, van Balveren L, et al
    COVID-19 vaccine reactogenicity - A cohort event monitoring study in the Netherlands using patient reported outcomes.
    Vaccine. 2022 Jan 17. pii: S0264-410X(22)00028.
    >> Share

  488. OHFUJI S, Tanaka T, Nakano T, Kase T, et al
    Annual trends in adverse events following mumps vaccination in Japan: A retrospective study.
    Vaccine. 2022 Jan 17. pii: S0264-410X(22)00023.
    >> Share

  489. BEDSTON S, Akbari A, Jarvis CI, Lowthian E, et al
    COVID-19 vaccine uptake, effectiveness, and waning in 82,959 health care workers: A national prospective cohort study in Wales.
    Vaccine. 2022 Jan 15. pii: S0264-410X(21)01535.
    >> Share

  490. TANAKA M, Okubo R, Hoshi SL, Ishikawa N, et al
    Cost-effectiveness of pertussis booster vaccination for preschool children in Japan.
    Vaccine. 2022 Jan 13. pii: S0264-410X(22)00003.
    >> Share

  491. SIMON JK, Staerke NB, Hemming-Harlo M, Layle S, et al
    Lot-to-lot consistency, safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in healthy adults aged >/=50 years: A randomized phase 3 trial (PNEU-TRUE).
    Vaccine. 2022 Jan 13. pii: S0264-410X(21)01675.
    >> Share

  492. MALTER KB, Tugel ME, Gil-Rodriguez M, Guardia G, et al
    Variability in non-core vaccination rates of dogs and cats in veterinary clinics across the United States.
    Vaccine. 2022 Jan 13. pii: S0264-410X(22)00006.
    >> Share

  493. WARNER EL, Barbati JL, Duncan KL, Yan K, et al
    Vaccine misinformation types and properties in Russian troll tweets.
    Vaccine. 2022 Jan 13. pii: S0264-410X(21)01648.
    >> Share

  494. MOYO P, Bosco E, Bardenheier BH, Rivera-Hernandez M, et al
    Variation in influenza vaccine assessment, receipt, and refusal by the concentration of Medicare Advantage enrollees in U.S. nursing homes.
    Vaccine. 2022 Jan 13. pii: S0264-410X(21)01688.
    >> Share

  495. WONG WHS, Leung D, Chua GT, Duque JSR, et al
    Adolescents' attitudes to the COVID-19 vaccination.
    Vaccine. 2022 Jan 12. pii: S0264-410X(22)00025.
    >> Share

  496. WOO EJ, Moro PL
    Postmarketing safety surveillance of high-dose quadrivalent influenza vaccine: Reports to the Vaccine Adverse Event Reporting System.
    Vaccine. 2022 Jan 11. pii: S0264-410X(22)00001.
    >> Share

  497. SHIMIZU S, Tanaka R, Itoh E, Maekawa-Matsuura M, et al
    Performance and usability evaluation of novel intradermal injection device Immucise and reanalysis of intradermal administration trials of influenza vaccine for the elderly.
    Vaccine. 2022 Jan 11. pii: S0264-410X(21)01669.
    >> Share

  498. BLYTH DM, Liang Z, Williams M, Murray CK, et al
    Immune interference revisited: Impact of live-attenuated influenza vaccine prior to yellow fever vaccination.
    Vaccine. 2022 Jan 11. pii: S0264-410X(21)01637.
    >> Share

  499. DANIEL CL, Williams J, Legg R, McGowen C, et al
    Factors associated with COVID-19 vaccination intentions among adults in the deep South.
    Vaccine. 2022 Jan 10. pii: S0264-410X(21)01667.
    >> Share

  500. PENG KW, Carey T, Lech P, Vandergaast R, et al
    Boosting of SARS-CoV-2 immunity in nonhuman primates using an oral rhabdoviral vaccine.
    Vaccine. 2022 Jan 10. pii: S0264-410X(21)01671.
    >> Share

  501. OMER I, Rosenberg A, Sefty H, Pando R, et al
    Lineage-matched versus mismatched influenza B vaccine effectiveness following seasons of marginal influenza B circulation.
    Vaccine. 2022 Jan 8. pii: S0264-410X(21)01664.
    >> Share

  502. VADLAMUDI NK, Patrick DM, Rose C, Sadatsafavi M, et al
    A population-based analysis to determine the impact of the 13-valent pneumococcal conjugate vaccine on community-acquired pneumonia in British Columbia, Canada.
    Vaccine. 2022 Jan 7. pii: S0264-410X(21)01673.
    >> Share

  503. FOO D, Sarna M, Pereira G, Moore HC, et al
    Longitudinal, population-based cohort study of prenatal influenza vaccination and influenza infection in childhood.
    Vaccine. 2022 Jan 7. pii: S0264-410X(21)01556.
    >> Share

  504. UWAMINO Y, Kurafuji T, Sato Y, Tomita Y, et al
    Young age, female sex, and presence of systemic adverse reactions are associated with high post-vaccination antibody titer after two doses of BNT162b2 mRNA SARS-CoV-2 vaccination: An observational study of 646 Japanese healthcare workers and universit
    Vaccine. 2022 Jan 7. pii: S0264-410X(22)00002.
    >> Share

  505. HSIAO A, Hansen J, Nunley KV, Lewis N, et al
    Safety of recombinant quadrivalent influenza vaccine compared to inactivated influenza vaccine in Chinese adults: An observational study.
    Vaccine. 2022 Jan 6. pii: S0264-410X(21)01641.
    >> Share

  506. EUSER S, Kroese FM, Derks M, de Bruin M, et al
    Understanding COVID-19 vaccination willingness among youth: A survey study in the Netherlands.
    Vaccine. 2022 Jan 5. pii: S0264-410X(21)01670.
    >> Share

  507. HUANG Z, Ji M, Ren J, Sun X, et al
    Effect of the framing of HPV vaccination on parents' willingness to accept an HPV vaccine.
    Vaccine. 2022 Jan 4. pii: S0264-410X(21)01659.
    >> Share

  508. GLADSTONE RA, Siira L, Brynildsrud OB, Vestrheim DF, et al
    International links between Streptococcus pneumoniae vaccine serotype 4 sequence type (ST) 801 in Northern European shipyard outbreaks of invasive pneumococcal disease.
    Vaccine. 2022 Jan 4. pii: S0264-410X(21)01377.
    >> Share

  509. LEDLIE S, Ricci C, Pan C, Rojas A, et al
    Yellow fever vaccine usage in the United States and risk of neurotropic and viscerotropic disease: A retrospective cohort study using three healthcare databases.
    Vaccine. 2022 Jan 4. pii: S0264-410X(21)01655.
    >> Share

  510. VILLENA R, Valenzuela MT, Bastias M, Santolaya ME, et al
    Invasive meningococcal disease in Chile seven years after ACWY conjugate vaccine introduction.
    Vaccine. 2022 Jan 4. pii: S0264-410X(21)01549.
    >> Share

  511. PENLINGTON M, Goulet P, Metcalfe B
    Improving knowledge and trust in vaccines: A survey-based assessment of the potential of the European Union Clinical Trial Regulation No 536/2014 plain language summary to increase health literacy.
    Vaccine. 2022 Jan 4. pii: S0264-410X(21)01653.
    >> Share

  512. ZHANG J, Ji Y, Wang Z, Jia Y, et al
    Effective improvements to the live-attenuated Newcastle disease virus vaccine by polyethylenimine-based biomimetic silicification.
    Vaccine. 2022 Jan 3. pii: S0264-410X(21)01662.
    >> Share

  513. KUZNETSOVA A, Ceregido MA, Jourquin A, Campora L, et al
    Fourteen years of the Pregnancy Registry on maternal immunisation with a reduced-antigen-content tetanus-diphtheria-acellular pertussis (Tdap) vaccine.
    Vaccine. 2022 Jan 3. pii: S0264-410X(21)01658.
    >> Share

  514. OHM M, Knol MJ, Vos ERA, Bogaard MJM, et al
    Seroprevalence of meningococcal ACWY antibodies across the population in the Netherlands: Two consecutive surveys in 2016/17 and 2020.
    Vaccine. 2022;40:59-66.
    >> Share

  515. KUJAWSKI SA, Yao L, Wang HE, Carias C, et al
    Impact of the COVID-19 pandemic on pediatric and adolescent vaccinations and well child visits in the United States: A database analysis.
    Vaccine. 2022 Jan 1. pii: S0264-410X(21)01672.
    >> Share

    December 2021
  516. PASCHALL AV, Ozdilek A, Briner SL, Brindley MA, et al
    Modulation of immunosuppressant drug treatment to improve SARS-CoV-2 vaccine efficacy in mice.
    Vaccine. 2021 Dec 31. pii: S0264-410X(21)01666.
    >> Share

  517. GROOM HC, Crane B, Naleway AL, Weintraub E, et al
    Monitoring vaccine safety using the vaccine safety Datalink: Assessing capacity to integrate data from Immunization Information systems.
    Vaccine. 2021 Dec 31. pii: S0264-410X(21)01656.
    >> Share

  518. LUBLIN A, Katz C, Gruzdev N, Yadid I, et al
    Protection against avian coronavirus conferred by oral vaccination with live bacteria secreting LTB-fused viral proteins.
    Vaccine. 2021 Dec 30. pii: S0264-410X(21)01661.
    >> Share

  519. SAELAND E, van der Fits L, Bolder R, Heemskerk-van der Meer M, et al
    Immunogenicity and protective efficacy of adenoviral and subunit RSV vaccines based on stabilized prefusion F protein in pre-clinical models.
    Vaccine. 2021 Dec 29. pii: S0264-410X(21)01651.
    >> Share

  520. FAINGELERNT Y, Dagan R, Givon-Lavi N, van der Beek BA, et al
    The impact of the pneumococcal conjugate vaccines on the incidence of community-acquired alveolar pneumonia in premature compared with in term-born infants.
    Vaccine. 2021 Dec 29. pii: S0264-410X(21)01636.
    >> Share

  521. ASOGWA OA, de Hoog MLA, Bruijning-Verhagen PCJI
    Impact of 7-valent versus 10-valent pneumococcal conjugate vaccines on primary care consultations across various age groups in the Netherlands, 5 years after the switch: A time-series analysis.
    Vaccine. 2021 Dec 27. pii: S0264-410X(21)01533.
    >> Share

  522. REIS LR, Costa-Rocha IAD, Campi-Azevedo AC, Peruhype-Magalhaes V, et al
    Exploratory study of humoral and cellular immunity to 17DD Yellow Fever vaccination in children and adults residents of areas without circulation of Yellow Fever Virus.
    Vaccine. 2021 Dec 27. pii: S0264-410X(21)01638.
    >> Share

  523. KUSI KA, Ofori EA, Akyea-Mensah K, Kyei-Baafour E, et al
    Towards large-scale identification of HLA-restricted T cell epitopes from four vaccine candidate antigens in a malaria endemic community in Ghana.
    Vaccine. 2021 Dec 27. pii: S0264-410X(21)01650.
    >> Share

  524. CHOWDHURY F, Akter A, Bhuiyan TR, Tauheed I, et al
    A non-inferiority trial comparing two killed, whole cell, oral cholera vaccines (Cholvax vs. Shanchol) in Dhaka, Bangladesh.
    Vaccine. 2021 Dec 27. pii: S0264-410X(21)01623.
    >> Share

  525. SHUKLA S, Fressin F, Un M, Coetzer H, et al
    Optimizing vaccine distribution via mobile clinics: a case study on COVID-19 vaccine distribution to long-term care facilities.
    Vaccine. 2021 Dec 27. pii: S0264-410X(21)01657.
    >> Share

  526. RIBEIRO SP, De Moura Mattaraia VG, Almeida RR, Valentine EJG, et al
    A promiscuous T cell epitope-based HIV vaccine providing redundant population coverage of the HLA class II elicits broad, polyfunctional T cell responses in nonhuman primates.
    Vaccine. 2021 Dec 24. pii: S0264-410X(21)01550.
    >> Share

  527. DE KOFF EM, van Houten MA, de Heij F, Berbers GAM, et al
    Salivary antibody responses to ten-valent pneumococcal conjugate vaccination following two different immunization schedules in a healthy birth cohort.
    Vaccine. 2021 Dec 24. pii: S0264-410X(21)01622.
    >> Share

  528. FREEMAN RE, Thaker J, Daley MF, Glanz JM, et al
    Vaccine timeliness and prevalence of undervaccination patterns in children ages 0-19 months, U.S., National immunization Survey-Child 2017.
    Vaccine. 2021 Dec 24. pii: S0264-410X(21)01645.
    >> Share

  529. JUNE CHOE Y, Yi S, Hwang I, Kim J, et al
    Safety and effectiveness of BNT162b2 mRNA Covid-19 vaccine in adolescents.
    Vaccine. 2021 Dec 24. pii: S0264-410X(21)01654.
    >> Share

  530. THOMAS SJ, Perez JL, Lockhart SP, Hariharan S, et al
    Efficacy and safety of the BNT162b2 mRNA COVID-19 vaccine in participants with a history of cancer: subgroup analysis of a global phase 3 randomized clinical trial.
    Vaccine. 2021 Dec 24. pii: S0264-410X(21)01652.
    >> Share

  531. LACY J, Tessier E, Andrews N, White J, et al
    Impact of an accelerated measles-mumps-rubella (MMR) vaccine schedule on vaccine coverage: An ecological study among London children, 2012-2018.
    Vaccine. 2021 Dec 23. pii: S0264-410X(21)01619.
    >> Share

  532. BRENNAN T, Hidle A, Doshi RH, An Q, et al
    Cost of human papillomavirus vaccine delivery in a single-age cohort, routine-based vaccination program in Senegal.
    Vaccine. 2021 Dec 23. pii: S0264-410X(21)01531.
    >> Share

  533. RAHIM S, Ahmad Z, Abdul-Ghafar J
    The polio vaccination story of Pakistan.
    Vaccine. 2021 Dec 23. pii: S0264-410X(21)01595.
    >> Share

  534. FERNANDES C, Alves J, Rodrigues A, Azevedo J, et al
    Epidemiological impact of the human papillomavirus vaccination program on genital warts in Portugal: A retrospective, chart review study.
    Vaccine. 2021 Dec 22. pii: S0264-410X(21)01544.
    >> Share

  535. KIM HJ, Yun HJ, Kim J, Kym S, et al
    Antibody response to second dose of the BNT162b2 mRNA vaccine in the first 12 weeks in South Korea: A prospective longitudinal study.
    Vaccine. 2021 Dec 22. pii: S0264-410X(21)01620.
    >> Share

  536. ROMAIN-SCELLE N, Elias C, Vanhems P
    COVID-19 vaccine is correlated with favourable epidemiological indicators in the Auvergne-Rhone-Alpes region (France): An ecological study.
    Vaccine. 2021 Dec 22. pii: S0264-410X(21)01644.
    >> Share

  537. MANOMAIPIBOON A, Phumisantiphong U, Maneerit J, Chalearmchai Y, et al
    Immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 with 12-dose vials: An interim analysis.
    Vaccine. 2021 Dec 22. pii: S0264-410X(21)01632.
    >> Share

  538. KENNEDY RB, Ovsyannikova IG, Haralambieva IH, Grill DE, et al
    Proteomic assessment of humoral immune responses in smallpox vaccine recipients.
    Vaccine. 2021 Dec 21. pii: S0264-410X(21)01642.
    >> Share

  539. PORTH JM, Wagner AL, Treleaven E, Fleischer NL, et al
    Childhood vaccination timeliness following maternal migration to an informal urban settlement in Kenya.
    Vaccine. 2021 Dec 21. pii: S0264-410X(21)01625.
    >> Share

  540. TADAKUMA K, Maruyama T, Mori K, Fujiki N, et al
    Effectiveness of seasonal influenza vaccine in adult Japanese workers, 2017-2020.
    Vaccine. 2021 Dec 21. pii: S0264-410X(21)01624.
    >> Share

  541. ERBER W, Khan F, Zavadska D, Freimane Z, et al
    Effectiveness of TBE vaccination in southern Germany and Latvia.
    Vaccine. 2021 Dec 21. pii: S0264-410X(21)01639.
    >> Share

  542. PETERSEN MB, Jorgensen F, Lindholt MF
    Did the European suspension of the AstraZeneca vaccine decrease vaccine acceptance during the COVID-19 pandemic?
    Vaccine. 2021 Dec 21. pii: S0264-410X(21)01631.
    >> Share

  543. WILLIAMS KV, Zhai B, Alcorn JF, Patricia Nowalk M, et al
    A randomized controlled trial of antibody response to 2019-20 cell-based inactivated and egg-based live attenuated influenza vaccines in children and young adults.
    Vaccine. 2021 Dec 21. pii: S0264-410X(21)01643.
    >> Share

  544. SHAPIRO GK, Gottfredson N, Leask J, Wiley K, et al
    COVID-19 and missed or delayed vaccination in 26 middle- and high-income countries: An observational survey.
    Vaccine. 2021 Dec 21. pii: S0264-410X(21)01649.
    >> Share

  545. BLANCO S, Salome Konigheim B, Diaz A, Spinsanti L, et al
    Evaluation of the Gam-COVID-Vac and vaccine-induced neutralizing response against SARS-CoV-2 lineage P.1 variant in an Argentinean cohort.
    Vaccine. 2021 Dec 20. pii: S0264-410X(21)01634.
    >> Share

  546. NASREEN S, Wang J, Kwong JC, Crowcroft NS, et al
    Population-based incidence of invasive pneumococcal disease in children and adults in Ontario and British Columbia, 2002-2018: A Canadian Immunization Research Network (CIRN) study.
    Vaccine. 2021;39:7545-7553.
    >> Share

  547. IVANOVA-MARKOVA Y, Gonzalez-Dominguez A, Hidalgo A, Sanchez R, et al
    Cost of illness of invasive meningococcal disease caused by serogroup B Neisseria meningitidis in Spain.
    Vaccine. 2021;39:7646-7654.
    >> Share

  548. RANADE D, Jena R, Sancheti S, Deore V, et al
    Rapid, high throughput protein estimation method for saponin and alhydrogel adjuvanted R21 VLP Malaria vaccine based on intrinsic fluorescence.
    Vaccine. 2021 Dec 18. pii: S0264-410X(21)01627.
    >> Share

  549. HERRING WL, Zhang Y, Shinde V, Stoddard J, et al
    Clinical and economic outcomes associated with respiratory syncytial virus vaccination in older adults in the United States.
    Vaccine. 2021 Dec 18. pii: S0264-410X(21)01609.
    >> Share

  550. POUKKA E, Baum U, Palmu AA, Lehtonen TO, et al
    Cohort study of Covid-19 vaccine effectiveness among healthcare workers in Finland, December 2020 - October 2021.
    Vaccine. 2021 Dec 18. pii: S0264-410X(21)01640.
    >> Share

  551. WIDGREN K, Tomba GS, Leung KY, Giesecke J, et al
    Modelling varicella vaccination - What does a lack of surge in herpes zoster incidence tell us about exogenous boosting?
    Vaccine. 2021 Dec 17. pii: S0264-410X(21)01537.
    >> Share

  552. CHUNG NH, Chen YC, Yang SJ, Lin YC, et al
    Induction of Th1 and Th2 in the protection against SARS-CoV-2 through mucosal delivery of an adenovirus vaccine expressing an engineered spike protein.
    Vaccine. 2021 Dec 17. pii: S0264-410X(21)01635.
    >> Share

  553. CARLSON SJ, McKenzie L, Roberts L, Blyth CC, et al
    Does a major change to a COVID-19 vaccine program alter vaccine intention? A qualitative investigation.
    Vaccine. 2021 Dec 16. pii: S0264-410X(21)01629.
    >> Share

  554. GOLDBLATT D, Fiore-Gartland A, Johnson M, Hunt A, et al
    Towards a population-based threshold of protection for COVID-19 vaccines.
    Vaccine. 2021 Dec 15. pii: S0264-410X(21)01615.
    >> Share

  555. YU Y, Jia W, Lau MMC, Lau JTF, et al
    Levels and factors derived from the Health Action Process Approach of behavioral intentions to take up COVID-19 vaccination: A random population-based study.
    Vaccine. 2021 Dec 15. pii: S0264-410X(21)01628.
    >> Share

  556. CHEN X, Wang H
    On the rise of the new B.1.1.529 variant: Five dimensions of access to a COVID-19 vaccine.
    Vaccine. 2021 Dec 14. pii: S0264-410X(21)01596.
    >> Share

  557. ALMOHAYA AM, Alsubie H, Alqarni B, Alzayad B, et al
    Acute unsolicited adverse events following BNT162b2 vaccine in Saudi Arabia, a real-world data.
    Vaccine. 2021 Dec 13. pii: S0264-410X(21)01610.
    >> Share

  558. KURANI S, MacLaughlin KL, Jacobson RM, St Sauver JL, et al
    Socioeconomic disadvantage and human papillomavirus (HPV) vaccination uptake.
    Vaccine. 2021 Dec 13. pii: S0264-410X(21)01611.
    >> Share

  559. BOTTON J, Dray-Spira R, Baricault B, Drouin J, et al
    Reduced risk of severe COVID-19 in more than 1.4 million elderly people aged 75 years and older vaccinated with mRNA-based vaccines.
    Vaccine. 2021 Dec 11. pii: S0264-410X(21)01617.
    >> Share

  560. COSSU D, Ruberto S, Yokoyama K, Hattori N, et al
    Efficacy of BCG vaccine in animal models of neurological disorders.
    Vaccine. 2021 Dec 11. pii: S0264-410X(21)01613.
    >> Share

  561. LUTRICK K, Groom H, Fowlkes AL, Groover KD, et al
    COVID-19 vaccine perceptions and uptake in a national prospective cohort of essential workers.
    Vaccine. 2021 Dec 11. pii: S0264-410X(21)01593.
    >> Share

  562. HSIEH YL, Rak S, SteelFisher GK, Bauhoff S, et al
    Effect of the suspension of the J&J COVID-19 vaccine on vaccine hesitancy in the United States.
    Vaccine. 2021 Dec 11. pii: S0264-410X(21)01559.
    >> Share

  563. OLIVEIRA-SILVA J, Reis T, Lopes C, Batista-Silva R, et al
    Humoral response to the SARS-CoV-2 BNT162b2 mRNA vaccine: Real-world data from a large cohort of healthcare workers.
    Vaccine. 2021 Dec 11. pii: S0264-410X(21)01621.
    >> Share

  564. ZHAO AR, Bishai DM
    Public health spending, primary care, and perceived risk promoted vaccination against H1N1.
    Vaccine. 2021 Dec 10. pii: S0264-410X(21)01538.
    >> Share

  565. KATZ MA, Harlev EB, Chazan B, Chowers M, et al
    Early effectiveness of BNT162b2 Covid-19 vaccine in preventing SARS-CoV-2 infection in healthcare personnel in six Israeli hospitals (CoVEHPI).
    Vaccine. 2021 Dec 10. pii: S0264-410X(21)01580.
    >> Share

  566. AVILA-AGUERO ML, Camacho-Badilla K, Ulloa-Gutierrez R, Espinal-Tejada C, et al
    Epidemiology of pertussis in Costa Rica and the impact of vaccination: A 58-year experience (1961-2018).
    Vaccine. 2021 Dec 10. pii: S0264-410X(21)01552.
    >> Share

  567. KADKHODA K
    Post RNA-based COVID vaccines myocarditis: Proposed mechanisms.
    Vaccine. 2021 Dec 9. pii: S0264-410X(21)01594.
    >> Share

  568. ZHAO H, Li Y, Wang Z
    Adverse event of Sinovac Coronavirus vaccine: Deafness.
    Vaccine. 2021 Dec 9. pii: S0264-410X(21)01576.
    >> Share

  569. HOOK SA, Hansen AP, Niesobecki SA, Meek JI, et al
    Evaluating public acceptability of a potential Lyme disease vaccine using a population-based, cross-sectional survey in high incidence areas of the United States.
    Vaccine. 2021 Dec 8. pii: S0264-410X(21)01540.
    >> Share

  570. PEPIN J, Labbe AC, Carignan A, Parent ME, et al
    Does BCG provide long-term protection against SARS-CoV-2 infection? A case-control study in Quebec, Canada.
    Vaccine. 2021;39:7300-7307.
    >> Share

  571. VON REYN CF
    BCG versus rBCG: What is the way forward?
    Vaccine. 2021;39:7319-7320.
    >> Share

  572. VAN HOOIJ A, van den Eeden SJF, Khatun M, Soren S, et al
    BCG-induced immunity profiles in household contacts of leprosy patients differentiate between protection and disease.
    Vaccine. 2021;39:7230-7237.
    >> Share

  573. HEIJMENBERG I, Husain A, Sathkumara HD, Muruganandah V, et al
    ESX-5-targeted export of ESAT-6 in BCG combines enhanced immunogenicity & efficacy against murine tuberculosis with low virulence and reduced persistence.
    Vaccine. 2021;39:7265-7276.
    >> Share

  574. KOWALEWICZ-KULBAT M, Locht C
    BCG for the prevention and treatment of allergic asthma.
    Vaccine. 2021;39:7341-7352.
    >> Share

  575. LENNON RP, Block R Jr, Schneider EC, Zephrin L, et al
    Underserved population acceptance of combination influenza-COVID-19 booster vaccines.
    Vaccine. 2021 Dec 7. pii: S0264-410X(21)01597.
    >> Share

  576. MA J, Casadei E, Bruce TJ, Sepahi A, et al
    Long-term efficacy of nasal vaccination against enteric red mouth (ERM) disease and infectious hematopoietic necrosis (IHN) in juvenile rainbow trout (Oncorhynchus mykiss).
    Vaccine. 2021 Dec 7. pii: S0264-410X(21)01551.
    >> Share

  577. MARGOLIS MA, Brewer NT, Boynton MH, Lafata JE, et al
    Provider response and follow-up to parental declination of HPV vaccination.
    Vaccine. 2021 Dec 6. pii: S0264-410X(21)01529.
    >> Share

  578. PEREZ-VILAR S, Dores GM, Marquez PL, Ng CS, et al
    Safety surveillance of meningococcal group B vaccine (Bexsero(R)), Vaccine Adverse Event Reporting System, 2015-2018.
    Vaccine. 2021 Dec 6. pii: S0264-410X(21)01545.
    >> Share

  579. SULIS G, Basta NE, Wolfson C, Kirkland SA, et al
    Influenza vaccination uptake among Canadian adults before and during the COVID-19 pandemic: An analysis of the Canadian Longitudinal study on Aging (CLSA).
    Vaccine. 2021 Dec 4. pii: S0264-410X(21)01579.
    >> Share

  580. RAW RK, Rees J, Kelly CA, Wroe C, et al
    Prior COVID-19 infection is associated with increased Adverse Events (AEs) after the first, but not the second, dose of the BNT162b2/Pfizer vaccine.
    Vaccine. 2021 Dec 4. pii: S0264-410X(21)01577.
    >> Share

  581. BRONSTEIN MV, Kummerfeld E, MacDonald A 3rd, Vinogradov S, et al
    Willingness to vaccinate against SARS-CoV-2: The role of reasoning biases and conspiracist ideation.
    Vaccine. 2021 Dec 4. pii: S0264-410X(21)01553.
    >> Share

  582. FACK C, Wood R, Hatherill M, Cobelens F, et al
    The impact of a change in infant BCG vaccination policy on adolescent TB incidence rates: A South African population-level cohort study.
    Vaccine. 2021 Dec 3. pii: S0264-410X(21)01488.
    >> Share

  583. NGUYEN AT, Arnold BF, Kennedy CJ, Mishra K, et al
    Evaluation of a city-wide school-located influenza vaccination program in Oakland, California with respect to race and ethnicity: A matched cohort study.
    Vaccine. 2021 Dec 3. pii: S0264-410X(21)01547.
    >> Share

  584. IZAK M, Stoyanov E, Dezuraev K, Shinar E, et al
    Correlation of Anti-SARS-CoV-2 S1-specificIgG antibody levels and adverse events following vaccination with BNT162b2 mRNA COVID-19 vaccine in healthcare workers.
    Vaccine. 2021 Dec 3. pii: S0264-410X(21)01557.
    >> Share

  585. HERZBERG J, Vollmer T, Fischer B, Becher H, et al
    SARS-CoV-2-antibody response in health care workers after vaccination or natural infection in a longitudinal observational study.
    Vaccine. 2021 Dec 3. pii: S0264-410X(21)01555.
    >> Share

  586. YORSAENG R, Suntronwong N, Phowatthanasathian H, Assawakosri S, et al
    Immunogenicity of a third dose viral-vectored COVID-19 vaccine after receiving two-dose inactivated vaccines in healthy adults.
    Vaccine. 2021 Dec 3. pii: S0264-410X(21)01560.
    >> Share

  587. HELLE F, Moyet J, Demey B, Francois C, et al
    Humoral anti-SARS-CoV-2 immune response after two doses of Comirnaty vaccine in nursing home residents by previous infection status.
    Vaccine. 2021 Dec 3. pii: S0264-410X(21)01558.
    >> Share

  588. LI S, Chen W, Shen Y, Xia J, et al
    Molecular characterization of infectious bronchitis virus in Southwestern China for the protective efficacy evaluation of four live vaccine strains.
    Vaccine. 2021 Dec 2. pii: S0264-410X(21)01546.
    >> Share

  589. DUONG CH, Mueller JE, Tubert-Bitter P, Escolano S, et al
    Estimation of mid-and long-term benefits and hypothetical risk of Guillain-Barre syndrome after human papillomavirus vaccination among boys in France: A simulation study.
    Vaccine. 2021 Dec 2. pii: S0264-410X(21)01502.
    >> Share

  590. WANG CH, Kung WJ, Lee CH, Lee CF, et al
    High rates of colonization and antimicrobial resistance of group B streptococcus highlight the need for vaccination even after implementation of guidelines for intrapartum antibiotic prophylaxis.
    Vaccine. 2021 Dec 2. pii: S0264-410X(21)01543.
    >> Share

  591. MUNOZ-QUILES C, Lopez-Lacort M, Diez-Domingo J, Rodrigo-Casares V, et al
    Human papillomavirus vaccines effectiveness to prevent genital warts: A population-based study using health system integrated databases, 2009-2017.
    Vaccine. 2021 Dec 2. pii: S0264-410X(21)01536.
    >> Share

  592. NEWALL AT, Beutels P, Tuffaha HW, Hall PS, et al
    How can early stage economic evaluation help guide research for future vaccines?
    Vaccine. 2021 Dec 2. pii: S0264-410X(21)01462.
    >> Share

  593. PRICE J, Mooney J, Bain C, Bawa JT, et al
    National stakeholder preferences for next-generation rotavirus vaccines: Results from a six-country study.
    Vaccine. 2021 Dec 2. pii: S0264-410X(21)01443.
    >> Share

  594. VALCKX S, Crevecoeur J, Verelst F, Vranckx M, et al
    Individual factors influencing COVID-19 vaccine acceptance in between and during pandemic waves (July-December 2020).
    Vaccine. 2021 Dec 1. pii: S0264-410X(21)01414.
    >> Share

  595. EZE P, Aniebo CL, Agu UJ, Agu SA, et al
    Validity of maternal recall for estimating childhood vaccination coverage - Evidence from Nigeria.
    Vaccine. 2021 Dec 1. pii: S0264-410X(21)01534.
    >> Share

  596. WIRTZ C, Mohamed Y, Engel D, Sidibe A, et al
    Integrating HPV vaccination programs with enhanced cervical cancer screening and treatment, a systematic review.
    Vaccine. 2021 Dec 1. pii: S0264-410X(21)01447.
    >> Share

    November 2021
  597. ATTWELL K, Rizzi M, McKenzie L, Carlson SJ, et al
    COVID-19 vaccine Mandates: An Australian attitudinal study.
    Vaccine. 2021 Nov 30. pii: S0264-410X(21)01530.
    >> Share

  598. SUGISHITA Y, Sugawara T
    Effectiveness and cost-effectiveness of influenza vaccination for elderly people.
    Vaccine. 2021 Nov 29. pii: S0264-410X(21)01257.
    >> Share

  599. PORRAS C, Sampson JN, Herrero R, Gail MH, et al
    Rationale and design of a double-blind randomized non-inferiority clinical trial to evaluate one or two doses of vaccine against human papillomavirus including an epidemiologic survey to estimate vaccine efficacy: The Costa Rica ESCUDDO trial.
    Vaccine. 2021 Nov 29. pii: S0264-410X(21)01486.
    >> Share

  600. ZOU X, He J, Zheng J, Liang M, et al
    Evaluation of effectiveness, safety and cost-benefit of the 23- valent pneumococcal capsular polysaccharide vaccine for HIV-Infected patients.
    Vaccine. 2021 Nov 29. pii: S0264-410X(21)01532.
    >> Share

  601. LAURENZ M, von Eiff C, Borchert K, Jacob C, et al
    Vaccination rates and adherence in premature infants before and after pneumococcal conjugate vaccine schedule change for term infants - A claims database analysis in Germany.
    Vaccine. 2021 Nov 28. pii: S0264-410X(21)01437.
    >> Share

  602. LI H, Monslow MA, Freed DC, Chang D, et al
    Novel adjuvants enhance immune responses elicited by a replication-defective human cytomegalovirus vaccine in nonhuman primates.
    Vaccine. 2021 Nov 28. pii: S0264-410X(21)01416.
    >> Share

  603. MALTEZOU HC, Anastassopoulou C, Hatziantoniou S, Poland GA, et al
    Anaphylaxis rates associated with COVID-19 vaccines are comparable to those of other vaccines.
    Vaccine. 2021 Nov 27. pii: S0264-410X(21)01539.
    >> Share

  604. CASTRO F, Pascale JM, Slocum Hewitt I, Calvo A, et al
    Mass vaccination campaign during the 2016 influenza outbreak in Panama: Challenges and implications for COVID-19 vaccination efforts.
    Vaccine. 2021 Nov 27. pii: S0264-410X(21)01504.
    >> Share

  605. SCHMITZ M, Luminet O, Klein O, Morbee S, et al
    Predicting vaccine uptake during COVID-19 crisis: A motivational approach.
    Vaccine. 2021 Nov 27. pii: S0264-410X(21)01542.
    >> Share

  606. JIN P, Sun F, Liu Q, Wang Q, et al
    An oral vaccine based on chitosan/aluminum adjuvant induces both local and systemic immune responses in turbot (Scophthalmus maximus).
    Vaccine. 2021 Nov 26. pii: S0264-410X(21)01396.
    >> Share

  607. GULPINAR G, Uzun MB
    Examining community pharmacists' intention to provide pharmacist-driven vaccination services: A structural equation modelling.
    Vaccine. 2021 Nov 26. pii: S0264-410X(21)01499.
    >> Share

  608. ROBERTSON JS, Loizides U, Adisa A, Lopez de la Rica Manjavacas A, et al
    International Nonproprietary Names (INN) for novel vaccine substances: A matter of safety.
    Vaccine. 2021 Nov 26. pii: S0264-410X(21)01528.
    >> Share

  609. ENGEL D, Afeli ADJ, Morgan C, Zeck W, et al
    Promoting adolescent health through integrated human papillomavirus vaccination programs: The experience of Togo.
    Vaccine. 2021 Nov 26. pii: S0264-410X(21)01466.
    >> Share

  610. AHMED S, Dorin F, Satter SM, Sarker AR, et al
    The economic burden of rotavirus hospitalization among children < 5 years of age in selected hospitals in Bangladesh.
    Vaccine. 2021;39:7082-7090.
    >> Share

  611. CANNON K, Elder C, Young M, Scott DA, et al
    A trial to evaluate the safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine in populations of adults >/=65 years of age with different prior pneumococcal vaccination.
    Vaccine. 2021 Nov 25. pii: S0264-410X(21)01352.
    >> Share

  612. KLEINWAKS G, Schmit V, Morrison J
    Considering human challenge trials for tuberculosis vaccine development.
    Vaccine. 2021 Nov 25. pii: S0264-410X(21)01469.
    >> Share

  613. URUENA A, Badano MN, Bare P, Gonzalez J, et al
    Humoral and cellular immune memory response 12 years following single dose vaccination against hepatitis A in Argentinian children.
    Vaccine. 2021 Nov 24. pii: S0264-410X(21)01482.
    >> Share

  614. BUCHMAN TG, Simpson SQ, Sciarretta KL, Finne KP, et al
    Seasonal influenza vaccination is associated with reduced risk of death among Medicare beneficiaries().
    Vaccine. 2021 Nov 23. pii: S0264-410X(21)01461.
    >> Share

  615. BETTENCOURT PJG, Joosten SA, Lindestam Arlehamn CS, Behr MA, et al
    100 years of the Bacillus Calmette-Guerin vaccine.
    Vaccine. 2021 Nov 22. pii: S0264-410X(21)01483.
    >> Share

  616. SUN P, Jani V, Johnson A, Cheng Y, et al
    T cell and memory B cell responses in tetravalent DNA, tetravalent inactivated and tetravalent live-attenuated prime-boost dengue vaccines in rhesus macaques.
    Vaccine. 2021 Nov 22. pii: S0264-410X(21)01325.
    >> Share

  617. DINC HO, Saltoglu N, Can G, Balkan II, et al
    Inactive SARS-CoV-2 vaccine generates high antibody responses in healthcare workers with and without prior infection.
    Vaccine. 2021 Nov 22. pii: S0264-410X(21)01507.
    >> Share

  618. LENTZEN MP, Huebenthal V, Kaiser R, Kreppel M, et al
    A retrospective analysis of social media posts pertaining to COVID-19 vaccination side effects.
    Vaccine. 2021 Nov 22. pii: S0264-410X(21)01526.
    >> Share

  619. AREGA SM, Knobel DL, Toka FN, Conan A, et al
    Non-specific effects of veterinary vaccines: a systematic review.
    Vaccine. 2021 Nov 20. pii: S0264-410X(21)01479.
    >> Share

  620. HARA M, Koshida R, Nakano T
    Parents' views on mumps, mumps vaccine, and the factors associated with vaccination in Japan.
    Vaccine. 2021 Nov 20. pii: S0264-410X(21)01449.
    >> Share

  621. YE K, Shi D, Zhang Z, Bian L, et al
    A chemiluminescence immunoassay for precise automatic quality control of glycoprotein in human rabies vaccine.
    Vaccine. 2021 Nov 20. pii: S0264-410X(21)01393.
    >> Share

  622. LIN C, Tu P, Terry TC
    Moving the needle on racial disparity: COVID-19 vaccine trust and hesitancy.
    Vaccine. 2021 Nov 20. pii: S0264-410X(21)01444.
    >> Share

  623. CHEN T, Dai M, Xia S
    Perceived facilitators and barriers to intentions of receiving the COVID-19 vaccines among elderly Chinese adults.
    Vaccine. 2021 Nov 19. pii: S0264-410X(21)01484.
    >> Share

  624. CAMBON L, Schwarzinger M, Alla F
    Increasing acceptance of a vaccination program for coronavirus disease 2019 in France: A challenge for one of the world's most vaccine-hesitant countries.
    Vaccine. 2021 Nov 19. pii: S0264-410X(21)01467.
    >> Share

  625. MUSCATELLO DJ, Nazareno AL, Turner RM, Newall AT, et al
    Influenza-associated mortality in Australia, 2010 through 2019: High modelled estimates in 2017.
    Vaccine. 2021 Nov 19. pii: S0264-410X(21)01464.
    >> Share

  626. BELLIZZI S, Aidyralieva C, Al-Shaikh A, Muthu N, et al
    Inclusiveness of prisons in COVID-19 vaccination deployment: Evidence from Jordan.
    Vaccine. 2021 Nov 18. pii: S0264-410X(21)01468.
    >> Share

  627. ORTEGA-SANCHEZ IR, Mott JA, Kittikraisak W, Khanthamaly V, et al
    Cost-effectiveness of seasonal influenza vaccination in pregnant women, healthcare workers and adults >= 60 years of age in Lao People's Democratic Republic.
    Vaccine. 2021 Nov 18. pii: S0264-410X(21)01445.
    >> Share

  628. IRVING SA, Ball SW, Booth SM, Regan AK, et al
    A multi-country investigation of influenza vaccine coverage in pregnant individuals, 2010-2016.
    Vaccine. 2021 Nov 18. pii: S0264-410X(21)01463.
    >> Share

  629. HAFNER-GIESSAUF H, Horn S, Schwantzer G, Sprenger-Mahr H, et al
    Cholecalciferol supplementation to improve the hepatitis B vaccination response in hemodialysis patients: A first randomized open label pilot study (DeVitaHep).
    Vaccine. 2021 Nov 18. pii: S0264-410X(21)01474.
    >> Share

  630. BLAIN AE, Reese HE, Marjuki H, Topaz N, et al
    Serogroup A, C, W, and Y meningococcal disease in persons previously vaccinated with a serogroup ACWY meningococcal vaccine - United States, 2014-2018.
    Vaccine. 2021 Nov 18. pii: S0264-410X(21)01480.
    >> Share

  631. WANG W, Wang Y, Wang Y, Yan F, et al
    Vaccine bidding, procurement and distribution management practices in mainland China: A nationwide study.
    Vaccine. 2021 Nov 18. pii: S0264-410X(21)01465.
    >> Share

  632. NGUYEN KH, Anneser E, Toppo A, Allen JD, et al
    Disparities in national and state estimates of COVID-19 vaccination receipt and intent to vaccinate by race/ethnicity, income, and age group among adults >/= 18 years, United States.
    Vaccine. 2021 Nov 18. pii: S0264-410X(21)01485.
    >> Share

  633. KITRO A, Sirikul W, Piankusol C, Rirermsoonthorn P, et al
    Acceptance, attitude, and factors affecting the intention to accept COVID-19 vaccine among Thai people and expatriates living in Thailand.
    Vaccine. 2021 Nov 17. pii: S0264-410X(21)01476.
    >> Share

  634. JEAN BAPTISTE AE, Bawa S, Oteri AJ, Dieng B, et al
    Nationwide measles supplementary immunization activities to increase immunity levels in Nigeria.
    Vaccine. 2021;39 Suppl 3:C1-C2.
    >> Share

  635. KORAVE J, Bawa S, Ageda B, Ucho A, et al
    Internal displacement; an impediment to the successful implementation of planned measles supplemental activities in Nigeria, a case study of Benue State.
    Vaccine. 2021;39 Suppl 3:C76-C81.
    >> Share

  636. HOFF NA, Bratcher A, Mukadi P, Ahuka S, et al
    Increasing Ebola transmission behaviors 6 months post-vaccination: Comparing vaccinated and unvaccinated populations near 2018 Mbandaka Ebola outbreak in the Democratic Republic of Congo.
    Vaccine. 2021 Nov 16. pii: S0264-410X(21)01404.
    >> Share

  637. VOSS G, Jacquet JM, Tornieporth N, Kampmann B, et al
    Meeting report: CEPI consultation on accelerating access to novel vaccines against emerging infectious diseases for pregnant and lactating women, London, 12-13 February 2020.
    Vaccine. 2021 Nov 16. pii: S0264-410X(21)01382.
    >> Share

  638. VOHRA P, Chintoan-Uta C, Bremner A, Mauri M, et al
    Evaluation of a Campylobacter jejuni N-glycan-ExoA glycoconjugate vaccine to reduce C. jejuni colonisation in chickens.
    Vaccine. 2021 Nov 16. pii: S0264-410X(21)01434.
    >> Share

  639. LIANG Q, Li H, Chang X, Zhang H, et al
    A phase 3 clinical trial of MINHAI PCV13 in Chinese children aged from 7 months to 5 years old.
    Vaccine. 2021;39:6947-6955.
    >> Share

  640. BRAKEL KA, Binjawadagi B, French-Kim K, Watts M, et al
    Coexpression of respiratory syncytial virus (RSV) fusion (F) protein and attachment glycoprotein (G) in a vesicular stomatitis virus (VSV) vector system provides synergistic effects against RSV infection in a cotton rat model.
    Vaccine. 2021;39:6817-6828.
    >> Share

  641. BOBO FT, Asante A, Woldie M, Dawson A, et al
    Child vaccination in sub-Saharan Africa: Increasing coverage addresses inequalities.
    Vaccine. 2021 Nov 15. pii: S0264-410X(21)01439.
    >> Share

  642. ESPARZA J, Damaso CR
    Searching for the origin of the smallpox vaccine: Edward Jenner and his little-known horsepox hypothesis.
    Vaccine. 2021 Nov 15. pii: S0264-410X(21)01441.
    >> Share

  643. AMEND KL, Turnbull B, Zhou L, Marks MA, et al
    Vaccine initiation and 3-dose series completion of 4vHPV vaccine among US insured males 2012-2016.
    Vaccine. 2021 Nov 15. pii: S0264-410X(21)01403.
    >> Share

  644. SILAS J, Jones A, Weiss-Cohen L, Ayton P, et al
    The seductive allure of technical language and its effect on covid-19 vaccine beliefs and intentions.
    Vaccine. 2021 Nov 15. pii: S0264-410X(21)01472.
    >> Share

  645. MURPHY RP, Taaffe C, Ahern E, McMahon G, et al
    A meta-analysis of influenza vaccination following correspondence: Considerations for COVID-19.
    Vaccine. 2021 Nov 15. pii: S0264-410X(21)01470.
    >> Share

  646. ROGERS JH, Cox SN, Hughes JP, Link AC, et al
    Trends in COVID-19 vaccination intent and factors associated with deliberation and reluctance among adult homeless shelter residents and staff, 1 November 2020 to 28 February 2021 - King County, Washington.
    Vaccine. 2021 Nov 15. pii: S0264-410X(21)01471.
    >> Share

  647. CHOKEPHAIBULKIT K, Puthanakit T, Bhat N, Mansouri S, et al
    A phase 2 randomized controlled dose-ranging trial of recombinant pertussis booster vaccines containing genetically inactivated pertussis toxin in women of childbearing age.
    Vaccine. 2021 Nov 14. pii: S0264-410X(21)01425.
    >> Share

  648. BURKE RM, Shih S, Hsiung CA, Yen C, et al
    Impact of rotavirus vaccination on rotavirus hospitalizations in Taiwanese children.
    Vaccine. 2021 Nov 14. pii: S0264-410X(21)01397.
    >> Share

  649. REESE HE, McNamara LA, Vianzon V, Blain A, et al
    Serogroup B meningococcal disease in persons previously vaccinated with a serogroup B meningococcal vaccine - United States, 2014-2019.
    Vaccine. 2021 Nov 13. pii: S0264-410X(21)01438.
    >> Share

  650. ROSENTHAL S, Cummings CL
    Influence of rapid COVID-19 vaccine development on vaccine hesitancy.
    Vaccine. 2021 Nov 13. pii: S0264-410X(21)01448.
    >> Share

  651. HARMON SHE, Faour DE, MacDonald NE
    Mandatory immunization and vaccine injury support programs: A survey of 28 GNN countries.
    Vaccine. 2021 Nov 12. pii: S0264-410X(21)01390.
    >> Share

  652. CHHABRIA S, Stanford FC
    A long shot: The importance of needle length in vaccinating patients with obesity against COVID-19.
    Vaccine. 2021 Nov 11. pii: S0264-410X(21)01442.
    >> Share

  653. VIZCARRA P, Haemmerle J, Velasco H, Velasco T, et al
    BNT162b2 mRNA COVID-19 vaccine Reactogenicity: The key role of immunity.
    Vaccine. 2021 Nov 11. pii: S0264-410X(21)01417.
    >> Share

  654. AW R, Ashik MR, Islam AAZM, Khan I, et al
    Production and purification of an active CRM197 in Pichia pastoris and its immunological characterization using a Vi-typhoid antigen vaccine.
    Vaccine. 2021 Nov 10. pii: S0264-410X(21)01432.
    >> Share

  655. COLOMBATTI OLIVIERI MA, Moyano RD, Mon ML, Gravisaco MJ, et al
    Evaluation of a virulent strain of Mycobacterium avium subsp. Paratuberculosis used as a heat-killed vaccine.
    Vaccine. 2021 Nov 10. pii: S0264-410X(21)01433.
    >> Share

  656. MCLEAN HQ, Levine MZ, King JP, Flannery B, et al
    Serologic response to sequential vaccination with enhanced influenza vaccines: Open label randomized trial among adults aged 65-74 years.
    Vaccine. 2021 Nov 10. pii: S0264-410X(21)01415.
    >> Share

  657. BABUADZE GG, Echanove J, Lamarre C, deLaVega MA, et al
    A novel DNA platform designed for vaccine use with high transgene expression and immunogenicity.
    Vaccine. 2021 Nov 10. pii: S0264-410X(21)01315.
    >> Share

  658. RODRIGUES CMC, Plotkin SA
    The influence of interval between doses on response to vaccines.
    Vaccine. 2021 Nov 10. pii: S0264-410X(21)01381.
    >> Share

  659. RADWAN NF, Abu-Sheasha GA, Bedwani RN, Yassine OG, et al
    Vaccine wastage and cost saving after multi-dose vial policy implementation in Egypt: A success story.
    Vaccine. 2021 Nov 9. pii: S0264-410X(21)01400.
    >> Share

  660. SHAH SFA, Ginossar T, Bentley JM, Zimet G, et al
    Using the Theory of Planned behavior to identify correlates of HPV vaccination uptake among college students attending a rural university in Alabama.
    Vaccine. 2021 Nov 9. pii: S0264-410X(21)01431.
    >> Share

  661. SVENNERHOLM AM, Qadri F, Lundgren A, Kaim J, et al
    Induction of mucosal and systemic immune responses against the common O78 antigen of an oral inactivated ETEC vaccine in Bangladeshi children and infants.
    Vaccine. 2021 Nov 9. pii: S0264-410X(21)01389.
    >> Share

  662. THULUVA S, Matur R, Tsa K, Gv SR, et al
    A single blind randomized phase 3 study to evaluate safety and immunogenicity of inactivated hepatitis A vaccine (HAPIBEV(TM)) in 1-15 years-old healthy hepatitis A vaccine-naive children.
    Vaccine. 2021 Nov 8. pii: S0264-410X(21)01326.
    >> Share

  663. HOSANGADI D, Martin EK, Watson M, Bruns R, et al
    Supporting use of thermostable vaccines during public health emergencies: Considerations and recommendations for the future.
    Vaccine. 2021 Nov 8. pii: S0264-410X(21)01398.
    >> Share

  664. MCKINNON B, Quach C, Dube E, Tuong Nguyen C, et al
    Social inequalities in COVID-19 vaccine acceptance and uptake for children and adolescents in Montreal, Canada.
    Vaccine. 2021 Nov 8. pii: S0264-410X(21)01426.
    >> Share

  665. WU K, Choi A, Koch M, Elbashir S, et al
    Variant SARS-CoV-2 mRNA vaccines confer broad neutralization as primary or booster series in mice.
    Vaccine. 2021 Nov 8. pii: S0264-410X(21)01435.
    >> Share

  666. VILLANUEVA-UY MET, Lam HY, Aldaba JG, Uy TMZ, et al
    Cost-effectiveness of rotavirus vaccination in the Philippines: A modeling study.
    Vaccine. 2021 Nov 6. pii: S0264-410X(21)01290.
    >> Share

  667. CUEVAS-JUAREZ E, Pando-Robles V, Palomares LA
    Flavivirus vaccines: Virus-like particles and single-round infectious particles as promising alternatives.
    Vaccine. 2021 Nov 6. pii: S0264-410X(21)01383.
    >> Share

  668. SHARUN K, Tiwari R, Saied AA, Dhama K, et al
    SARS-CoV-2 vaccine for domestic and captive animals: An effort to counter COVID-19 pandemic at the human-animal interface.
    Vaccine. 2021 Nov 6. pii: S0264-410X(21)01386.
    >> Share

  669. GOODE JR, Cook P, Cuttino S, Gatewood SBS, et al
    Early experience with COVID-19 vaccine in a Federally-Qualified Healthcare Center for the homeless.
    Vaccine. 2021 Nov 6. pii: S0264-410X(21)01388.
    >> Share

  670. DE HAAS TDJ, Yeung KHT, Hutubessy R, van der Putten IM, et al
    Programme costs for introducing age/gestation-based universal influenza vaccine schedules for young children and pregnant women in Hong Kong.
    Vaccine. 2021;39:6762-6780.
    >> Share

  671. LAU CL, Mayfield HJ, Sinclair JE, Brown SJ, et al
    Risk-benefit analysis of the AstraZeneca COVID-19 vaccine in Australia using a Bayesian network modelling framework.
    Vaccine. 2021 Nov 4. pii: S0264-410X(21)01428.
    >> Share

  672. SANZ-ROJO S, Jimenez-Garcia R, Lopez-de-Andres A, de Miguel-Diez J, et al
    Influenza vaccination uptake among high-risk target groups and health care workers in Spain and change from 2017 to 2020.
    Vaccine. 2021 Nov 3. pii: S0264-410X(21)01392.
    >> Share

  673. VASUDEVAN L, Ostermann J, Wang Y, Harrison SE, et al
    Predictors of HPV vaccination in the southern US: A survey of caregivers from 13 states.
    Vaccine. 2021 Nov 3. pii: S0264-410X(21)01356.
    >> Share

  674. RIBERA-CANO A, Dupont M, Houze-Cerfon CH, Houze-Cerfon V, et al
    Evaluation of a prototype decontamination mobile unit (UMDEO) for COVID-19 vaccination: A cross-sectional survey in France.
    Vaccine. 2021 Nov 3. pii: S0264-410X(21)01429.
    >> Share

  675. MIYA TV, Groome MJ, de Assis Rosa D
    TLR genetic variation is associated with Rotavirus-specific IgA seroconversion in South African Black infants after two doses of Rotarix vaccine.
    Vaccine. 2021 Nov 2. pii: S0264-410X(21)01384.
    >> Share

  676. PIERRON A, Bozon F, Berceanu A, Fontan J, et al
    Vaccination coverage in hematological patients undergoing chemotherapy: Should we move towards personalized vaccination?
    Vaccine. 2021 Nov 2. pii: S0264-410X(21)01369.
    >> Share

  677. MALTEZOU HC
    Vaccination of healthcare personnel in the COVID-19 era: A call for actions.
    Vaccine. 2021 Nov 2. pii: S0264-410X(21)01427.
    >> Share

  678. CASSONE A, Cauda R
    Multicomponent vaccines to fight SARS-CoV-2 variants of concern.
    Vaccine. 2021 Nov 1. pii: S0264-410X(21)01402.
    >> Share

  679. WAGNER A, Jasinska J, Tomosel E, Zielinski CC, et al
    Absent antibody production following COVID19 vaccination with mRNA in patients under immunosuppressive treatments.
    Vaccine. 2021 Nov 1. pii: S0264-410X(21)01401.
    >> Share

    October 2021
  680. LIU H, Zhou C, An J, Song Y, et al
    Development of recombinant COVID-19 vaccine based on CHO-produced, prefusion spike trimer and alum/CpG adjuvants.
    Vaccine. 2021 Oct 30. pii: S0264-410X(21)01399.
    >> Share

  681. MALTEZOU HC, Panagopoulos P, Sourri F, Giannouchos TV, et al
    COVID-19 vaccination significantly reduces morbidity and absenteeism among healthcare personnel: A prospective multicenter study.
    Vaccine. 2021 Oct 30. pii: S0264-410X(21)01387.
    >> Share

  682. KHOURY J, Najjar-Debbiny R, Hanna A, Jabbour A, et al
    COVID-19 vaccine - Long term immune decline and breakthrough infections.
    Vaccine. 2021 Oct 30. pii: S0264-410X(21)01370.
    >> Share

  683. GORDON SF, Clothier HJ, Morgan H, Buttery JP, et al
    Immune thrombocytopenia following immunisation with Vaxzevria ChadOx1-S (AstraZeneca) vaccine, Victoria, Australia.
    Vaccine. 2021 Oct 29. pii: S0264-410X(21)01350.
    >> Share

  684. GARCIA-GRIMSHAW M, Ceballos-Liceaga SE, Michel-Chavez A, Garcia-Alanis M, et al
    Transient sensory symptoms among first-dose recipients of the BNT162b2 mRNA COVID-19 vaccine: A case-control study.
    Vaccine. 2021 Oct 29. pii: S0264-410X(21)01391.
    >> Share

  685. MAZUR A, Benitez S, Chuffart-Finsterwald S, La Rotta R, et al
    COVAX no fault compensation program for COVID-19 vaccine injuries in 92 low and middle income countries.
    Vaccine. 2021 Oct 28. pii: S0264-410X(21)01380.
    >> Share

  686. MARTIN S, Vanderslott S
    "Any idea how fast 'It's just a mask!' can turn into 'It's just a vaccine!'": From mask mandates to vaccine mandates during the COVID-19 pandemic.
    Vaccine. 2021 Oct 28. pii: S0264-410X(21)01351.
    >> Share

  687. NOWALK MP, D'Agostino HEA, Zimmerman RK, Saul SG, et al
    Agreement among sources of adult influenza vaccination in the age of immunization information systems.
    Vaccine. 2021 Oct 26. pii: S0264-410X(21)01372.
    >> Share

  688. JEON S, Kelly M, Yun J, Lee B, et al
    Scalable production and immunogenicity of a cholera conjugate vaccine.
    Vaccine. 2021 Oct 26. pii: S0264-410X(21)01312.
    >> Share

  689. CAPPOZZO F, Dal Zotto A, Scollo M, Bernardini D, et al
    dTap vaccination uptake during pregnancy: Pregnant women-focused and health professionals-focused predictors in the Veneto Region (Italy).
    Vaccine. 2021 Oct 25. pii: S0264-410X(21)01321.
    >> Share

  690. HUANG J, Bai Y, Ding H, Wang B, et al
    Acceptance of pneumococcal vaccination in older adults: A general population-based survey.
    Vaccine. 2021 Oct 25. pii: S0264-410X(21)01344.
    >> Share

  691. CHANTHAVANICH P, Versage E, Van Twuijver E, Hohenboken M, et al
    Antibody responses against heterologous A/H5N1 strains for an MF59-adjuvanted cell culture-derived A/H5N1 (aH5N1c) influenza vaccine in healthy pediatric subjects.
    Vaccine. 2021 Oct 25. pii: S0264-410X(21)01317.
    >> Share

  692. OLANIPEKUN T, Abe T, Effoe V, Westney G, et al
    Changes in COVID-19 vaccine acceptance rate among recovered critically Ill patients: A 12-month follow-up study.
    Vaccine. 2021 Oct 25. pii: S0264-410X(21)01324.
    >> Share

  693. OPRIESSNIG T, Rawal G, McKeen L, Filippsen Favaro P, et al
    Evaluation of the intranasal route for porcine reproductive and respiratory disease modified-live virus vaccination.
    Vaccine. 2021 Oct 24. pii: S0264-410X(21)01353.
    >> Share

  694. LOEB M, Russell ML, Kelly-Stradiotto C, Fuller N, et al
    Adjuvanted trivalent influenza vaccine versus quadrivalent inactivated influenza vaccine in Hutterite Children: A randomized clinical trial.
    Vaccine. 2021 Oct 23. pii: S0264-410X(21)01355.
    >> Share

  695. MYAT TW, Thu HM, Tate JE, Burnett E, et al
    Rotavirus infection among children under five years of age hospitalized with acute gastroenteritis in Myanmar during 2018-2020 - Multicentre surveillance before rotavirus vaccine introduction.
    Vaccine. 2021 Oct 23. pii: S0264-410X(21)01323.
    >> Share

  696. FAN X, Li X, Wan K, Zhao X, et al
    Construction and immunogenicity of a T cell epitope-based subunit vaccine candidate against Mycobacterium tuberculosis.
    Vaccine. 2021 Oct 23. pii: S0264-410X(21)01354.
    >> Share

  697. SHACHOR-MEYOUHAS Y, Hussein K, Szwarcwort-Cohen M, Weissman A, et al
    Single BNT162b2 vaccine dose produces seroconversion in under 60 s cohort.
    Vaccine. 2021 Oct 23. pii: S0264-410X(21)01327.
    >> Share

  698. TRAN VN, Nguyen HA, Le TTA, Truong TT, et al
    Factors influencing adverse events following immunization with AZD1222 in Vietnamese adults during first half of 2021.
    Vaccine. 2021;39:6485-6491.
    >> Share

  699. ANDRADE G
    Covid-19 vaccine hesitancy, conspiracist beliefs, paranoid ideation and perceived ethnic discrimination in a sample of University students in Venezuela.
    Vaccine. 2021 Oct 22. pii: S0264-410X(21)01371.
    >> Share

  700. SHUBITZ LF, Robb EJ, Powell DA, Bowen RA, et al
    Deltacps1 vaccine protects dogs against experimentally induced coccidioidomycosis.
    Vaccine. 2021 Oct 22. pii: S0264-410X(21)01349.
    >> Share

  701. VAN BEEK LF, Langereis JD, van den Berg van Saparoea HB, Gillard J, et al
    Intranasal vaccination with protein bodies elicit strong protection against Streptococcus pneumoniae colonization.
    Vaccine. 2021 Oct 22. pii: S0264-410X(21)01313.
    >> Share

  702. DAR SA, Kole S, Shin SM, Jeong HJ, et al
    Comparative study on antigen persistence and immunoprotective efficacy of intramuscular and intraperitoneal injections of squalene - aluminium hydroxide (Sq + Al) adjuvanted viral hemorrhagic septicaemia virus vaccine in olive flounder (Paralichthys o
    Vaccine. 2021 Oct 22. pii: S0264-410X(21)01345.
    >> Share

  703. ABU-RAYA B, Maertens K, Munoz FM, Zimmermann P, et al
    Factors affecting antibody responses to immunizations in infants born to women immunized against pertussis in pregnancy and unimmunized women: Individual-Participant Data Meta-analysis.
    Vaccine. 2021;39:6545-6552.
    >> Share

  704. FAN S, Li D, Zhao H, Yu L, et al
    Ameliorated immunity elicited by intradermal inoculation in individuals vaccinated with inactivated SARS-CoV-2 vaccine.
    Vaccine. 2021 Oct 22. pii: S0264-410X(21)01375.
    >> Share

  705. MAKOVITZKI A, Lerer E, Kafri Y, Adar Y, et al
    Evaluation of a downstream process for the recovery and concentration of a Cell-Culture-Derived rVSV-Spike COVID-19 vaccine candidate.
    Vaccine. 2021 Oct 22. pii: S0264-410X(21)01376.
    >> Share

  706. WANG J, Wagner AL, Chen Y, Jaime E, et al
    Would COVID-19 vaccination willingness increase if mobile technologies prohibit unvaccinated individuals from public spaces? A nationwide discrete choice experiment from China.
    Vaccine. 2021 Oct 22. pii: S0264-410X(21)01340.
    >> Share

  707. JAMES EK, Bokemper SE, Gerber AS, Omer SB, et al
    Persuasive messaging to increase COVID-19 vaccine uptake intentions.
    Vaccine. 2021 Oct 22. pii: S0264-410X(21)01368.
    >> Share

  708. NETANEL C, Ben-Aharon O, Ben-Ari Z, Chodick G, et al
    Evaluation of a universal hepatitis B vaccination program and antenatal screening for hepatitis B surface antigen: Results from a real-world study 2015-2016.
    Vaccine. 2021 Oct 20. pii: S0264-410X(21)01287.
    >> Share

  709. DANKWA EA, Donnelly CA, Brouwer AF, Zhao R, et al
    Estimating vaccination threshold and impact in the 2017-2019 hepatitis A virus outbreak among persons experiencing homelessness or who use drugs in Louisville, Kentucky, United states.
    Vaccine. 2021 Oct 19. pii: S0264-410X(21)01308.
    >> Share

  710. KIM D, Pekgun P, Yildirim I, Keskinocak P, et al
    Resource allocation for different types of vaccines against COVID-19: Tradeoffs and synergies between efficacy and reach.
    Vaccine. 2021 Oct 18. pii: S0264-410X(21)01346.
    >> Share

  711. DANG TKNS, Rivero Cabrera R, Yeung KHT, van der Putten IM, et al
    Feasibility of age- and gestation-based routine universal influenza vaccines schedules for children aged 6 months - 2 years and pregnant women.
    Vaccine. 2021 Oct 18. pii: S0264-410X(21)01291.
    >> Share

  712. CHEN AT, Stacey HD, Marzok A, Singh P, et al
    Effect of inactivated influenza vaccination on human coronavirus infection: Secondary analysis of a randomized trial in Hutterite colonies.
    Vaccine. 2021 Oct 18. pii: S0264-410X(21)01341.
    >> Share

  713. MAKI Y, Kashiwagi S, Kimizuka Y
    Laser vaccine adjuvants: Light-augmented immune responses.
    Vaccine. 2021 Oct 16. pii: S0264-410X(21)01233.
    >> Share

  714. CHAPIN-BARDALES J, Myers T, Gee J, Shay DK, et al
    Reactogenicity within 2 weeks after mRNA COVID-19 vaccines: Findings from the CDC v-safe surveillance system.
    Vaccine. 2021 Oct 16. pii: S0264-410X(21)01339.
    >> Share

  715. ALI SAHRAIAN M, Ghadiri F, Azimi A, Naser Moghadasi A, et al
    Adverse events reported by Iranian patients with multiple sclerosis after the first dose of Sinopharm BBIBP-CorV.
    Vaccine. 2021;39:6347-6350.
    >> Share

  716. AYAZ S, Dibben O, Chapman D
    Presence of defective viral genes in H1N1 live attenuated influenza vaccine strains is not associated with reduced human cell fitness or vaccine effectiveness.
    Vaccine. 2021 Oct 15. pii: S0264-410X(21)01320.
    >> Share

  717. SILVER MC, Neumann PJ, Ma S, Kim DD, et al
    Frequency and impact of the inclusion of broader measures of value in economic evaluations of vaccines.
    Vaccine. 2021 Oct 13. pii: S0264-410X(21)01285.
    >> Share

  718. MOGHNIEH R, Mekdashi R, El-Hassan S, Abdallah D, et al
    Immunogenicity and reactogenicity of BNT162b2 booster in BBIBP-CorV-vaccinated individuals compared with homologous BNT162b2 vaccination: Results of a pilot prospective cohort study from Lebanon.
    Vaccine. 2021 Oct 13. pii: S0264-410X(21)01314.
    >> Share

  719. LALWANI SK, Ramanan PV, Sapru A, Sundaram B, et al
    Safety and immunogenicity of a multidose vial formulation of 13-valent pneumococcal conjugate vaccine administered with routine pediatric vaccines in healthy infants in India: A phase 4, randomized, open-label study.
    Vaccine. 2021 Oct 13. pii: S0264-410X(21)01208.
    >> Share

  720. BUUS M, da Silva I, Nielsen S, Thysen SM, et al
    Coverage and factors associated with receiving campaign polio vaccines in an urban population in Guinea-Bissau.
    Vaccine. 2021 Oct 12. pii: S0264-410X(21)01150.
    >> Share

  721. PARK WJ, Yoon YK, Kim Y, Park JS, et al
    Development of a bivalent conjugate vaccine candidate against rotaviral diarrhea and tuberculosis using polysaccharide from Mycobacterium tuberculosis conjugated to DeltaVP8* protein from rotavirus.
    Vaccine. 2021 Oct 9. pii: S0264-410X(21)01282.
    >> Share

  722. MCNAY LA, Arnoczy G, Martell M, Mock P, et al
    Community-based hospitals: New partners for government-sponsored clinical research during public health emergencies.
    Vaccine. 2021;39:6183-6185.
    >> Share

  723. HART P, Farrar J
    The influenza vaccines roadmap - A better future through improved influenza vaccines.
    Vaccine. 2021 Oct 8. pii: S0264-410X(21)01286.
    >> Share

  724. VERBERK JDM, van Dongen JAP, van de Kassteele J, Andrews NJ, et al
    Impact analysis of rotavirus vaccination in various geographic regions in Western Europe.
    Vaccine. 2021 Oct 8. pii: S0264-410X(21)01262.
    >> Share

  725. BRYDEN GM, Rockloff M, Browne M, Unsworth C, et al
    Effect of contamination and purity priming on attitudes to vaccination and other health interventions: A randomised controlled experiment.
    Vaccine. 2021 Oct 8. pii: S0264-410X(21)01278.
    >> Share

  726. VANDERMEULEN C, Leroux-Roels I, Vandeleur J, Staniscia T, et al
    A new fully liquid presentation of MenACWY-CRM conjugate vaccine: Results from a multicentre, randomised, controlled, observer-blind study.
    Vaccine. 2021 Oct 8. pii: S0264-410X(21)01283.
    >> Share

  727. FU LY, Torres R, Caleb S, Cheng YI, et al
    Vaccination coverage among young homeless children compared to US national immunization survey data.
    Vaccine. 2021 Oct 8. pii: S0264-410X(21)01288.
    >> Share

  728. MOTTELSON A, Vandeweerdt C, Atchapero M, Luong T, et al
    A self-administered virtual reality intervention increases COVID-19 vaccination intention.
    Vaccine. 2021 Oct 8. pii: S0264-410X(21)01311.
    >> Share

  729. HUMBLE RM, Sell H, Dube E, MacDonald NE, et al
    Canadian parents' perceptions of COVID-19 vaccination and intention to vaccinate their children: Results from a cross-sectional national survey.
    Vaccine. 2021 Oct 8. pii: S0264-410X(21)01309.
    >> Share

  730. BYRNE T, Patel P, Shrotri M, Beale S, et al
    Trends, patterns and psychological influences on COVID-19 vaccination intention: Findings from a large prospective community cohort study in England and Wales (Virus Watch).
    Vaccine. 2021 Oct 8. pii: S0264-410X(21)01281.
    >> Share

  731. MULLER-PEBODY B, Sinnathamby MA, Warburton F, Rooney G, et al
    Impact of the childhood influenza vaccine programme on antibiotic prescribing rates in primary care in England.
    Vaccine. 2021 Oct 6. pii: S0264-410X(21)01284.
    >> Share

  732. GIERSING B, Shah N, Kristensen D, Amorij JP, et al
    Strategies for vaccine-product innovation: Creating an enabling environment for product development to uptake in low- and middle-income countries.
    Vaccine. 2021 Oct 6. pii: S0264-410X(21)00996.
    >> Share

  733. REIDENBERG BE, Hirsch K, Costello CM, Russo M, et al
    Drive through COVID19 vaccination for developmentally disabled persons.
    Vaccine. 2021 Oct 6. pii: S0264-410X(21)01279.
    >> Share

  734. MUKHERJEE N, Julian E, Torrelles JB, Svatek RS, et al
    Effects of Mycobacterium bovis Calmette et Guerin (BCG) in oncotherapy: Bladder cancer and beyond.
    Vaccine. 2021 Oct 6. pii: S0264-410X(21)01256.
    >> Share

  735. ALLEVA DG, Delpero AR, Scully MM, Murikipudi S, et al
    Development of an IgG-Fc fusion COVID-19 subunit vaccine, AKS-452.
    Vaccine. 2021 Oct 5. pii: S0264-410X(21)01294.
    >> Share

  736. LAZAROS G, Anastassopoulou C, Hatziantoniou S, Kalos T, et al
    A case series of acute pericarditis following COVID-19 vaccination in the context of recent reports from Europe and the United States.
    Vaccine. 2021 Oct 5. pii: S0264-410X(21)01295.
    >> Share

  737. DRAPER M, Stergiopoulos S
    Shingles vaccination uptake in Massachusetts adults aged 50 years and older.
    Vaccine. 2021 Oct 5. pii: S0264-410X(21)01223.
    >> Share

  738. BRUCE YU Y, Taraban MB, Briggs KT
    All vials are not the same: Potential role of vaccine quality in vaccine adverse reactions.
    Vaccine. 2021 Oct 5. pii: S0264-410X(21)01280.
    >> Share

  739. VADREVU KM, Raju D, Rani S, Reddy S, et al
    Persisting antibody responses to Vi polysaccharide-tetanus toxoid conjugate (Typbar TCV(R)) vaccine up to 7years following primary vaccination of children<2years of age with, or without, a booster vaccination.
    Vaccine. 2021 Oct 5. pii: S0264-410X(21)00966.
    >> Share

  740. CORCORAN KE, Scheitle CP, DiGregorio BD
    Christian nationalism and COVID-19 vaccine hesitancy and uptake.
    Vaccine. 2021 Oct 2. pii: S0264-410X(21)01289.
    >> Share

  741. SRICHAN P, Thohinung U, Kodyee S, Apidechkul T, et al
    Vaccine serocoverage under the expanded program on immunization among hill tribe children in Thailand: A cross-sectional study.
    Vaccine. 2021 Oct 1. pii: S0264-410X(21)01264.
    >> Share

    September 2021
  742. NIEUWENHUIZEN NE, Zyla J, Zedler U, Bandermann S, et al
    Weaker protection against tuberculosis in BCG-vaccinated male 129 S2 mice compared to females.
    Vaccine. 2021 Sep 30. pii: S0264-410X(21)01230.
    >> Share

  743. LEWIS G, Lazzaro T, Crawford NW
    Recurrent lipoatrophy following multiple vaccinations: A case study.
    Vaccine. 2021 Sep 30. pii: S0264-410X(21)01237.
    >> Share

  744. KHAIMOVA R, Fischetti B, Cope R, Berkowitz L, et al
    Serological response with Heplisav-B(R) in prior Hepatitis B vaccine non-responders living with HIV.
    Vaccine. 2021 Sep 29. pii: S0264-410X(21)01251.
    >> Share

  745. FRANCIS-OLIVIERO F, Bozoki S, Micsik A, Kieny MP, et al
    Research priorities to increase vaccination coverage in Europe (EU joint action on vaccination).
    Vaccine. 2021 Sep 28. pii: S0264-410X(21)01224.
    >> Share

  746. YACOUB MR, Cucca V, Asperti C, Ramirez GA, et al
    Efficacy of a rational algorithm to assess allergy risk in patients receiving the BNT162b2 vaccine.
    Vaccine. 2021 Sep 28. pii: S0264-410X(21)01239.
    >> Share

  747. ROMANO CJ, Hall C, Khodr ZG, Bukowinski AT, et al
    History of pandemic H1N1-containing influenza vaccination and risk for spontaneous abortion and birth defects.
    Vaccine. 2021 Sep 28. pii: S0264-410X(21)01171.
    >> Share

  748. HOFMEISTER MG, Weng MK, Thoroughman D, Thomasson ED, et al
    Prevalence of indications for adult hepatitis A vaccination among hepatitis A outbreak-associated cases, Three US States, 2016-2019.
    Vaccine. 2021 Sep 28. pii: S0264-410X(21)01254.
    >> Share

  749. MOON JE, Greenleaf ME, Regules JA, Debois M, et al
    A phase IIA extension study evaluating the effect of booster vaccination with a fractional dose of RTS,S/AS01E in a controlled human malaria infection challenge.
    Vaccine. 2021 Sep 27. pii: S0264-410X(21)01203.
    >> Share

  750. CASEY RM, Adrien N, Badiane O, Diallo A, et al
    National introduction of HPV vaccination in Senegal-Successes, challenges, and lessons learned.
    Vaccine. 2021 Sep 27. pii: S0264-410X(21)01075.
    >> Share

  751. SINGH AK, Srikrishna G, Bivalacqua TJ, Bishai WR, et al
    Recombinant BCGs for tuberculosis and bladder cancer.
    Vaccine. 2021 Sep 27. pii: S0264-410X(21)01231.
    >> Share

  752. VIEIRA REZENDE RP, Braz AS, Guimaraes MFB, Ribeiro SLE, et al
    Characteristics associated with COVID-19 vaccine hesitancy: A nationwide survey of 1000 patients with immune-mediated inflammatory diseases.
    Vaccine. 2021 Sep 25. pii: S0264-410X(21)01260.
    >> Share

  753. BLEICHER I, Kadour-Peero E, Sagi-Dain L, Sagi S, et al
    Early exploration of COVID-19 vaccination safety and effectiveness during pregnancy: interim descriptive data from a prospective observational study.
    Vaccine. 2021 Sep 25. pii: S0264-410X(21)01234.
    >> Share

  754. SHEVZOV-ZEBRUN N, Caplan A
    Parental consent for vaccination of minors against COVID-19.
    Vaccine. 2021 Sep 25. pii: S0264-410X(21)01250.
    >> Share

  755. FISHER KA, Nguyen N, Crawford S, Fouayzi H, et al
    Preferences for COVID-19 vaccination information and location: Associations with vaccine hesitancy, race and ethnicity.
    Vaccine. 2021 Sep 25. pii: S0264-410X(21)01261.
    >> Share

  756. MOLODECKY NA, Jafari H, Safdar RM, Ahmed JA, et al
    Modelling the spread of serotype-2 vaccine derived-poliovirus outbreak in Pakistan and Afghanistan to inform outbreak control strategies in the context of the COVID-19 pandemic.
    Vaccine. 2021 Sep 25. pii: S0264-410X(21)01228.
    >> Share

  757. ZENG W, Cui Y, Jarawan E, Avila C, et al
    Optimizing immunization schedules in endemic cholera regions: cost-effectiveness assessment of vaccination strategies for cholera control in Bangladesh.
    Vaccine. 2021 Sep 24. pii: S0264-410X(21)01235.
    >> Share

  758. AKSNES BN, Walldorf JA, Nkwenkeu SF, Zoma RL, et al
    Vaccination information, motivations, and barriers in the context of meningococcal serogroup A conjugate vaccine introduction: A qualitative assessment among caregivers in Burkina Faso, 2018.
    Vaccine. 2021 Sep 24. pii: S0264-410X(21)01229.
    >> Share

  759. FADLYANA E, Rusmil K, Tarigan R, Rahmadi AR, et al
    A phase III, observer-blind, randomized, placebo-controlled study of the efficacy, safety, and immunogenicity of SARS-CoV-2 inactivated vaccine in healthy adults aged 18-59 years: An interim analysis in Indonesia.
    Vaccine. 2021 Sep 24. pii: S0264-410X(21)01255.
    >> Share

  760. SINGH AK, Phatak SR, Singh R, Bhattacharjee K, et al
    Antibody response after first and second-dose of ChAdOx1-nCOV (Covishield(TM)(R)) and BBV-152 (Covaxin(TM)(R)) among health care workers in India: The final results of cross-sectional coronavirus vaccine-induced antibody titre (COVAT) study.
    Vaccine. 2021 Sep 24. pii: S0264-410X(21)01258.
    >> Share

  761. YAMAZAKI Y, Ikeda M, Imada T, Furuno K, et al
    A phase 3, multicenter, single-arm, open-label study to assess the safety, tolerability, and immunogenicity of a single dose of 13-valent pneumococcal conjugate vaccine in Japanese participants aged 6-64 years who are considered to be at increased ris
    Vaccine. 2021 Sep 23. pii: S0264-410X(21)01168.
    >> Share

  762. MOORE KA, Ostrowsky JT, Kraigsley AM, Mehr AJ, et al
    A Research and Development (R&D) roadmap for influenza vaccines: Looking toward the future.
    Vaccine. 2021 Sep 23. pii: S0264-410X(21)01028.
    >> Share

  763. CHOWDHURY F, Akter A, Rahman Bhuiyan T, Tauheed I, et al
    A non-inferiority trial comparing two recombinant vaccines (Hepa-B vs. Engerix-B) for hepatitis B among adults in Dhaka, Bangladesh.
    Vaccine. 2021 Sep 21. pii: S0264-410X(21)01222.
    >> Share

  764. MELGAARD A, Krogsgaard LW, Randrup T, Plana-Ripoll O, et al
    Pre-vaccination vulnerability and suspected adverse events following HPV vaccination. A case-control study nested in the Danish national birth cohort.
    Vaccine. 2021 Sep 21. pii: S0264-410X(21)01232.
    >> Share

  765. LIU CH, Huang WT, Chie WC, Arnold Chan K, et al
    Safety surveillance of varicella vaccine using tree-temporal scan analysis.
    Vaccine. 2021 Sep 21. pii: S0264-410X(21)01226.
    >> Share

  766. GIESE H, Neth H, Gaissmaier W
    Determinants of information diffusion in online communication on vaccination: The benefits of visual displays.
    Vaccine. 2021 Sep 21. pii: S0264-410X(21)01195.
    >> Share

  767. MAHAPATRA SR, Dey J, Kaur T, Sarangi R, et al
    Immunoinformatics and molecular docking studies reveal a novel Multi-Epitope peptide vaccine against pneumonia infection.
    Vaccine. 2021 Sep 20. pii: S0264-410X(21)01204.
    >> Share

  768. PARK SJ, Kang YM, Cho HK, Kim DY, et al
    Cross-protective efficacy of inactivated whole influenza vaccines against Korean Y280 and Y439 lineage H9N2 viruses in mice.
    Vaccine. 2021 Sep 20. pii: S0264-410X(21)01207.
    >> Share

  769. ANGSUWATCHARAKON P, Puthanakit T, Bunjoungmanee P, Anugulruengkitt S, et al
    High seroprevalence of rubella in Thai children with a 2-dose MMR national immunization policy.
    Vaccine. 2021 Sep 20. pii: S0264-410X(21)01127.
    >> Share

  770. SCHNEIDER JC, Chen HC, Bautista E, Retallack D, et al
    Safety and immunogenicity of Px563L, a recombinant anthrax vaccine candidate, in a two-dose regimen for post-exposure prophylaxis in healthy adults.
    Vaccine. 2021 Sep 17. pii: S0264-410X(21)01123.
    >> Share

  771. WILEY KE, Levy D, Shapiro GK, Dube E, et al
    A user-centered approach to developing a new tool measuring the behavioural and social drivers of vaccination.
    Vaccine. 2021 Sep 17. pii: S0264-410X(21)01186.
    >> Share

  772. ELBASHA EH, Choi Y, Daniels V, Goveia MG, et al
    Cost-effectiveness of routine catch-up hepatitis a vaccination in the United States: Dynamic transmission modeling study.
    Vaccine. 2021 Sep 17. pii: S0264-410X(21)01147.
    >> Share

  773. MANSUY JM, Sagna AS, Laurent M, Izopet J, et al
    COVID-19 diagnosis in a Senegalese company: A model for COVID-19 vaccination?
    Vaccine. 2021 Sep 17. pii: S0264-410X(21)01227.
    >> Share

  774. RAINA MACINTYRE C, Costantino V, Chanmugam A
    The use of face masks during vaccine roll-out in New YorkCity and impact on epidemic control.
    Vaccine. 2021 Sep 16. pii: S0264-410X(21)01164.
    >> Share

  775. WANG J, Wu QS, Lu J, Ni YH, et al
    Low vaccination coverage of pneumococcal conjugate vaccines (PCVs) in Shanghai, China: A database analysis based on birth cohorts from 2012 to 2020.
    Vaccine. 2021 Sep 16. pii: S0264-410X(21)01190.
    >> Share

  776. OZAWA S, Chen HH, Rao GG, Eguale T, et al
    Value of pneumococcal vaccination in controlling the development of antimicrobial resistance (AMR): Case study using DREAMR in Ethiopia.
    Vaccine. 2021 Sep 16. pii: S0264-410X(21)00471.
    >> Share

  777. CHARD AN, Martinez M, Matanock A, Kassem AM, et al
    Estimation of oral poliovirus vaccine effectiveness in Afghanistan, 2010-2020.
    Vaccine. 2021 Sep 16. pii: S0264-410X(21)01199.
    >> Share

  778. MOSINA L, Kulper-Schiek W, Jacques-Carroll L, Earnshaw A, et al
    Supporting National Immunization Technical Advisory Groups in the WHO European Region in developing national COVID-19 vaccination recommendations through online communication platform.
    Vaccine. 2021 Sep 16. pii: S0264-410X(21)01225.
    >> Share

  779. AUGUSTO HERNANDES ROCHA T, Grapiuna de Almeida D, Shankar Kozhumam A, Cristina da Silva N, et al
    Microplanning for designing vaccination campaigns in low-resource settings: A geospatial artificial intelligence-based framework.
    Vaccine. 2021 Sep 15. pii: S0264-410X(21)01197.
    >> Share

  780. ABAYNEH T, Getachew B, Gelaye E, Traxler R, et al
    Viability evaluation of freeze dried and suspension anthrax spore vaccine formulations stored at different temperatures.
    Vaccine. 2021 Sep 15. pii: S0264-410X(21)01202.
    >> Share

  781. LEE SI, Jeong CG, Ul Salam Mattoo S, Nazki S, et al
    Protective immunity induced by concurrent intradermal injection of porcine circovirus type 2 and Mycoplasma hyopneumoniae inactivated vaccines in pigs.
    Vaccine. 2021 Sep 15. pii: S0264-410X(21)00921.
    >> Share

  782. SULIMAN S, Pelzer PT, Shaku M, Rozot V, et al
    Meeting report: Virtual Global Forum on Tuberculosis Vaccines, 20-22 April 2021.
    Vaccine. 2021 Sep 15. pii: S0264-410X(21)01154.
    >> Share

  783. KOSHAL SS, Ray A, Mehra R, Kaur A, et al
    Partnering for rotavirus vaccine introduction in India: A retrospective analysis.
    Vaccine. 2021 Sep 15. pii: S0264-410X(21)01193.
    >> Share

  784. KIM DY, Kang YM, Cho HK, Park SJ, et al
    Development of a recombinant H9N2 influenza vaccine candidate against the Y280 lineage field virus and its protective efficacy.
    Vaccine. 2021 Sep 14. pii: S0264-410X(21)01149.
    >> Share

  785. VAN HOOSTE WLC
    Influenza vaccination at the workplace.
    Vaccine. 2021 Sep 14. pii: S0264-410X(21)01188.
    >> Share

  786. BENJAMIN-CHUNG J, Arnold BF, Mishra K, Kennedy CJ, et al
    City-wide school-located influenza vaccination: A retrospective cohort study.
    Vaccine. 2021 Sep 14. pii: S0264-410X(21)01161.
    >> Share

  787. KNUF M, Haas H, Garcia-Corbeira P, Turriani E, et al
    Hexavalent vaccines: What can we learn from head-to-head studies?
    Vaccine. 2021 Sep 13. pii: S0264-410X(21)01146.
    >> Share

  788. MKOPI A, Mtenga S, Festo C, Mhalu G, et al
    Factors affecting non-coverage of measles-rubella vaccination among children aged 9-59 months in Tanzania.
    Vaccine. 2021 Sep 13. pii: S0264-410X(21)01196.
    >> Share

  789. PALACHE A, Rockman S, Taylor B, Akcay M, et al
    Vaccine complacency and dose distribution inequities limit the benefits of seasonal influenza vaccination, despite a positive trend in use.
    Vaccine. 2021 Sep 11. pii: S0264-410X(21)01157.
    >> Share

  790. YOSHIKAWA T
    Third-generation smallpox vaccine strain-based recombinant vaccines for viral hemorrhagic fevers.
    Vaccine. 2021 Sep 11. pii: S0264-410X(21)01169.
    >> Share

  791. PARADOWSKA-STANKIEWICZ I, Rumik A, Bogusz J, Zbrzezniak J, et al
    Duration of protection against Bordetella pertussis infection elicited by whole-cell and acellular vaccine priming in Polish children and adolescents.
    Vaccine. 2021 Sep 9. pii: S0264-410X(21)01167.
    >> Share

  792. FUJISAWA S, Murata S, Takehara M, Aoyama J, et al
    In vitro characterization of adipocyte plasma membrane-associated protein from poultry red mites, Dermanyssus gallinae, as a vaccine antigen for chickens.
    Vaccine. 2021 Sep 8. pii: S0264-410X(21)01166.
    >> Share

  793. THOMPSON MG, Soto G, Perez A, Newes-Adeyim G, et al
    Influenza vaccine effectiveness within prospective cohorts of healthcare personnel in Israel and Peru 2016-2019.
    Vaccine. 2021 Sep 8. pii: S0264-410X(21)00982.
    >> Share

  794. PERRY M, Akbari A, Cottrell S, Gravenor MB, et al
    Inequalities in coverage of COVID-19 vaccination: A population register based cross-sectional study in Wales, UK.
    Vaccine. 2021 Sep 8. pii: S0264-410X(21)01198.
    >> Share

  795. PLATT HL, Cardona JF, Haranaka M, Schwartz HI, et al
    A phase 3 trial of safety, tolerability, and immunogenicity of V114, 15-valent pneumococcal conjugate vaccine, compared with 13-valent pneumococcal conjugate vaccine in adults 50 years of age and older (PNEU-AGE).
    Vaccine. 2021 Sep 7. pii: S0264-410X(21)01097.
    >> Share

  796. ABREU E SILVA HB, Correa HP, Ribeiro IA, Nascimento VAM, et al
    Impact of six years of routine varicella vaccination on the disease-related hospitalizations at Minas Gerais, Brazil.
    Vaccine. 2021 Sep 7. pii: S0264-410X(21)01009.
    >> Share

  797. KUNITOKI K, Funato M, Mitsunami M, Kinoshita T, et al
    Access to HPV vaccination in Japan: Increasing social trust to regain vaccine confidence.
    Vaccine. 2021 Sep 7. pii: S0264-410X(21)01145.
    >> Share

  798. MOLL K, Wong HL, Fingar K, Ke Zhou C, et al
    Vaccine exposure during pregnancy among privately and publicly insured women in the United States, 2016-2018.
    Vaccine. 2021 Sep 7. pii: S0264-410X(21)01151.
    >> Share

  799. VAN DONGEN JAP, Rouers EDM, Bonten MJM, Bruijning-Verhagen PCJ, et al
    Evaluation of non-specific effects of human rotavirus vaccination in medical risk infants.
    Vaccine. 2021 Sep 7. pii: S0264-410X(21)01115.
    >> Share

  800. JACOBI CJ, Vaidyanathan B
    Racial differences in anticipated COVID-19 vaccine acceptance among religious populations in the US.
    Vaccine. 2021 Sep 7. pii: S0264-410X(21)01184.
    >> Share

  801. MOORE DCBC, Nehab MF, Camacho KG, Reis AT, et al
    Low COVID-19 vaccine hesitancy in Brazil.
    Vaccine. 2021 Sep 7. pii: S0264-410X(21)01192.
    >> Share

  802. EBERHARDT J, Ling J
    Predicting COVID-19 vaccination intention using protection motivation theory and conspiracy beliefs.
    Vaccine. 2021 Sep 7. pii: S0264-410X(21)01189.
    >> Share

  803. WAINSTOCK T, Yoles I, Sergienko R, Sheiner E, et al
    Prenatal maternal COVID-19 vaccination and pregnancy outcomes.
    Vaccine. 2021 Sep 7. pii: S0264-410X(21)01191.
    >> Share

  804. SULIMAN DM, Nawaz FA, Mohanan P, Modber MAKA, et al
    UAE efforts in promoting COVID-19 vaccination and building vaccine confidence.
    Vaccine. 2021 Sep 7. pii: S0264-410X(21)01194.
    >> Share

  805. BHAT S, Caldera F, Farraye FA
    Standardizing shared vaccination responsibilities among specialists to improve vaccination rates of immunosuppressed patients.
    Vaccine. 2021 Sep 4. pii: S0264-410X(21)01121.
    >> Share

  806. RANE MS, Rohani P, Halloran ME
    Durability of protection after 5 doses of acellular pertussis vaccine among 5-9 year old children in King County, Washington.
    Vaccine. 2021 Sep 4. pii: S0264-410X(21)01118.
    >> Share

  807. SISNOWSKI J, Vujovich-Dunn C, Gidding H, Brotherton J, et al
    Differences in school factors associated with adolescent HPV vaccination initiation and completion coverage in three Australian states.
    Vaccine. 2021 Sep 4. pii: S0264-410X(21)01124.
    >> Share

  808. LEVIN D, Shimon G, Fadlon-Derai M, Gershovitz L, et al
    Myocarditis following COVID-19 vaccination - A case series.
    Vaccine. 2021 Sep 4. pii: S0264-410X(21)01172.
    >> Share

  809. BOZORGI A, Fahimnia B
    Micro array patch (MAP) for the delivery of thermostable vaccines in Australia: A cost/benefit analysis.
    Vaccine. 2021 Sep 3. pii: S0264-410X(21)01036.
    >> Share

  810. BOZORGI A, Fahimnia B
    Transforming the vaccine supply chain in Australia: Opportunities and challenges.
    Vaccine. 2021 Sep 3. pii: S0264-410X(21)01066.
    >> Share

  811. SONG JY, Chang CJ, Andrews C, Diez-Domingo J, et al
    Safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by sequential PPSV23 vaccination in healthy adults aged>/=50years: A randomized phase III trial (PNEU-PATH).
    Vaccine. 2021 Sep 3. pii: S0264-410X(21)01071.
    >> Share

  812. LAWRENCE J, Kitchin N, Anderson AS, Pride MW, et al
    Safety and immunogenicity of different Clostridioides (Clostridium) difficile vaccine formulations in two early phase randomized studies of healthy adults aged 50-85 years.
    Vaccine. 2021 Sep 3. pii: S0264-410X(21)00592.
    >> Share